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Abstract 
 
Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CFTR protein, an 
anion channel that conducts Cl- and HCO3- and regulates amiloride-sensitive Na+ channels. In 
both animal and in vitro models, CFTR dysfunction results in excessive neutrophilic 
inflammation, Na+ absorption and inflammasome activation, with a strong interleukin (IL)-1 
signature. 
This study’s hypothesis is that CF is associated with a pathogenic increase in Na+ 
transport, which occurs due to the loss of CFTR-dependent inhibition of amiloride-sensitive 
Na+ channels and drives excessive inflammation and metabolism at the molecular and systemic 
level. 
Primary human monocytes, macrophages and bronchial epithelial cell lines, with 
characterised CF-associated mutations, were cultured in vitro and stimulated for NLRP3 
inflammasome activation. Differentiated macrophages were characterised using flow 
cytometry. Cytokines, ion fluxes and metabolites were measured from in vitro stimulations 
using colorimetric and fluorometric assays. 
Patients with CF were observed to have a systemic proinflammatory cytokine signature 
accompanied by an in vitro hyperactivation of the NLRP3 inflammasome and metabolic 
pathways associated with proinflammatory immune phenotypes. Excessive Na+ influx in cells 
with CF-associated mutations, which created a propensity for excessive K+ efflux and cellular 
energy demand upon stimulation, was observed in this study. Primary CF monocytes and 
epithelial cell lines hyper-responded to NLRP3 stimulation with disproportionate IL-1b and 
IL-18 secretion, inhibited by pre-treatment with small molecule and peptide inhibitors of Na+ 
channels, metabolic pathways and the NLRP3 inflammasome. In addition, a small cohort of 
patients with CF-associated mutations on a 3-month study of small molecule CFTR modulator 
therapy showed a reduction in inflammation and glycolysis. 
This is the first study to demonstrate a link between excess Na+ absorption, a 
characteristic intrinsic feature of CF, and increased inflammation and metabolism.  Future 
therapies will need to focus on rectifying Na+ absorption if they are to obtain maximal 
therapeutic benefit. 
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Chapter 1 
 
Introduction 
 
1.1 Cystic Fibrosis Pathophysiology 
 
The cystic fibrosis transmembrane conductance regulator (CFTR) is a membrane-
associated N-linked glycoprotein, which functions as a Cl- and HCO3- channel and a regulator 
of amiloride-sensitive Na+ channels (Cheng et al., 1990, Berdiev et al., 2009, Bhalla and 
Hallows, 2008, Donaldson et al., 2002, Garcia-Caballero et al., 2009, Hobbs et al., 2013, König 
et al., 2002, Konstas et al., 2003, Kunzelmann, 2003). CFTR is highly expressed on the apical 
surface of epithelia (Riordan et al., 1989), but is also expressed by many other cell types, such 
as neurons and lymphocytes (Besancon et al., 1994, Bonfield et al., 2012, Cafferata et al., 2000, 
Collaco et al., 2013, Dong et al., 2015, Ettorre et al., 2014, Gao and Su, 2015, Kulka et al., 
2002, Painter et al., 2006, Sorio et al., 2011, Su et al., 2011, Weyler et al., 1999, Zaidi et al., 
2004). Innate immune cells, such as monocytes and neutrophils, increase CFTR expression 
when they encounter danger signals and enter tissue from the blood. This migration 
differentiates the monocyte cell into an active macrophage, which has been shown to have 
increased CFTR expression compared to its monocytic precursor (Del Porto et al., 2011).  
When mutated, the CFTR is responsible for the multisystem disease that characterises 
cystic fibrosis (CF). The identification of the CF gene to locus 7cen-q22 was first described in 
1985 (Wainwright et al., 1985) and the CFTR gene was identified as the cause of CF in 1989 
(Kerem et al., 1989, Riordan et al., 1989, Rommens et al., 1989), establishing the underlying 
molecular basis of CF (Cheng et al., 1990). There are six molecular classes of CFTR mutation 
  
 
 
19 
that are classified depending on the severity of the cellular defect they cause. There are 
currently 2028 CFTR mutations (http://www.genet.sickkids.on.ca) which have been grouped 
into seven classes according their functional defect (Table 1). 
 
Table 1: The molecular classification of CFTR mutations. Mutations are classified 
according to functional defects. Examples of mutations and classes of mutations are shown in 
this table. A summary of available cell lines used in this thesis are highlighted in bold. Each 
cell line has at least one allele of one of the associated mutations for that class and also share 
the cellular abnormality for that class (Ratjen et al., 2015). The cell lines highlighted in bold 
are used in this study. 
CLASS MOLECULAR 
ABNORMALITY 
EXAMPLE 
MUTATION 
CELL LINE APPROVED 
CORRECTIVE 
DRUG 
I No functioning CFTR 
produced 
W1282X IB3-1 No 
II Impaired protein folding F508del CuFi-1, 
CFNPE14o- 
Correctors 
III Problems with gating G551D, R117H, 
F508del 
CFBE45o- 
CuFi-4 
Potentiators 
IV Poor Conductance R347H, R117H CFBE45o- No 
V Abnormal Splicing 621+1G>T, R117H CFBE45o- No 
VI Poor Stability S1455X, F508del CuFi-1, 
CF14o- 
No 
VII No mRNA dele2,3(21kb) KO cell line No 
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The severity of the cellular defect directly impacts upon the severity of disease and 
clinical manifestations. This is evident in individuals with severe class I or class VII mutations 
where no protein (or mRNA with class VII) is produced causing complete abrogation of CFTR 
function (De Boeck and Amaral, 2016). These classes of mutation also pose therapeutic 
problems as there is no CFTR protein to target with small molecule correctors or potentiators. 
Carriers of a single mutated CFTR allele alongside a wild type CFTR allele remain 
asymptomatic, also indicating that 50% of wild type CFTR expression is enough to avoid a CF 
pathology. There are some reports that there is an increased prevalence of CFTR mutations in 
diseases such as idiopathic pancreatitis (Sosnay et al., 2013). The phenotypic expression of CF 
varies widely, even in patients with the same mutations. This may be attributable to both 
environmental factors and epigenetics (Brennan and Schrijver, 2016). 
 In order to describe the variations in the function of CFTR between mutations, it is 
necessary to understand the structure and function of the CFTR transmembrane protein. The 
CFTR gene is a member of the transport system ATP-binding cassette super-family. The CFTR 
protein functions as an anion channel for Cl- and HCO3-. The CFTR contains two sites that are 
able to bind and hydrolyse ATP, and also a series of transmembrane domains that form the 
channel in the plasma membrane (Figure 1.1.1). 
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 Figure 1.1.1: The CFTR and ENaC ion channels. The CFTR (cystic fibrosis transmembrane 
conductance regulator) has 5 domains: the TMBD (transmembrane domain) 1, which has six 
transmembrane peptides, the NBD (nucleotide binding domain) 1, which has ATP hydrolytic 
activity, the R (regulatory) domain, which as phosphorylation sites that control channel 
activity, followed by TMD2 and NBD2. When active the channel opens briefly to allow Cl- 
and HCO3- to efflux from the cell. The ENaC (epithelial Na+ channel) has 3 subunits and allows 
Na+ ion influx (Kim and Skach, 2012). 
 
The dysfunctional class III mutations (Table 1) weaken ATP hydrolysis, and the class 
IV mutations cause inferior Cl- conductance across the membrane. Other mutation classes 
affect the stability and structure of CFTR and result in diminished expression on the cell 
surface. This may be due to alterations in the CFTR gene, terminating transcription, or reduced 
protein stability due to atypical splicing or protein mis-folding in the endoplasmic reticulum 
(ER) (Ratjen et al., 2015). The varying levels of CFTR expression and function affect the 
successful cellular transport of Cl- ions, causing organ-specific manifestations. As CFTR is 
highly expressed in glandular epithelial cells, the primary organs affected by mutations in the 
CFTR are the lungs, pancreas, gastrointestinal tract and male reproductive system.  
Lung disease remains the most common cause of morbidity and mortality in patients 
with CF. This is a result of an absence or reduction in CFTR function, which predisposed 
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patients to recurrent pulmonary infections, airway inflammation and defective mucociliary 
clearance. Pulmonary colonisation and infections due to Staphylococcus aureus, Haemophilus 
Influenzae, Pseudomonas aeruginosa (P. aeruginosa)  and Burkholderia cepacia complex 
(BCC) are particularly common (Coutinho et al., 2008). Male infertility is a characteristic 
feature in the majority of males with CF and results from obstructive azoospermia due to ductal 
obstructions and reduced mucociliary transport (Cohen and Prince, 2012, Ratjen et al., 2015). 
Reduced bicarbonate efflux due to CFTR dysfunction contributes to highly adherent and 
viscous mucous. 
There is a wide variation in the phenotypic expression of CF which is largely due to the 
impact of the various genotypes on CFTR protein folding, quantity of functioning CFTR and 
the amount of stable CFTR, which is able to anchor to the cell surface (Mehta, 2005, Farinha 
et al., 2013). The CFTR is a glycoprotein expressed on the apical membrane of epithelial 
surfaces and is the only large adenine nucleotide-binding cassette (ABC) protein family 
member to act as an ion channel (Valdivieso and Santa-Coloma, 2013). The CFTR has two 
transmembrane domains (TMD) and two nucleotide-binding domains (NBD) in addition to a 
regulatory (R) domain (Kim and Skach, 2012). The R-domain contains phosphorylation sites 
that regulate the activity of the ion channel. It is the phosphorylation of the R-domain by protein 
kinase A (PKA) that allows the NBDs to interact, causing a conformational change within the 
TMDs, opening the channel. The CFTR does have ATPase activity that contributes to channel 
activity, but the hydrolysis of ATP does not seem to be required for channel opening (Collaco 
et al., 2013). The idea that the CFTR is able to function as an ATP channel is unfounded. 
Chloride ions (Cl-), glutathione and bicarbonate (HCO3) efflux through the active and open 
CFTR channel. In the presence of a mutated CFTR, the efflux of these anions is dysfunctional 
causing dysregulated hydration and control of pH at epithelial cell surfaces. The multisystem 
manifestations in CF are generated by this epithelial surface disruption. 
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Secondary functions of the CFTR protein exist in non-epithelial, non-polarised cells 
such as immune cells (Riordan, 2008). There is evidence that the CFTR has a role in 
phagocytosis and may contribute to poor clearance of pathogens in CF (Bonfield et al., 2012, 
Van de Weert-van Leeuwen et al., 2013). The CFTR is also considered to be a receptor for 
certain pathogens, such as Chlamydia trachomatis and Salmonella typhi (Pier et al., 1998), to 
gain entry into host cells. 
A lack of CFTR is also associated with certain downstream events that are thought to 
contribute to disease. Na+ influx is enhanced on epithelial surfaces in CF through the epithelial 
Na+ channel (ENaC). There is strong evidence that CFTR is able to inhibit ENaC activity 
through a variety of mechanisms, although the precise method of inhibition is unclear (Berdiev 
et al., 2009, Donaldson et al., 2002, Garcia-Caballero et al., 2009, König et al., 2002, König et 
al., 2001, Konstas et al., 2003, Kunzelmann, 2003, Mall et al., 2004). One potential mechanism 
is through a secreted protein that inhibits ENaC via its extracellular domains causing ag-
subunit internalisation, termed short palate and nasal epithelial clone 1 (SPLUNC1) (also 
known as Bactericidal/permeability-increasing fold-containing family A1 (BPIFA1)). 
SPLUNC1 is an allosteric inhibitor of ENaC and forms a complex with the b-subunit of ENaC 
whilst the ag-subunits are internalised (Kim et al., 2018). SPLUNC1 has been described as an 
innate defence protein capable of autocrine ENaC inhibition (Hobbs et al., 2013). SPLUNC1 
has bactericidal permeability increasing protein (BPI) structure that has been shown to be 
degraded by the high level of airway proteases, particularly neutrophil elastase in the CF and 
COPD airways (Jiang et al., 2013). The augmented Na+ absorption is responsible for the 
dehydration of the epithelial airway surface and accumulation of acidic mucous in CF (Riordan, 
2008). This fact is enforced by the CF mouse model that overexpresses b-chain of the ENaC 
channel and displays a comparable lung phenotype to human CF (Mall et al., 2004). 
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Recent publications have described the CFTR interactome, with the mutated DF508 
CFTR having distinctly different protein-protein interactions compared to wild-type (WT) 
CFTR (Pankow et al., 2015). Interesting changes in the CFTR interactome exist in metabolic 
pathways and evidence from other studies have described important mitochondrial dysfunction 
and altered calcium metabolism. This is important to the pathophysiology of CF as 
mitochondrial dysfunction will have knock-on effects on the clearance of airway pathogens. 
Examples of this are reactive oxygen species (ROS) generation, antioxidant secretion, and 
defects in autophagy in CF cells. All of these examples will make the airway environment more 
susceptible to oxidative damage in CF. 
As CFTR is a plasma membrane protein expressed on the surface of cells, once 
translated the peptide will follow the secretory pathway of protein trafficking to reach its 
destination and native conformation. However, this does not mean that the CFTR protein’s 
vigorous trafficking checkpoints finish at the Golgi apparatus. Farinha et al. propose five 
conformation checkpoints that the CFTR is required to pass in order to be successfully 
expressed on the cell surface (Farinha et al., 2013). The initial checkpoints are localized to the 
ER, where heat shock proteins check for basic CFTR conformation and protein folding. 
Calnexin examines the CFTR for correct glycosylation, in a second checkpoint. Once these 
two checkpoints are passed, the CFTR enters the secretory pathway, where two further 
checkpoints inspect CFTR for ER retention motifs and positive secretory signals such as di-
acidic (DAD) motifs. The final checkpoint that Farinha et al. describe involves chaperone 
attachment at the plasma membrane. Prolonged chaperone attachment to CFTR, due to 
incorrect CFTR docking or vesicle fusion to the plasma membrane, causes CFTR to be targeted 
for endocytosis. These chaperones include the Rab GTPases (Farinha et al., 2013). 
With the recent advances in knowledge of the ER export and folding of CFTR, new 
molecular therapies have been brought to the market for the treatment of CF. The Vertex® 
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Pharmaceutical drugs VX-770 (ivacaftor) (Wainwright et al., 2015) and VX-809 (lumacaftor) 
are used in combination (Orkambi) to treat certain genotypes of CF. VX-770 is a potentiator, 
that improves the transport of Cl- through the channel, keeping the CFTR permanently open 
via unconventional gating. VX-809 is a corrector that acts as a chaperone molecule, increasing 
the number of CFTR molecules (regardless of functionality) at the cell surface (Figure 1.1.2). 
There is no current cure for CF but new small molecule therapies are being developed to treat 
the underlying defect. Ivacaftor is approved for gating and residual function mutations and a 
combination of ivacaftor with either lumacaftor or tezacaftor for class III mutations (Table 1). 
Phase 2 results for triple therapy using VX-659 or VX-445 in combination with tezacaftor and 
ivacaftor have resulted in significant improvement in lung function and sweat Cl- in both 
patients homozygous and heterozygous to Phe508del	(https://investors.vrtx.com/) (Table 1). 
To date, gene therapy in CF has only been proof-of-principle, and CFTR gene expression has 
not been of the required efficiency to have a therapeutic benefit (Lee et al., 2005, Alton et al., 
2015). 
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Figure 1.1.2: Molecular targets of ivacaftor and lumacaftor. Vertex® Pharmaceutical drugs 
VX-770 (ivacaftor) and VX-809 (lumacaftor) are used in combination (Orkambi) to treat 
certain genotypes of CF. Ivacaftor is a potentiator, that improves the transport of Cl- through 
the channel, keeping the CFTR permanently open via unconventional gating. Lumacaftor is a 
corrector that acts as a chaperone molecule, increasing the number of CFTR molecules 
(regardless of functionality) at the cell surface by improving CFTR folding in the ER. CFTR- 
Cystic fibrosis transmembrane conductance regulator. 
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1.2 Inflammation in CF 
 
The body’s first line in defence from invading pathogens is the innate immune system. 
This refers to the myeloid-derived immune cells and anatomical barriers that are designed to 
combat and control constant pathogenic invasions from being established. The respiratory tract 
is a biological barrier that uses ciliated epithelial cells, resident macrophages and peripheral, 
migrating neutrophils and monocytes as the first line of airway defence (Whitsett and Alenghat, 
2015). In CF, airway dehydration, defective mucociliary transport, low pH levels of mucus, 
denaturing of defensins and impairment of granule trafficking in neutrophils and reduced 
bactericidal abilities of macrophages, all contribute to the inadequate clearance of respiratory 
infections (Ratjen et al., 2015, Bonfield et al., 2012, Bruscia and Bonfield, 2016a, Bruscia et 
al., 2009, Del Porto et al., 2011, Keiser et al., 2015, Lubamba et al., 2015, Downey et al., 2009, 
Hayes et al., 2011, Law and Gray, 2017, Machen, 2006, Ng et al., 2014, Painter et al., 2006, 
Pohl et al., 2014, Taylor et al., 2016, Watt et al., 2005). As a result, patients with CF develop 
recurrent pulmonary infections due to bacteria, fungi and viruses. The immunological status of 
CF lungs is pro-inflammatory, with continual release of reactive oxygen species (ROS), 
neutrophil extracellular traps (NETs) (Marcos et al., 2015), inflammatory cytokines and 
chemokines that all function in the recruitment of inflammatory immune cell subsets, such as 
the T Helper 17 (Th17) cell (Dubin et al., 2007). Further indications of airway inflammation in 
CF can be characterised by increased neutrophil infiltrations and an increase in related pro-
inflammatory cytokines, such as tumour necrosis factor (TNF), interleukin (IL)-6, IL-8  
(Greally et al., 1993) and IL-1b and IL-18 (Grassmé et al., 2014, Clauzure et al., 2014, 
Fritzsching et al., 2015, Iannitti et al., 2016, Levy et al., 2009, Reiniger et al., 2007, Rimessi et 
al., 2015). In addition, the anti-inflammatory cytokine IL-10 is decreased in CF bronchial 
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alveolar lavage (BAL) fluid compared to healthy controls (HC) (Bonfield et al., 1995). The 
multitudinous neutrophils within the CF lung create a perfect storm of inflammatory mediators, 
releasing oxidants, proteinases and DNA, which stimulate further release of inflammatory 
cytokines (Devaney et al., 2003). 
The origin or cause of this persistent pro-inflammatory state is debated: whether the 
recurrent infections maintain the inflammation or whether intrinsic dysfunction of the 
epithelium or immune cells predisposes effected organs to become inflamed, even when sterile. 
Both hypotheses are valid, with CF infants presenting with inflamed and infected lungs in early 
disease stage (Koehler et al., 2004) (Table 2). In favour of pathogen-led inflammation is the 
fact that macrophage phagocytosis is fully functional regardless of CFTR mutation (Del Porto 
et al., 2011). Additionally, haematopoietic cells have been observed as the major source of pro-
inflammatory cytokines in response to live bacteria, with airway epithelial cells responding 
weakly to microbial challenge in CF (Tang et al., 2012). This viewpoint attributes the origins 
of inflammation and its maintenance to indirect effects of the mutated CFTR on inflammatory 
pathways (Machen, 2006). Indirect mechanisms include increased acidification and oxidation 
of mucous in the airways, allowing the colonisation of pathogenic colonies and biofilm 
formation. In contrast, there are many examples of intrinsic defects related to CF, that could 
contribute to an augmented inflammatory state, including increased NF-kB activity 
(Venkatakrishnan et al., 2000, Weber et al., 2001), however this has been refuted (Tang et al., 
2012). Experimental studies have developed sterile murine models with an overexpression of 
the Na+ ion channel ENaC, causing a CF-like lung disease prior to infection, indicating an 
intrinsic CF-defect in which loss of CFTR-dependent ENaC inhibition induces mucous 
dehydration and inflammatory processes independent of infection (Mall et al., 2004). However, 
this animal model does not present with a disease that is truly representative of human CF due 
to the presence of fully functional CFTR. Irrespective of the basis of the inflammation, it is 
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agreed that the CF lungs are a highly inflammatory site, with many immune cell infiltrates and 
pro-inflammatory cytokines. 
 
1.3 The inflammasomes 
 
One of the most potent proinflammatory cytokines is IL-1b. It is part of a superfamily 
of cytokines denoted as the IL-1 cytokines, comprising seven pro-inflammatory members and 
four anti-inflammatory members (Palomo et al., 2015). An IL-1 cytokine will bind to its 
specific receptor from the IL-1 receptor (IL-1R) family, triggering co-receptor recruitment and 
downstream intracellular signalling. Due to the proinflammatory members’ highly potent 
inflammatory effects, IL-1 cytokines are highly regulated, by IL-1 antagonists, decoy receptors 
and a tight control over production and maturation of IL-1 cytokine release (Palomo et al. 
2015). One of the forms of cellular control over IL-1 cytokine production is a type of cellular 
rheostat, known as the inflammasomes (Martinon et al., 2002, Muruve et al., 2008, Tschopp 
and Schroder, 2010). Classical cytokine secretion involves gene transcription and translation 
of biologically active peptides that are secreted via the endoplasmic reticulum (ER)-Golgi 
pathway. However, IL-1 cytokines, specifically proinflammatory IL-1b and IL-18, are formed 
as inactive pro-peptides that require cleavage at their N-terminal and are secreted via a non-
classical pathway. The required cleavage is facilitated by inflammasomes, large multimeric 
protein structures, although proteinase-3, elastase and chymase have all been observed 
performing the required cleavage in myeloid cells (Palomo et al., 2015). Inflammasome 
formation is initiated when intracellular pattern recognition receptors (PRR) (Table 3), such as 
the AIM2-like receptor (ALR) and nucleotide-binding domain and leucine-rich repeat 
containing (NLR) receptor, detect pathogen associated molecular patterns (PAMPs) and danger 
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associated molecular patterns (DAMPs) (De Nardo et al., 2014). The inflammasome is utilised 
by myeloid cells primarily, as well as stromal epithelial cells that are capable of detecting 
pathogens using PRRs. Downstream signalling from PRRs upregulate inflammatory proteins 
in response to the detected PAMPs or DAMPs. A group of these inflammatory proteins is able 
to assemble into what is known as an inflammasome complex. The primary purpose of 
canonical and non-canonical inflammasomes is to cleave inactive pro-caspase-1 or pro-
caspases-4/-5 (pro-caspase-11 in mouse) respectively, into their active forms. When active, 
caspase-1 cleaves pro-IL-1 cytokines, whereas both capase-1 and caspases-4/-5 or -11 are 
capable of inducing cell pyroptosis, a type of controlled, inflammation-driven cell death 
(Bergsbaken et al., 2009, de Gassart and Martinon, 2015, He et al., 2015, Miao et al., 2010, 
Yang et al., 2015). However, there is evidence that caspases-4/-5 or -11 are required for IL-1b 
and IL-18 secretion in response to gram-negative bacterial PAMPs (Kayagaki et al., 2015). The 
recruitment of pro-caspases to an inflammasome requires large pro-caspase pro-domains, such 
as the caspase activation and recruitment domain (CARD) (Lamkanfi, 2011, Lamkanfi and 
Dixit, 2014). When recruited, pro-caspases develop enzymatic activity and mature into active 
caspases. The two members of the IL-1 family that are cleaved and activated by caspase-1 are: 
IL-1b and IL-18. IL-1b has a role in inducing T-cell differentiation into Th1 and Th17 cells, 
as well as aiding antibody production. Pro-IL-1b transcription is induced by NF-kB activity 
whereas pro-IL-18 is constitutively expressed in macrophages (Puren et al., 1999). When 
active, IL-18 is able to skew T-cells towards a Th17 subset and promotes pro-inflammatory 
IL-17 secretion (Palomo et al., 2015). Inflammasomes are characterised by the PRRs that form 
their scaffold and detects specific PAMPs or DAMPs. The AIM2 inflammasome contains the 
ALR PRR and the NLRP1, NLRP3 and NLRC4 inflammasomes contain the NLR PRR (Table 
3). There are other inflammasomes that have been described, such as the pyrin inflammasome, 
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but they are not as well characterised (Aubert et al., 2016). The Pyrin inflammasome is 
activated by bacterial modifications of Rho GTPases, such as the glucosyltransferase cytotoxin 
B secreted by C. difficile (TcdB) (Xu et al., 2014, Aubert et al., 2016, Park et al., 2016). This 
type of molecular pattern has been described as a homeostasis altering molecular process 
(HAMP) (Liston and Masters, 2017). NLRP2, NLRP6, NLRP7 and NLRP12 have also been 
described as orchestrating caspase-1 dependent IL-1b secretion but are not well characterised 
(Broz and Dixit, 2016, Lamkanfi and Dixit, 2014). 
A recent publication by He et al. described a new component of the inflammasome, 
gasdermin D (GSDMD) (He et al., 2015). GSDMD was found to have a role in IL-1b and IL-
18 secretion as well as pyroptosis. The authors suggest that GSDMD may function through the 
puncturing of holes in the cell surface, facilitating both cytokine secretion and pyroptosis. The 
authors also show that GSDMD has a role in suppressing apoptosis, favouring pyroptotic cell 
death (Kayagaki et al., 2015). Depending on the PRR at the basis of the inflammasome, 
different PAMPs and DAMPs will stimulate its formation. Inflammasomes are highly 
evolutionarily conserved within mammals, however drawing conclusions from animal models 
and relating the findings to human disease may be flawed, as inflammasome activation differs 
between species such as the structure and activity of the caspases between human and mouse, 
for example. 
The NLRP3 inflammasome has been characterised most comprehensively, as it is the 
basis of one of the monogenic autoinflammatory diseases, Muckle-Wells syndrome (MWS) 
(Agostini et al., 2004). Two signals are required to activate the NLRP3 inflammasome: (1) a 
signal that activates NF-kB transcription factor, which induces expression of NLRP3 
inflammasome components and IL-1b and IL-18, and (2) a signal that stimulates the activation 
of NLRP3 and the formation of the NLRP3 inflammasome (Figure 1.4.1) (Mathews et al., 
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2014). The range of activators for NLRP3 is broad, with a large variety of PAMPs and DAMPs 
from various sources able to trigger NLRP3 inflammasome assembly. It is therefore unlikely 
that NLRP3 is specific to all of the stimulants, and it has hence been hypothesised that NLRP3 
detects indirect cellular changes caused by the presence of the PAMP or DAMP (Table 3) (Shi 
et al., 2016). Mutations within the NLRP3 gene are responsible for the autoinflammatory 
disease MWS (Agostini et al., 2004). It was within this disease model that the relationship of 
NLRP3 and ASC was first described, with the mutation triggering constitutive NLRP3 
inflammasome activation and spontaneous IL-1b secretion from MWS macrophages. 
Autoinflammatory diseases are characterised by the activation of innate immune cells causing 
self-directed inflammation and tissue damage (McDermott, 2004, McDermott and 
Aksentijevich, 2002, McDermott et al., 1999, McGonagle and McDermott, 2006, Pathak et al., 
2016, Peckham et al., 2017, Savic et al., 2012). Autoinflammatory diseases are successfully 
treated using recombinant IL-1RA (Church et al., 2008) and are discussed further in section 
6.1. 
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Table 2:  Common pathogenic infections in CF. Pathogens that cause the most common/severe infections in CF (Killick et al., 2013, van 't Wout et al., 2015, 
Sutterwala et al., 2007, Blohmke et al., 2008, Coutinho et al., 2008, Kim and Lee, 2014, Kozutsumi et al., 1988, Stokes et al., 2016).  
 
 
 
TAXONOMIC RANK 
 
 
DESCRIPTION OF INFECTION 
 
 
PRR 
MYCOBACTERIUM 
SPECIES 
Bacteria Most commonly Mycobacterium avium. Has been associated with low Pseudomonas aeruginosa colonisation 
and therefore good prognosis. 
TLR-1, TLR-2, 
TLR-4, TLR-9, 
RIG-1, NOD2, 
DECTIN-1, 
Mannose receptor 
and DC-SIGN 
STAPHYLOCOCCUS 
AUREUS 
Bacteria Highly prevalent in children with CF, causing damage to airways and co-infect with Pseudomonas aeruginosa. TLR-2, TLR-1, 
TLR-6, TLR-7 and 
TLR-9 
PSEUDOMONAS 
AERUGINOSA 
Bacteria This gram-negative motile rod-shaped bacterium colonises approximately 50% of CF patients. It is an 
opportunistic member of the normal respiratory microbiota. Biofilms are commonly formed releasing alginate 
polymers, which facilitates antibiotic avoidance. 
TLR-2, TLR-4, 
TLR-5, TLR-9, 
NOD1, 
NLRC4/IPAF and 
CFTR 
BURKHOLDERIA 
CEPACIA 
Bacteria These gram-negative rod-shaped bacteria, thought to be passed on via oral transmission through kissing. It has 
a highly mutated genome, with high antibiotic resistance rates. It is also difficult to genotype due to difficulties 
in cell culture. 
TLR-4, TLR-5 
RESPIRATORY 
SYNCYTIAL VIRUS 
Paramyxovirus Major pathogen in children with CF. Increased epithelial damage and IL-18 secretion. Increased neutrophil 
infiltration and elastase release. 
TLR2, TLR-6, 
TLR-4, TLR-3, 
TLR-7, RIG-1, 
NOD2, NLRP3 
INFLUENZA Orthomyxovirus Major pathogen in older children and adults with CF. TLR-3, TLR-7, 
TLR-8, TLR-9, 
RIG-1, MDA5, 
NLRX1, IPS-1, 
NLRP3 
RHINOVIRUS Picornavirus Increased IL-8 and increased neutrophil myeloperoxidase. TLR2, TLR-7, 
TLR-8, RIG1, 
MDA5 
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1.4 Inflammasomes in CF 
 
 
Figure 1.4.1: The NLRP3 inflammasome. PAMPs (pattern associated molecular pattern) 
from pathogens will be recognised by the cell via innate immune receptors causing cytokine 
transcription and translation. DAMP (danger associated molecular pattern) such as ATP will 
open K+ channels and cause activation of the inflammasome components: LRR (leucine rich 
repeats), NACHT (NAIP, CIITA, HET-E and TP1) and PYD (pyrin domain). The NACHT 
domain becomes exposed and is removed from LRR auto-repression. The NLRP3 will then 
oligomerise and recruit ASC (apoptosis-associated speck-like protein containing a carboxy-
terminal CARD) via its CARD (caspase-recruitment domain) domain. ASC is then able to 
recruit pro-caspase 1 which auto-cleaves and becomes active. Active caspase is then able to 
cleave pro-IL (interleukin)-1B, pro-IL-18 and gasdermin D (GSDMD). The active IL-1B and 
IL-18 are then secreted, which is GSDMD (cleaved) dependent (based on (Tschopp and 
Schroder, 2010)).  
 
  
35 
  
INFLAMM
ASOME 
PRR SCAFFOLD 
PROTEINS 
CASPASE CYTOKINE 
RELEASED 
STIMULANT SPECIFIC 
PATHOGEN 
OTHER FUNCTIONS AND 
STIMULI 
AIM2 ALR p10, p20, 
CARD, PYD, 
ASC, HIN200 
Caspase-1 IL-18 
IL-1β 
Intracellular DNA Francisella tularensi; 
cytomegalovirus; 
Vaccinia virus; Listeria 
monocytogenes 
Links with systemic lupus 
erythematosus pathology 
NLRP1 NLR p10, p20, 
CARD, FIIND, 
NACHT 
Caspase-1 IL-18 
IL-1β 
Nlrp1 cleavage Lymphocytic 
choriomeningitis virus 
(LCMV); Bacillus 
anthracis 
LeTx toxin cleaves Nlrp1b in mouse 
models, suggesting this may be an 
important event in activation 
NLRP3 NLR p10, p20, 
CARD, PYD, 
ASC, NACHT 
Caspase-1 IL-18 
IL-1β 
Bacterial, viral and 
fungal PAMPs; 
Crystals, β-amyloid 
plaques, ATP, 
hyaluronan DAMPs 
Primarily detects LPS via 
TLR4 
Detect cellular changes associated with 
the presence of PAMPs and DAMPs. 
K+ ion efflux, mitochondrial 
translocation, ROS production, 
mtDNA, cathepsins and cardiolipin. 
Requires two signals 
NLRC4 NLR 
(Naip) 
p10, p20, 
CARD, 
NACHT 
Caspase-1 IL-18 
IL-1β 
Flagellin and bacterial 
T3SS and T4SS 
Salmonella Typhimurium, 
Shigella flexneri, 
Pseudomonas 
aeruginosa, Burkholderia 
thailandensis, and 
Legionella pneumophila  
Significant differences between mouse 
and human homologs. The murine Naip 
loci are highly polymorphic compared 
to the single human homolog. Nlrc4 
phosphorylation also is thought to 
activate this inflammasome 
Table 3: Canonical NLRP3 inflammasome components and stimulants.  ROS: reactive oxygen species, mtDNA: mitochondrial DNA (Cai et 
al., 2014, D'Osualdo et al., 2015, Fernandes-Alnemri et al., 2009, Grinstein et al., 2015, Hornung et al., 2009, Munoz-Planillo et al., 2009, Munoz-
Planillo et al., 2013, Yang et al., 2013a) 
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1.5 Mitochondrial metabolism 
 
 The study of mitochondrial metabolism has been dominated by the field of oncology, 
with advances in the understanding of how a cancerous cell is able to switch from oxidative 
phosphorylation (OXPHOS) to glycolysis (Bertaux et al., 2018, Wen et al., 2012, Khalid et al., 
2017). A cell primarily uses OXPHOS during a resting, senescent or memory state, which 
provides a cell with continuous, efficient, high-yield ATP production. Glycolysis on the other 
hand provides an active, effector cell with fast ATP production to carry out rapid cellular 
functions. A cancerous cell will utilise glycolysis, termed the Warburg effect, due to oncogene 
activation allowing the cell to proliferate quickly and migrate during metastasis, a cancer cell’s 
effector functions (Khalid et al., 2017). Metabolism has become a valid target for new 
generation chemotherapies, to target this distinct metabolic profile of cancerous cells. Figure 
1.5.1 summarises mitochondrial metabolism, with further details of the metabolic pathways in 
chapter 4.1.2. 
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Figure 1.5.1: Cellular metabolism- Glycolysis, TCA cycle and OXPHOS. Cellular 
metabolism takes place within the cytoplasm and mitochondria. Glucose is metabolised into 
pyruvate during glycolysis and transported into the mitochondria to fuel TCA cycle. 
Metabolites such as NADH and FADH produced by the intermediate TCA steps then fuel 
OXPHOS, which transports electrons across the mitochondrial inner membrane, termed the 
ETC. ADP- Adenosine di-phosphate; ATP- Adenosine tri-phosphate; TCA- The citric acid; 
ETC- Electron transport chain; NADH- Nicotinamide adenine dinucleotide (reduced form of 
NAD+); FADH- Flavin adenine dinucleotide. 
 
Immune cells also utilise glycolysis, or the Warburg effect, when activated into an 
effector phenotype (Norata et al., 2015, Everts et al., 2012, Lamkanfi, 2011, Tannahill et al., 
2013a, Wen et al., 2012). Therefore, measuring the activity of metabolic pathways can provide 
a marker of the inflammatory state of an immune cell population. Interestingly, recent 
publications in the field of immunometabolism have not only supported the metabolic profile 
of active or senescent immune cells but have made molecular links between the accumulation 
of certain metabolites during metabolic switching and downstream inflammatory pathway 
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activation (Buck et al., 2016, Kelly and O'Neill, 2015, Mills et al., 2016, Mills et al., 2017, 
Mills and O'Neill, 2016, Mills et al., 2018, O'Neill, 2016, O'Neill, 2015, Tannahill et al., 
2013b). Both systems, metabolism and inflammation, are inextricably linked and exist in a 
reciprocal relationship where one system’s activation or will influence the other and vice versa. 
These studies focus on the in vitro activation of the macrophage and elucidate the influence 
glycolysis in particular has on proinflammatory pathways such as the inflammasome. 
Immune cells, such as macrophages do not become resistant to insulin as they use the 
glucose transporter (GLUT) 1 (Macintyre et al., 2014, Tannahill et al., 2013a), which is 
independent of insulin control, whereas many other tissues such as muscle and adipose utilise 
the insulin-dependent GLUT4. This observation highlights the importance of glucose as a fuel 
for macrophage survival and effector function. The availability of glucose for macrophage 
metabolism is not limited by, or under the control of insulin. In the disease type-2 diabetes 
(T2D), insulin resistance is chronic and therefore macrophage glucose-dependent activation 
occurs. Notably, fatty acid oxidation decreases with glycolysis as adipose is created rather than 
metabolised as fuel (Wen et al., 2012).  
Mills et al describe how LPS stimulated M1-type macrophages switch to glycolytic 
metabolism, which also induces a subsequent break in the TCA cycle, causing an accumulation 
of certain metabolites specific to these break-points (Mills et al., 2017, Mills et al., 2016). The 
breakpoint at complex 2 (SDH), which converts succinate to fumarate as part of the TCA cycle 
(Figure 1.5.2), begins to oxidise succinate, which accumulates and induces reverse electron 
transport (RET). Electrons transfer from complex 2 to complex 1, increasing mitochondrial 
ROS (mROS) production by complex 1. mROS has been shown to induce the activation of 
transcription factor HIF1a. IL1b is a known transcriptional target of HIF1a. Inhibition of SDH, 
complex 1 or RET inhibits this HIF1a-induced IL1B expression. The glycolytic switch within 
myeloid cells in HIF1a knockout-mice is impaired, with reduced ATP and impaired 
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macrophage functions in anaerobic environments (Cramer et al., 2003). These investigations 
elucidated the mechanisms behind LPS induced M1-type macrophage activation, NLRP3 
inflammasome assembly and mROS production (Chouchani et al., 2014, Littlewood-Evans et 
al., 2016, Mills et al., 2016, Tannahill et al., 2013a). 
 
 
Figure 1.5.2: Glycolysis drives inflammation through succinate-dependent IL-1β 
production. LPS stimulated macrophages switch to glycolytic metabolism. A subsequent 
break in TCA cycle, causing an accumulation of specific metabolites at these break-points 
which have inflammatory consequences, such as HIF1a-dependent IL-1b expression. LPS- 
Lipopolysaccharide; TLR- Toll like receptor; ATP- Adenosine tri-phosphate; IL- Interleukin; 
HIF1a- hypoxia-inducible factor 1 alpha. 
 
 A second point in TCA cycle has been identified where metabolism and inflammation 
meet. In a resting or senescent cell isocitrate dehydrogenase converts citrate into succinate, 
instead of itaconate. M1-type macrophages prevent this conversion, allowing an accumulation 
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of itaconate. The accumulation of itaconate has been shown to have inhibitory effects on RET 
and SDH-dependent succinate oxidation. Pre-treatment of a soluble derivative of itaconate (4-
octyl itaconate) was able to also inhibit SDH in M1-type macrophages, inhibiting mROS-
driven IL1B expression in vitro and in vivo (Cordes et al., 2016, Lampropoulou et al., 2016, 
Mills et al., 2018). Interestingly, other SDH inhibitors did not activate the anti-inflammatory 
transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) in macrophages, whereas 
itaconate at its derivative did. NRF2 induces an anti-inflammatory program in macrophages by 
inducing antioxidants. The authors observed that the known NRF2 regulator, kelch-like ECH-
associated protein 1 (KEAP1) binds to NRF2 and targets it for proteasomal degradation. 
Itaconate and fumarate, a similar metabolite, were found to inhibit KEAP1 via novel covalent 
modifications, known as dicarboxypropylation, such as multiple alkylations on multiple 
cysteines and a lysine. Itaconate’s post-translational upregulation of NRF2 decreased IL-1b 
and HIF1a but not TNF or NF-kB. Therefore, itaconate can be considered an anti-
inflammatory metabolite promoting cell survival through prevention of chronic oxidative stress 
and subsequent inhibition of specific proinflammatory cytokine expression (Cordes et al., 
2016, Lampropoulou et al., 2016, Mills et al., 2018). 
It is clear that not only is metabolism a marker of inflammation in immune cells, but 
that the two systems regulate one another, contributing to the other’s activity and fate. 
 
1.6 Current therapies for CF 
  
 Commonly used treatments for CF target the inflammation and infection in the lung as 
well as the comorbidities associated with CF (© Cystic Fibrosis Trust Registered Charity No. 
(England and Wales) 1079049, 2018). Various oral and nebulised antibiotics are used on a 
daily basis to reduced pulmonary exacerbations, decline in lung function and improve quality 
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of life. Anti-inflammatory agents such as low dose macrolides steroids and high dose NSAID 
are also used   (Coutinho et al., 2008). Mucolytic agents such as DNase and hypertonic saline 
help improve mucociliary clearance (Elborn, 2016). Pancreatic malabsorption is common in 
CF with pancreatitis occurring in some patients with pancreatic sufficiency. As a result, many 
patients have malabsorption and require pancreatic enzyme replacement. Nutritional 
requirements are increased in CF, in part due to malabsorption. As a result, patients are 
prescribed a high calorie and high-fat diet with pancreatic enzyme and fat-soluble vitamin 
supplementation. Gastrointestinal complications such as distal intestinal obstruction syndrome 
is also relatively common.  
Despite treatments, patients with CF will often deteriorate due to progression of 
bronchiectasis and lung damage. Suitable patients with end-stage lung disease can be 
considered for lung transplantation, which carries a 50%, 10-year survival. The median age of 
patients with CF in the UK is 20 years with predicted life expectancy  for people born between 
2012-2016 increasing to 47-years old, (Jeffery, 2017). This is a huge improvement from 40-
years ago when individuals with CF died in infancy. However, the median age of death remains 
around 30 years of age, with a significant number of younger patients still dying.  In addition, 
median life expectancy does not consider the intensity of treatment and the impact of CF on 
quality of life. Additionally, to prevent cross-infection, patients with CF are isolated from other 
individuals with CF, as they are at a particular risk of spreading the specific infections (Table 
2) that colonise the CF lung (Duff, 2002). This creates a painful and somewhat lonely existence 
where it can be difficult to share experiences face-to-face with fellow patients with CF. To date 
ivacaftor is the only highly efficacious drug available to treat CFTR dysfunction in patients 
with CF. Treatment is limited to gating and residual function mutations and can result in 
significantly increases life-expectancy and quality of life. 
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New therapies are in the pipe-line, including more advanced small molecules and gene 
therapies, discussed in section 5.1 in detail. 
 
1.7 Targeting autoinflammation- current therapeutics 
 
 Established biologic therapies are now in use for highly efficacious treatment of 
autoinflammatory diseases (sections 1.3 and 6.1). These biologics target IL-1b through IL-1 
blockade with either an anti-IL-1b antibody (canakinumab) or a recombinant, soluble receptor 
antagonist, IL-1Ra (anakinra) (Dinarello et al., 2012, Dinarello and van der Meer, 2013, 
Hawkins et al., 2003, Palomo et al., 2015, Schlesinger, 2014). The majority of patients with 
diagnosed systemic autoinflammatory disease (SAID) benefit from IL-1 blockade, with 
evidence that many undiagnosed or undifferentiated SAID (uSAID) patients would also benefit 
from IL-1 blockade and anakinra may prove useful for diagnosing uSAID patients (Harrison 
et al., 2015). 
 
1.8 Targeting metabolism- current therapeutics 
 
 As previously discussed, metabolism and inflammatory responses are inextricably 
linked with metabolic reprogramming occurring synchronously with activation of 
inflammatory pathways and differentiation into proinflammatory phenotypes (Bettencourt and 
Powell, 2017). Metabolism is therefore a possible therapeutic target that has significant 
potential. In addition to being able to target the inflammatory response, metabolism is 
differentially active in proinflammatory, and potentially pathogenic immune cells providing a 
degree of selectivity with non-specific small molecule administration. Further selectivity exists 
between innate and adaptive immune cells in terms of the metabolic pathways used for distinct 
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types of activation in the two arms of the immune system. Theoretically, innate immune-driven 
autoinflammation can be specifically targeted using small molecule drugs against metabolic 
pathways and metabolites. 
 Elevated glycolysis is a common feature of both innate and adaptive immune cell 
activation. Innate immune cells use this type of rapid ATP production to induce responsive 
cytokine secretion and phenotypic functions such as chemotaxis and phagocytosis. This was 
shown by reduced IL-1b secretion when the glycolytic enzyme hexokinase was inhibited with 
the small molecule with 2-deoxy-glucose (2DG), but TNF was not supporting the fact that 
metabolism is a dynamic and complex system that can be specifically and accurately targeted 
for specific therapeutic goals (Mills et al., 2016, Mills et al., 2017, Mills and O'Neill, 2016, 
Mills et al., 2018). The effects of 2DG are most likely due to the prevention of succinate 
accumulation, limiting succinate’s role in modulating HIF1a-dependent innate immune 
inflammatory pathways, which has been extensively descried in section 1.4. Further evidence 
that innate immune inflammation can be targeted specifically by disturbing metabolic networks 
with small molecules exists with ROS. NO is elevated during glycolysis, with effects on the 
inhibition of OXPHOS, activation of NLRP3 and bacterial killing (Mills et al., 2017). 
Treatment with metformin, a drug that activates AMPK and has been used in diabetes is able 
to decrease ROS production specifically. Itaconate has been recently described as an anti-
inflammatory metabolite (section 1.4) that functions by competitive inhibition of succinate 
dehydrogenase (SDH). 
 By using the above molecules to inhibit key points in innate immune cell metabolism, 
not only will proinflammatory innate immune cells be inhibited but anti-inflammatory immune 
cells may be promoted. M2-type macrophages are characterised as anti-inflammatory 
macrophages and typically use OXPHOS rather than glycolysis that proinflammatory M1-type 
macrophages employ. In addition, the use of ROS, succinate and HIF1a-dependent IL-1b 
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secretion are pathways that are specific to the innate immune system and therefore their 
inhibition would not, theoretically effect adaptive immune cells.  
 
 
1.9 Hypotheses 
 
The following hypotheses were formulated based on the current literature and clinical 
observations made at Cystic Fibrosis Adult Ward, St James Hospital, Leeds. 
 
1.9.1 List of Hypotheses 
 
1. A proinflammatory, innate immune-driven, cytokine signature exists in vivo and in 
vitro in patients and cells with CF-associated mutations that is associated with 
inflammasome activation. 
2. The NLRP3 inflammasome is hyper-responsive in cells with CF-associated mutations 
due to intrinsic CFTR-dependent defects. 
3. Immune cells with CF-associated mutations have a proinflammatory phenotype, 
characterised by cytokine secretion, cell surface markers and active metabolic 
pathways. 
4. Modulating the intrinsic CFTR-dependent defect with small molecules ivacaftor and 
lumacaftor regulates the proinflammatory phenotype of cells with CF-associated 
mutations. 
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1.9.2 Aims and Objectives 
 
Hypothesis 1: 
a. To establish the serum cytokine signature from patients with CF-associated mutations 
in comparison to healthy control (HC), non-CF bronchiectasis (NCFB) and SAID 
cohorts. 
b. To establish the secreted, in vitro cytokine signature from monocytes from patients with 
CF-associated mutations in comparison to HC, NCFB and SAID cohorts, as well as 
human bronchial epithelial cell (HBEC) lines with and without CF-associated 
mutations. 
c. To understand whether the inflammatory response/signature in CF is dependent on 
CFTR intrinsic defects by the use of small molecule inhibition of multiple ion channels 
known to be pathogenic in CF. 
 
Hypothesis 2: 
a. To establish the activity of multiple inflammasomes (including NLRP3) in monocytes 
from patients with CF-associated mutations in comparison to HC, NCFB and SAID 
cohorts, as well as HBEC lines with and without CF-associated mutations. 
b. To characterise the inflammatory phenotype of monocytes from patients with CF-
associated mutations in comparison to HC, NCFB and SAID cohorts, by cytokine 
secretion and cell surface markers. 
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Hypothesis 3: 
a. To characterise the inflammatory phenotype of monocytes from patients with CF-
associated mutations in comparison to HC, NCFB and SAID cohorts, as well as HBEC 
lines with and without CF-associated mutations by the activity of metabolic pathways. 
b. To explore whether inhibition of certain metabolic pathways can modulate 
inflammatory cytokine secretion in monocytes from patients with CF-associated 
mutations in comparison to HC, NCFB and SAID cohorts, as well as HBEC lines with 
and without CF-associated mutations. 
 
Hypothesis 4: 
a. To explore whether ivacaftor and lumacaftor can modulate inflammatory cytokine 
secretion in monocytes from patients with CF-associated mutations in comparison to 
HC, NCFB and SAID cohorts, as well as HBEC lines with and without CF-associated 
mutations. 
b. To explore whether ivacaftor and lumacaftor can modulate metabolism in PBMCs from 
patients with CF-associated mutations over 3-months.  
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Chapter 2 
 
2.0 Materials and Methods 
 
2.1 Patient Cohorts 
 
Patients with cystic fibrosis (CF) were recruited from the Adult Cystic Fibrosis Unit at 
St James’s University Hospital, Leeds. All patients had two disease-causing CFTR mutations 
and clinical features consistent with the diagnosis of CF. (F508del/F508del, n = 34; 
F508del/c.1521_1523delCTT, n =3; 3849+10KB C>T/F508del, n=1; c.1040G>C/R347P, n=1; 
F508del/621+1 (G>T), n=1) (table 4). 
We saw no statistically significant difference in terms of serum cytokines between 
stable patients (n=14) and those who had acute arthritis or infection (n=26). Patients included 
in Figs 2-4 were all F508del/F508del with no sign of infection. Patients with NCFB and SAID 
were recruited from the Leeds Regional bronchiectasis unit and Department of Clinical 
Immunology and Allergy, respectively. All patients with a SAID had characterised mutations 
in a known disease-causing gene (TRAPS n=2, Muckle-Wells n=2, A20 haploinsufficiency 
n=1, PAAND n=1, MEFV n=2, FMF n=2, HIDS n=2 and Schnitzler syndrome n=1). Age and 
sex matched healthy controls were recruited from the research laboratories at the Wellcome 
Trust Benner Building, St James’s University Hospital, Leeds, UK. 
All patient samples collected are approved by the Health Research Authority REC 
reference 17/YH/0084. All patients enrolled on this study provided their full consent for their 
samples to be used for research purposes, detailed in the above REC reference. 
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(mmol/
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FEV
1 
l/s 
FEV
1 
(%) 
Weig
ht 
(kg) 
BMI 
(kg/m
2) 
Anti-
inflammatory 
Medication 
Antibiotics CRP  Active Joint 
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Bacteria CFA 
diagnosis 
ever 
CFR
D 
Figures 
CF00
1 
F 27 Phe508del/Phe508
del 
N/A 1.23 47 47.3 18.4 Azithromycin 500 
mg 3-times a 
week  
Elective IV 
antibiotics / 
mild 
exacerbation 
started on 
13/07/2015 
Tigecycline 
and 
Meropenem 
for 2 weeks 
8.7 Joint pain in 
right hip 
and left 
shoulder the 
previous 
week. 
Asymptoma
tic at time 
of bloods.  
 
Stenotrophomo
nas maltophilia 
Yes  No 3.3.1.1 
3.3.4.1 
CF00
2 
M 24 Phe508del/Phe508
del 
N/A 0.64 15 51.2 16.6 None None 17.5 None Chronic 
Pseudomonas 
aeruginosa 
No No 3.3.1.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
CF00
3 
M 26 Phe508del/Phe508
del 
N/A 1.48 35 63.6 21.3 None Start of iv 
antibiotics 
14/07/2015. 
IV 
Aztreonam 
and 
temocillin  
140 Some 
aching in 
knee joints 
but no clear 
CFA 
Bcc - 
multivorans 
Yes  No 3.3.1.1 
3.3.4.1 
3.6.1 – 
3.6.2 
3.7.1.1 
CF00
4 
M 38 Phe508del/Phe508
del 
N/A 1.38 36 57.5 19.6 None Ending IV 
antibiotics 
23/06/2015 
to 
20/07/2015. 
Ceftazidime, 
colomycin 
and 
teicoplanin 
8.3 None Chronic 
Pseudomonas 
aeruginosa 
Yes  Yes 3.3.1.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
3.6.1 – 
3.6.2 
3.7.1.1 
Append
ix 
Figure 5 
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CF00
5 
M 31 Phe508del/Phe508
del 
N/A 2.2 63 81.5 28.9 Azithromycin 500 
mg 3-times a 
week / 
methotrexate  
Start of IV 
antibiotics. 
Blood pre-
dose. Chest 
symptoms 
and joint 
pain  
<5 Active joint 
pain 
Chronic 
Pseudomonas 
aeruginosa 
Yes. 
Rheumato
id Arthritis 
No 3.3.1.1 
3.3.4.1 
CF00
6 
M 21 Phe508del/Phe508
del 
N/A 1.67 38 49.8 15.9 None Started IV 
antibioitcs 
with mild 
pulmonary 
exacerbation
. Colomycin 
and 
Aztreonam 
IV 
22 Vasculitic 
rash lower 
limbs 
Chronic 
Pseudomonas 
aeruginosa 
Yes No 3.3.1.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
3.6.1 – 
3.6.2 
3.7.1.1 
CF00
7 
F 21 Phe508del/Phe508
del 
N/A 0.62 19 46.3 17.0 Azithromycin 500 
mg 3-times a 
week 
Pulmonary 
exacerbation 
on 
meropenem 
and 
Tobramycin 
46 None Chronic 
Pseudomonas 
aeruginosa 
Yes No 3.3.1.1 
3.3.4.1 
CF00
8 
M 34 Phe508del/Phe508
del 
N/A 3.28 79 70.0 22.1 None None Not 
availabl
e 
Wrist and 
back pain 
Chronic 
Pseudomonas 
aeruginosa 
Yes No 3.3.1.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
CF00
9 
F 39 Phe508del/Phe508
del 
N/A 1.31 45 64.3 24.1 Montelukast - 
hydroxychloroqui
ne - azithromycin 
500 mg 3-times a 
week 
Start iv 
antibiotics 
on 
35/07/2015 
for 
pulmonary 
exacerbation 
Teocoplanin 
/ 
meropenem 
/ tobramycin  
<5 Joint pain 
elbow, 
wrists, hips, 
knees 
Chronic 
Pseudomonas 
aeruginosa 
Yes Yes 3.3.1.1 
3.3.4.1 
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CF01
0 
M 20 Phe508del/Phe508
del 
N/A 1.96 49 39.4 13.6 None Admitted 
1/8/2015 
with 
pulmonary 
exacerbation 
meropenem 
tobramycin 
cotrimoxazol
e  
140 None Achromobactin, 
mycobacterium 
abscessus 
No Yes 3.3.1.1 
3.3.4.1 
CF01
1 
F 41 Phe508del/Phe508
del 
N/A 1.53 49 83.4 28.5 Azithromycin 500 
mg 3-times a 
week. 
Prednisolone 
started on 
16/9/2018 30 mg 
Start of IV 
antibiotics 
on 
16/9/2015 
Tobramycin 
and 
ceftazidime 
<5 Knee and 
small joint 
pain 
Chronic 
Pseudomonas 
aeruginosa 
Yes Yes 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.6.1 – 
3.6.2 
3.7.1.1 
Append
ix 
Figure 5 
 
CF01
2 
M 33 Phe508del/Phe508
del 
N/A 1.23 29 78.0 24.7 None Pulmonary 
exacerbation 
and started 
tobramycin 
and 
meropenem 
on 
14/07/2015 
286 None Chronic 
Pseudomonas 
aeruginosa 
No Yes 3.3.1.1 
3.3.3.1 
3.3.4.1 
CF01
3 
F 22 Phe508del/Phe508
del 
86 2.58 80 54.3 20.4 Azithromycin 500 
mg 3-times a 
week 
Admitted 
20/9/2015 
tobramycin 
and 
ceftazidime 
mild 
pulmonry 
exacerbation 
15.2 Joint pain 
throughout 
the body 
especially 
hips 
Chronic 
Pseudomonas 
aeruginosa 
No No 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.6.1 – 
3.6.2 
3.7.1.1 
Append
ix 
Figure 5 
 
CF01
4 
F 33 Phe508del/Phe508
del 
N/A 1.52 56 51.9 21.2 None Course of 
antibiotics 
colomycin 
and 
meropenem 
8.4 Joint pain in 
knees and 
ankles 
Chronic 
Pseudomonas 
aeruginosa 
No Yes 3.3.1.1 
3.3.3.1 
3.3.4.1 
Append
ix 
Figure 5 
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CF01
5 
M 23 Phe508del/Phe508
del 
N/A 3.57 85 74.8 25.1 Montelukast None   No joint 
pain 
Achromobactin, 
mycobacterium 
abscessus 
No No 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
CF01
6 
F 50 Phe508del/Phe508
del 
111 2.25 90 65.7 25.7 Ibuprofen None <5 Palindromic 
joint pain - 
all joints 
Intermitted 
Pseudomonas 
aeruginosa 
Yes No 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
CF01
7 
F 19 Phe508del/Phe508
del 
100 2.48 86 46.2 19.3 None End home IV 
antibiotics 
on 
19/01/2016 
meropenem 
and 
colomycin  
<5 Joint pain 
affecting 
wrists, 
fingers and 
knees. 
Often 
exacerbated 
by IV 
antibiotics 
Chronic 
Pseudomonas 
aeruginosa 
Yes No 3.3.1.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
3.6.1 – 
3.6.2 
3.7.1.1 
4.3.1- 
4.6.2 
Append
ix 
Figure 5 
 
CF01
8 
F 25 Phe508del/Phe508
del 
116 1.13 35 47.9 17.9 Ibuprofen, 
Azithromycin 500 
mg three times a 
week  
None 37 Joint pains 
hands 
fingers, 
neck, spine 
Chronic 
Pseudomonas 
aeruginosa 
Yes Yes 3.3.1.1 
3.3.3.1 
3.3.4.1 
CF01
9 
M 25 Phe508del/Phe508
del 
N/A 2.71 63 68.0 22.6 Montelukast Admitted for 
IV antibiotics 
21/01/2015 
Fosfomycin 
and 
tobramycin  
47 Ankles, 
knees wrist, 
shoulders 
Chronic 
Pseudomonas 
aeruginosa 
Yes Yes 3.3.1.1 
3.3.4.1 
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CF02
0 
F 23 C.1521_1523delctt
/ Phe508del 
N/A 2.16 70 55.8 21.8 None End of IV 
antibiotics 
Tigecycline 
Tazocin and 
tobramycin 
started 
11/01/2016. 
Tazocin rash 
on 
26/01/2015 -
allergy 
58 Arthralgia 
on 
admission 
but resolved 
Bcc - 
multivorans 
No No 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
3.6.1 – 
3.6.2 
3.7.1.1 
4.3.1- 
4.6.2 
CF02
1 
F 45 Phe508del/Phe508
del 
N/A 1.52 60 58.4 23.4 Post lung 
transplant 
Methotrexate 
prednisolone 
tacrolimus  
None 25 Active joint 
pain 
Chronic 
Pseudomonas 
aeruginosa 
Yes Yes 3.3.1.1 
3.3.4.1 
CF02
2 
M 46 Phe508del/Phe508
del 
85 0.94 27 62.9 22.3 Azithromycin 500 
mg 3-times a 
week 
Influenza-A 
IV colomycin 
and 
tigecycline 
4/2/2015 / 
Tamiflu 
261 None Stenotrophomo
nas maltophilia 
Yes No 3.3.1.1 
3.3.3.1 
3.3.4.1 
CF02
3 
F 37 Phe508del/Phe508
del 
N/A 0.76 26 56.7 21.1 Prednisolone 5 
mg 
26/2/2016 
started 1/12 
meropenem 
and 
aztreonam.     
8.6 Active joint 
pains 
affecting 
most joints 
Chronic 
Pseudomonas 
aeruginosa 
Yes No 3.3.1.1 
3.3.4.1 
3.6.1 – 
3.6.2 
3.7.1.1 
CF02
4 
F 28 Phe508del/Phe508
del 
N/A 0.6 21 57.9 26.0 Azithromycin 500 
mg 3-times a 
week 
IV antibiotics 
started on 
12/2/2016 
Colomycin 
and 
Fosfomycin. 
Fever 
109 Aching 
joints knees, 
hips and 
wrists 
Chronic 
Pseudomonas 
aeruginosa 
Yes Yes 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.6.1 – 
3.6.2 
3.7.1.1 
4.3.1- 
4.6.2 
CF02
5 
M 51 3849+10KB C>T/ 
Phe508del 
50 0.56 16 92.4 32.3 None  IV for 
pulmonary 
exacerbation 
9/2/2016 
Ceftazidime 
Teicoplanin 
51 None Stenotrophomo
nas maltophilia, 
Staphylococcus, 
Haemophilus 
No No 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
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3.8.1.1 
– 
3.9.3.2 
4.3.1- 
4.6.2 
CF02
6 
F 20 Phe508del/Phe508
del 
115 1.21 39 59.2 23.1 Clarithromycin 
(part of NTM 
treatment), 
prednisolone 15 
mg  
Cefoxitin 3-
times a 
week, 
clarithromyci
n, linezolid 
5.5 Joint pains Mycobacterium 
abscessus and 
steotrophomona
s maltophilia 
Yes No 3.3.1.1 
3.3.3.1 
3.3.4.1 
3.6.1 – 
3.6.2 
3.7.1.1 
3.8.1.1 
– 
3.9.3.2 
CF02
7 
M 38 Phe508del/R347P N/A 0.68 17 72.8 23.0 Montelukast IV 
Fosfomycin 
and 
aztreonam 
42 None Chronic 
pseudomonas 
No Yes 3.3.1.1 
3.3.4.1 
CF02
8 
F 43 Phe508del/Phe508
del 
N/A 0.54 21 51.5 20.1 Hydroxychloroqui
ne  
Fosfomycin 
and 
meropenem 
69 Joint pain Chronic 
pseudomonas 
Yes Yes 3.3.1.1 
3.3.2.1 
3.3.4.1 
CF02
9 
M 30 Phe508del/Phe508
del 
N/A 0.69 17 57.4 19.9 None Meropenem, 
temocillin, 
tigecycline 
66 None Burkholdeeria 
multivorans 
No No 3.3.1.1 
3.3.2.1 
3.3.3.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
CF03
0 
M 31 Phe508del/Phe508
del 
N/A 0.74 17 65.2 20.1 Azithromycin 500 
mg 3-times a 
week 
Pre orkambi 
IV imipenem 
and 
tobramycin 
9-16/5/2016 
27 None Chronic 
pseudomonas 
maltophilia 
No Yes 3.3.1.1 
3.3.2.1 
3.3.4.1 
CF03
1 
F 36 Phe508del/Phe508
del 
N/A 0.86 35 55.1 23.2 Azithromycin 500 
mg 3-times a 
week 
Pre orkambi 
and post IV 
ceftazidime 
9/6/2016 
<5 None Chronic 
pseudomonas, 
maltophilia 
No Yes 3.3.1.1 
3.3.2.1 
3.3.4.1 
CF03
2 
M 31 Phe508del/Phe508
del 
N/A 0.94 24 59.2 21.0 Azithromycin as 
part of NTM 
treatment 
Pre orkambi. 
NTM 
treatment 
oral 
moxifloxacin
, minocycline 
and 
azithromycin 
13.1 None Mycobacterium 
abscessus, 
intermittent 
pseudomonas, 
stenotrophomo
nas  
No No 3.3.1.1 
3.3.2.1 
3.3.4.1 
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CF03
3 
F 41 Phe508del/Phe508
del 
N/A 0.6 25 46.4 20.0 None Pre-orkambi 
no IV 
antibiotics 
11.9 None Chronic 
pseudomonas 
No Yes 3.3.1.1 
3.3.2.1 
3.3.3.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
4.3.1- 
4.6.2 
CF03
4 
M 34 Phe508del/Phe508
del 
N/A 1.85 43 76.8 23.4 Hydrocortisone 
oral Naproxen  
IV 
ceftazidime 
<5 Joint pain in 
hands and 
knees 
Chronic 
pseudomonas 
Yes No 3.3.1.1 
3.3.2.1 
3.3.3.1 
3.3.4.1 
CF03
5 
M 22 Phe508del/621+1 
(G>T) 
N/A 1.43 0 55.1 19.3 Montelukast, 
Azithromycin 500 
mg 3-times a 
week 
IV colomycin 
and 
meropenem. 
long term 
ceftazidime.  
31 Joint pains 
shoulder 
hips back 
Chronic 
pseudomonas 
stenotrophomo
nas maltophilia 
Yes Yes 3.3.1.1 
3.3.2.1 
3.3.3.1 
3.3.4.1 
4.3.1- 
4.6.2 
CF03
6 
M 29 C.1521_1523delctt
/ Phe508del 
105 1.18 27 57.3 18.7 Azithromycin 500 
mg 3-times a 
week 
Pre-start of 
Orkambi and 
on last few 
days of IV 
antibiotics. 
Colomycin 
and tazocin 
<5 None Chronic 
pseudomonas 
and 
achromobactin 
No No 3.3.2.1 
3.3.1.1 
3.3.3.1 
3.3.4.1 
3.4.1.1 
– 
3.5.2.1 
3.8.1.1 
– 
3.9.3.2 
CF03
7 
M 40 Phe508del/Phe508
del 
120 1.16 31 56.8 20.0 Prednisolone 10 
mg 
Pulmonary 
exacerbation
. Colomycin, 
ciprofloxacin 
and septrin. 
140 Joint pain Achromobactin Yes No 3.3.1.1 
3.3.2.1 
3.3.3.1 
3.3.4.1 
4.3.1- 
4.6.2 
CF03
8 
F 41 Phe508del/Phe508
del 
N/A 0.62 0 47.9 20.7 Naproxen 250 mg 
Prednisolone 10 
mg 
Admitted for 
IV 
ceftazidime 
2 g 
2/11/2017 
and 
43 Joint pain. 
Small and 
large joint. 
Variable 
Chronic 
Burkholderia 
cenocepacia 
Yes Yes 3.3.3.1 
3.3.4.1 
4.3.1- 
4.6.2 
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nebulised 
Azli 
CF03
9 
M 36 Phe508del/Phe508
del 
N/A 1 0 58.0 20.8 Azithromycin 500 
mg 3-times a 
week 
Pre-orkambi.  <5 None Chronic 
burkholderia 
multivorans 
No Yes 3.3.3.1 
3.3.4.1 
4.3.1- 
4.6.2 
CF04
0 
M 28 Phe508del/Phe508
del 
N/A 0.95 0 48.3 16.0 Azithromycin 500 
mg 3-times a 
week 
Aztreonam 
and 
tobramycin  
31 None Chronic 
Pseudomonas 
aeruginosa 
No No 3.3.3.1 
3.3.4.1 
4.3.1- 
4.6.2 
Table 4: Available patient information form the CF cohort recruited to this study. Details of study code, genotype, anti-inflammatory 
medication, exacerbation status study code, gender, age, genotype, sweat chloride (mmol/l), FEV1 l/s, FEV1 (%), weight (kg), BMI (kg/m2), anti-
inflammatory medication, antibiotics, C-reactive protein (CRP), active joint symptoms, bacteria, cystic fibrosis arthritis (CFA) diagnosis, cystic 
fibrosis related diabetes (CFRD) and which figures within this study the patient’s samples and data are included. The clinical information was 
provided by the clinical team at St James Hospital Adult CF ward, Leeds.
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2.2 Patient Sample Processing 
 
Patient blood (50mL) were collected using 9mL Vacuette tubes (Greiner-bio-one) 
containing either clot activator or K3EDTA. Blood in clot activator tubes were allowed to clot 
for 60 min followed by centrifuging at 1000xg for 10 min. Sera were collected into 1mL tubes 
for storage at -80oC. Blood collected in K3EDTA tubes were used for peripheral blood 
mononuclear cell (PBMC) isolation. EDTA treated blood were mixed with Phosphate-buffered 
saline (PBS) in a 1:1 ratio, carefully layered onto 13mL of Lymphoprep® (Axis-Shield) in 
50mL Falcon tubes and centrifuged at room temperature, 1100xg for 20 mins without brakes. 
The PBMCs ‘buffy layer’ on top of the Lymphoprep® layer was extracted and washed in 3x 
volume PBS. PBMCs were passed through Miltenyi MS magnetic columns using the Miltenyi 
Monocyte isolation kit II to isolate peripheral monocytes. Isolated monocytes plated in 6 well 
plates, seeded at 1x106 cells/mL/well in 1mL RPMI complete medium (Sigma) (supplemented 
with 10% (v/v) foetal bovine serum (FBS) (Gibco), 50 IU/ml penicillin, and 50 g/ml 
streptomycin (Sigma)). 
 
2.3 Cell Lines 
 
All cells were cultured in sterile conditions, using aseptic technique in a category two 
tissue culture hood and incubated in a humidified incubator at 37oC in 5% CO2 atmosphere. 
Four Human Bronchial Epithelial (HBE) cell lines were used: IB3-1 cells (a kind gift from 
Professor Eric Blair, Leeds, UK) with the CF mutation ∆F508/W1282X, CuFi-1 
∆F508/Phe508del (ATCC® CRL-4013TM), CuFi-4 ∆F508/G551D (ATCC® CRL-4015TM) 
and Beas-2B cells (ATCC® CRL-9609TM), the latter derived from a healthy control (HC), 
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and shown to express a full range of toll like receptors (TLR), including TLR4 (Ioannidis et al. 
2013). IB3-1 and Beas-2B cell lines were cultured in basal LHC medium (Thermo Fisher 
Scientific) (supplemented with 10% (v/v) FBS (Gibco), 50 IU/ml penicillin, and 50 g/ml 
streptomycin (Sigma)). CuFi-1 and CuFi-4 cells were cultured in supplemented BEGM bullet 
kit (CC-3170, Lonza). The differential growth media formulations are optimised to ensure no 
significant differences in inflammation due to the growth media in appendix figure 11. All 
HBE cells were cultured in vented, positively charged T75 C+ flasks (Sarstedt), to promote 
adherence, until they reached 90% confluency. Once confluent, HBE cells removed from the 
flask using 0.5% trypsin (Sigma) for 10 min at 37oC. The trypsin was neutralised with equal 
amount of 10% FBS in PBS (or LHC complete medium). The cells were harvested by 
centrifuging at 300xg 5 min. The cells are resuspended in 5mL of BEGM medium and the 
number of cells counted and plated in 6-well positively charged plates (Sarstedt), seeded at 
2x106 cells/mL/well overnight before stimulation/functional experiments.  
 
2.4 Cell stimulations and inflammasome functional assay 
 
Cells were pre-treated with the following compounds where indicated prior to NLRP3 
stimulation; Amiloride (100mM, 1hour) (Cayman Chemical), MCC950 (15nM, 1 hour) 
(Cayman Chemical), 2-DG (0.5mM, 2 hours) (Agilent), EIPA (10µM, 1 hour) (Cayman 
Chemical), NPPB (100µM, 1 hour) (Cayman Chemical), S18 derived peptide (25µM, 4 hours) 
(a kind gift from Spyryx Biosciences, Inc ®), ouabain (100nM, 24 hours) (Cayman Chemical), 
digoxin (100nM, 24 hours) (Cayman Chemical), OxPAC (30µg/mL, 1 hour) (Invivogen), Ac-
YVADD (2µg/mL, 1 hour) (Invivogen) and CFTR172 (10µg/mL, 1 hour) (Cayman Chemical). 
Inflammasome stimulation was achieved using LPS (10ng/mL) (Ultrapure EK, Invivogen) for 
4 hours with the addition of ATP (5mM, 30 minutes) (Invivogen), poly(dA:dT) dsDNA 
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(1µg/mL with Lipofectamine 2000, 1 hour) (Invivogen), TcdB (10ng/mL, 1 hour) (Cayman 
Chemical) or flagellin (10ng/mL with Lipofectamine 2000, 1 hour) (Invivogen) in the hour of 
the LPS stimulation. 
 
Stimulant Working concentration Total incubation time 
Lipopolysaccharide (LPS) 10 ng/mL 4 hours 
ATP 5 mM 30 minutes 
poly(dA:dT) dsDNA 1 µg/mL 1 hour 
TcdB 10 ng/mL 1 hour 
Flagellin 10 ng/mL 1 hour 
Ouabain 100 nM  24 hours 
Nigericin 1 µM 30 minutes 
Amiloride 100 mM  1 hour 
MCC950 15 nM  1 hour 
2-DG 0.5 mM  2 hours 
EIPA 10 µM 1 hour 
NPPB 100 µM 1 hour 
S18-derived peptide 25 µM 4 hours 
Digoxin 100 nM  24 hours 
OxPAC 30 µg/mL 1 hour 
Ac-YVADD 2 µg/mL 1 hour 
CFTR172 10 µg/mL 1 hour 
 
Table 5: Details of the in vitro stimulants and inhibitors used throughout this study, including 
the working concentration and incubation time. 
 
2.5 ELISA 
 
Cytokines (IL-1b, IL-18, IL-1Ra, TNF, IFN-g and IL-6) from serum and cell culture 
supernatants were detected by ELISA kits (Invitrogen) using matched antibody pairs, as per 
the manufactures recommendations. Briefly capture antibodies were coated onto the plates and 
covered with a plate sealer overnight at room temperature. The wells were washed twice with 
PBS with 0.1% Tween 20 (PBST) and tapped dry. Sera (100µl) and/or supernatants (100µl) 
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from cell cultures were added to the plates in duplicate along with the cytokine standards and 
the plates covered with plate sealers. After 2 hrs incubation at room temperature the contents 
of the plates were aspirated off and the wells washed 3 times with PBST and tap dried. Anti-
cytokine antibody-HRP conjugates were added to all wells at 100µl/well and the plate 
incubated for 2 hrs. The anti-cytokine antibody-HRP conjugates were removed by aspiration 
and the wells washed 5 times with PBST. Substrate reagents (100µl/well) were added to all 
wells and incubated for up to 30 min and the reaction stopped with 50µl/well of stop reagent. 
The absorbance of the wells was read at 450nm and the reference wavelength at 620nm. The 
one-site total curve was used to generate the calibration curve, based on the company cytokine 
standards, and interpolation of data points. All standard curves were compared to previous 
standard curves for that assay. All duplicate sample measurements were <10% of each other to 
ensure technical repeats were accurate and reliable. 
 
2.6 RT-qPCR 
 
Cells were washed in PBS, covered and suspended in TRIzol™ Reagent (Sigma) and 
stored at 4°C (short-term) or at -80°C (long-term). Cells were lysed in the TRIzol™ Reagent 
(Ambion Life technologies) or using cell lysis buffer from the PureLink RNA mini Kit 
(Ambion) or the mirVana miRNA Isolation Kit (Ambion), which was then used to isolate the 
RNA from the samples. The RNA extraction was performed as per the manufacturers’ protocol. 
The High Capacity cDNA Reverse Transcription kit (Applied Biosystems) was used to 
convert the RNA to cDNA and the Taqman microRNA Reverse Transcription kit (Applied 
Biosystems) was used to convert the miRNAs to cDNA. The assay was performed as per the 
manufacturers’ protocol. cDNA was stored at -20°C.  
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The SYBR Green PCR Master mix (Applied Biosystems) was used to analyse the 
expression of selected primers in the cDNA. The cDNA was defrosted from -20°C storage and 
mixed with SYBR Green master mix and specific forward and reverse primers to the genes of 
interest. The mix and cDNA sample were then loaded onto a 96 well PCR plate and loaded on 
to the PCR machine (Applied Biosystems 7500 Real Time PCR System) as per the 
manufacturers’ protocol. 
Primers for SYBR Green RT-qPCR were ordered from Sigma (see below) based on 
work by Dr Rebecca J Mathews, a previous student in the McDermott group at University of 
Leeds (Mathews et al. 2014). 
 
Name  Sequence: (5' to 3')    Tm GC% MW Length 
IL1B F GGCCTCAAGGAAAAGAATCTGTAC 64.9 45.8 7395 24 
IL1B R GGGATCTACACTCTCCAGCTGTAGA 65.7 52 7642 25 
HPRT F GGAAAGAATGTCTTGATTGTGGAAG 65.6 40 7825 25 
HPRT R GGATTATACTGCCTGACCAAGGAA 65.9 45.8 7386 24 
 
 The Taqman® primers used in this study are detailed below: 
Gene  Assay ID  Dye 
SCNN1B Hs01548617_m1 FAM 
IFNG  Hs00989291_m1 FAM 
 
2.7 Western Blot 
 
Samples were made up in dissociation buffer [1x dissociation buffer (100mM Tris-HCl, 
2% (w/v) sodium dodecyl sulphate, 10% (v/v) glycerol, 100mM dithiothreitol, 0.02% (w/v) 
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bromophenol blue, pH 6.8] and heated at 95oC for 5 min. Proteins were resolved by SDS-
PAGE on 10% acrylamide Tris-glycine gels and then transferred to Hybond PVDF membranes 
(GE Healthcare). Following electrotransfer, the membranes were blocked for 1 h in PBST and 
5% (w/v) non-fat milk and then incubated with primary antibody diluted in 2% BSA (w/v) 
PBST overnight at 4°C. Antigens were probed using the following primary antibodies: anti-
SCNN1B (ARP72375_P050, Avia Systems Biology; 1ug/ml dilution). Primary antibodies 
were detected by incubation with horseradish peroxidase-conjugated secondary antibody anti-
rabbit IgG (7074S; Cell Signalling Technology), in PBST containing 2% (w/v) BSA. Bound 
horseradish peroxidase conjugates were visualized using the ECL® detection system 
(Millipore Immobilon chemiluminescent HRP substrate, Merck) for 5 minutes, before being 
imaged with the ChemiDoc Imaging system (Bio-Rad). 
 
2.8 Colorimetric assays for metabolites 
 
Intracellular ATP (ATP Assay Kit, Abcam) and succinate (Succinate Assay Kit, 
Abcam) were measured using cell lysates and extracellular glucose (Glucose assay kit, Abcam) 
and L-lactate (L-Lactate assay kit, Abcam) were measured from cell supernatants, whereby by 
both standard curve and samples were quantified using colorimetric procedure at OD 570 nm. 
Both measurements were made using the manufacturer’s recommendations. 
  
2.9 Seahorse Metabolic Analyser 
 
Live analysis of extracellular acidification rate (ECAR) and oxygen consumption rate 
(OCR) using the Cell Energy Phenotype kit on monocytes was performed, using the Seahorse 
XF-96 Extracellular Flux Analyser (Agilent Seahorse Bioscience). CD14+ monocytes were 
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purified from isolated PBMCs using MACS microbeads for negative selection, according to 
the manufacturer’s instructions (Miltenyi Biotec) (section 2.2). Monocytes and HBECs were 
seeded in triplicate in XF-96 cell culture plates (2 × 105 cells/well and 5x104, respectively) 
using appropriate culture medium. CellTak (Corning) was used to attach both cell types to the 
cell culture plate and prepared according to the manufacturer’s recommendations. The 
metabolism of monocytes and HBECs were analysed in four consecutive measurements in XF 
Base Medium (unbuffered DMEM with 5.5mM glucose and 2mM L-glutamine, pH adjusted 
to 7.4). After three basal measurements, three consecutive measurements were taken following 
the addition of 10µM oligomycin, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
(FCCP) (5µM) in order to determine basal and maximum OCR and ECAR. All data is 
normalised to total cellular protein using a microplate reader. Cells are lysed and used for 
quantitation with Bradford protein detection reagent with a standard protein concentration 
curve to ensure accurate quantitation and allow absolute comparison of data from assay to 
assay. This method assumes that the in vitro stimulation does not alter total cellular protein 
content significantly. The total protein values calculated using the Bradford assay are then 
inserted into the WAVE software for normalisation of the OCR and ECAR values. Details of 
seahorse OCR and ECAR traces are described in appendix figure 8 and 9. 
 
2.10 Lactate dehydrogenase (LDH) Cytotoxicity Assay 
 
The LDH Cytotoxicity Assay Kit (Pierce) was used, as per the manufacturers’ 
recommendations, with and without caspase-1 inhibitor, Ac-YVAD-cmk (InvivoGen), as a 
control for inflammasome-dependent cell death. Optimal cell density was calculated, and the 
chemical-mediated cytotoxicity assay was performed, whereby spontaneous and maximal 
LDH activity were calculated as controls for stimulation-mediated cytotoxicity. Absorbance 
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was measured at 490 nm and 680 nm and subtracted from each other. In order to quantify 
pyroptosis and discriminate it from other forms of cell death, lactose dehydrogenase (LDH) 
was measured with and without a caspase-1 inhibitor. LDH is released from a necrotic cell, 
which provides a distinguishing feature between necrosis and programmed cell death (PCD), 
such as apoptosis where LDH is contained within the apoptotic vesicles, or blebs. To further 
distinguish pyroptosis from necrosis, a caspase-1 inhibitor was used in a control sample to 
prevent pyroptosis. Any LDH that is detected in the presence of the caspase-1 inhibitor is then 
termed necrosis and is taken away from the LDH release from the experimental sample, 
without a caspase-1 inhibitor pre-treatment. The remaining LDH level is presented as caspase-
1-dependent pyroptosis, calculated as a percentage of complete necrotic cell death using lysis 
buffer and water controls. 
 
2.11 Transient Transfection  
Beas-2B cells were transiently transfected with 5 or 10µg of SCNN1B cDNA 
(Addgene) using Lipofectamine2000 reagent (Thermo Fisher Scientific) for 48h as per 
manufacturer’s instructions. Cells were harvested and immunoblotted for SCNN1B to confirm 
expression. 
 
2.12 Statistics 
No statistical methods were used to predetermine sample size. All analyses were performed 
using GraphPad Prism v 7. Differences were considered significant when P < 0.05. All bar 
graphs were expressed as median 95% confidence intervals. The Mann-Whitney non-
parametric test was performed (p values * = £0.05, **= £0.01, ***= £0.001 and ****= 
£0.0001) when comparing non-parametric populations. A repeated measures 2-way ANOVA 
statistical test was performed with Turkey’s multiple comparisons test with Bennett’s post-hoc 
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analysis was performed when calculating variance between samples (p values * = £0.05, **= 
£0.01, ***= £0.001 and ****= £0.0001). 
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Chapter 3 
 
3.0 NLRP3 inflammasome activation in CF 
 
3.1 Introduction 
 
3.1.1 Activation of the inflammasomes - PAMPS, DAMPS and HAMPS 
 
The inflammasomes and their structure, activation and regulation were discussed in 
detail in chapter 1, section 1.3. Briefly, inflammasomes are large, multi-protein complexes 
whose assembly requires two signalling events:  
1. a priming signal, such as toll-like receptor (TLR) recognition of 
lipopolysaccharide (LPS) with downstream NF-kB signalling, for expression of 
the component parts of an inflammasome complex (Marshall et al., 1999). 
2. a unique activating signal triggering assembly of the component parts of each 
unique inflammasome. 
Assembled inflammasomes are centred around a sentinel protein, such as nucleotide-
binding oligomerization domain (NOD)-like receptor (NLR) protein, which detects the unique 
activating signal and becomes active. Adapter proteins, such as apoptosis-associated, speck-
like protein containing a CARD (ASC), are recruited to and oligomerise from the initial 
sentinel protein. ASC specks recruit pro-caspase-1 molecules, which auto-cleave into their 
active form. Active caspase-1 molecules cleave the zymogens pro-IL-1b, pro-IL18 and 
gasdermin D (GSDMD). GSDMD is then able to form pores in the plasma membrane to allow 
non-conventional secretion of IL-1b and IL-18 (Section 1.3) (Martinon et al., 2002, Aglietti et 
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al., 2016). Inflammasomes have been extensively studied in vitro, with well-defined 
procedures for stimulating each individual inflammasome. There are five well-characterised 
inflammasomes reported in the literature, with an established structure and activating signal. 
These inflammasomes are NLRP1, NLRP3, NLRC4 (IPAF), AIM2 and Pyrin. 
NLRP1 is activated by lethal toxin (LeTx) from Bacillus anthracis (B. anthracis). LeTx 
has two subunits: an antigen binding subunit and a catalytic subunit. When LeTx enters the cell 
through anthrax binding sites, it cleaves MAPK proteins at the n-terminal, inhibiting a major 
signalling pathway within the host cell. With compromised MAPK signalling, immune cells 
are unable to effectively secrete cytokines and chemokines. This lack of immune signalling 
impairs neutrophil chemotaxis and increases pro-apoptotic signalling. The NLRP1 
inflammasome was not investigated in this study as there was no obvious biological relevance 
in CF pathology to justify its inclusion into the study’s design. 
There are a further four inflammasomes that have been described as being able to form 
a backbone of an inflammasome, but their precise activating signals are not yet characterised 
despite evidence of caspase-1 activation and IL-1b and IL-18 secretion (Broz and Dixit, 2016). 
These inflammasomes are NLRP2, NLRP6, NLRP7 and NLRP12 and were not investigated in 
this study due to the lack of data regarding their activating signal. 
In this study, four inflammasomes were specifically studied in vitro: NLRP3, NLRC4, 
Pyrin and AIM2. CFTR defects induce various ionic imbalances, so this study’s inflammasome 
of interest was NLRP3 due to its unique activating signal being K+ efflux. The precise 
mechanisms of NLRP3 activation still remains unclear, although it is thought that NLRP3 
detects changes in host-derived factors that are transmuted by a range of pathogens and 
environmental irritants. These altered host-derived factors include K+ efflux, cathepsin release 
and mitochondrial ROS (mROS), DNA (mtDNA) or translocation. Many particulates such as 
aluminium, silica, monosodium urate (MSU), cholesterol, and amyloid-b escape 
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phagolysosomes and release cathepsin B, activating NLRP3. External necrotic cell death 
releases ATP into the extracellular milieu, which activates the K+ channel P2X purinoceptor 7 
(P2X7) and decrease the intracellular K+ concentration to trigger NLRP3 inflammasome 
assembly (Munoz-Planillo et al., 2013). 
Due to the nature of the recurrent pulmonary bacterial, viral and fungal infections that 
are characteristic of CF (Filkins and O’Toole, 2015), both flagellin (and therefore NLRC4) and 
dsDNA (and therefore AIM2) were also investigated in this study as potential inflammasome 
activating signals in vitro. The Pyrin inflammasome was also investigated, partly due to its 
novelty but also that Rho GTPases have an influential role in the trafficking of CFTR to the 
cell surface (Cheng et al., 2005) (section 1.3). In addition, it has been proposed that 
heterozygous carriers of a CF-associated mutation have a selective advantage in some 
infectious diseases (Meindl, 1987, Regelmann et al., 1991, Romeo et al., 1989) such as Vibrio 
cholera (V. Cholera) and Clostridium difficile (C. difficile), which infect the digestive system 
causing diarrhoea, fluid loss and eventual dehydration through CFTR-dependent fluid loss 
(Hodges and Gill, 2010). However in the presence of a dysfunctional CFTR allele, roughly 
50% of Cl- transport will be lost in heterozygotes, thereby reducing fluid loss and providing a 
selective advantage for heterozygous carriers of a CF-associated mutation (Romeo et al., 1989). 
There are also published cases of asymptomatic C. difficile infection in patients with CF 
(Piccolo et al., 2017). With C. difficile TcdB being an established Pyrin inflammasome 
activating signal, this inflammasome was included in this study, to understand whether cells 
with CF-associated mutations may be protected from the inflammation associated with C. 
difficile TcdB as well as the associated fluid loss. Therefore, the NLRP3, NLRC4, AIM2 and 
Pyrin inflammasomes were investigated using the in vitro stimulation protocol discussed in 
section 2.4. 
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The initial, common priming signal to generate both the inflammasome sensor (e.g. 
NLRP3) and IL1b expression (IL18 is constitutively expressed) is thought to be common to all 
inflammasomes. There is evidence to suggest that pro-caspase-1 and ASC, two common 
constituents of the majority of inflammasomes, are also constitutively expressed (Gurung et 
al., 2015). Priming of the inflammasome can also be through sterile cytokine signalling, with 
evidence that TNF may also have a role in providing this initial signal in sterile inflammation, 
such as during ageing or autoinflammatory diseases (Bauernfeind et al., 2016). 
In vitro activation of the inflammasomes requires the addition of both the priming and 
activation signals sequentially. The NLRP3 inflammasome is commonly activated by K+ 
efflux, which is achieved in vitro using adenosine triphosphate (ATP) stimulation in order to 
open the K+ channel P2X7 and decrease the intracellular K+ concentration to trigger NLRP3 
inflammasome assembly (Munoz-Planillo et al., 2013). NLRC4 is activated by type-3 secretory 
system injection of flagellin, although the precise mechanism is still unclear (Zhao et al., 2011). 
In vitro the NLRC4 inflammasome is activated by transfected flagellin molecules. The Pyrin 
inflammasome is activated by bacterial modifications of Rho GTPases, such as the 
glucosyltransferase cytotoxin B secreted by C. difficile (TcdB) (Xu et al., 2014, Aubert et al., 
2016, Park et al., 2016) (section 1.3). Therefore in vitro activation of the Pyrin inflammasome 
is achieved by the addition of purified TcdB. Finally, the AIM2 inflammasome is activated by 
dsDNA and primed by LPS or interferon (IFN)-g (Fernandes-Alnemri et al., 2009, Hornung et 
al., 2009), which is also replicated in vitro. There are now many inflammasome inhibitors that 
are both potent and specific; in this study, a small molecule drug, named MCC950 that 
specifically inhibits NLRP3 activation, is used (mechanism unknown) (Coll et al., 2015). 
 Many cell types are able to produce an inflammasome response but the key cells in 
which inflammasome are assembled are cells of the myeloid and epithelial lineages. Both these 
cell types form part of the innate immune response with monocytes/macrophages and 
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neutrophils actively killing pathogens and the epithelial barrier maintaining tissue integrity as 
well as detecting invading organisms via pattern recognition receptor (PRR) detection of 
PAMPs and DAMPs (Whitsett and Alenghat, 2015). In this study both monocytes and 
epithelial cells are examined for in vitro NLRP3, NLRC4, AIM2 and Pyrin inflammasome 
activation. 
 
3.1.2 Studying the inflammasomes in vitro 
 
As previously discussed, ATP is a known activator of the NLRP3 inflammasome, via 
its opening of the P2X7 K+ channel (Gong et al., 2018). However, there are numerous 
molecules that are known to instigate NLRP3 inflammasome assembly. In this study three 
other, well-described NLRP3 activating molecules were considered- monosodium urate 
(MSU), ouabain and nigericin toxin. The former is well described in disease models of gout, 
in which urate crystals accumulate and activate the NLRP3 inflammasome. The second 
stimulant, ouabain is a small, non-specific inhibitor of the Na+/K+ ATP-gated channel. The 
latter is a pore-forming toxin from Streptomyces hygroscopicus, and activates NLRP3 via 
pannexin-1. Including ATP, all four stimulants induce K+ efflux and NLRP3 assembly and 
activation. During optimisation experiments (appendix figure 1), ATP and ouabain were the 
most potent and biologically relevant in terms of CF pathology: ATP and ouabain open and 
close ion channels respectively, making them pertinent molecules in the study of the NLRP3 
inflammasome, in the context of channelopathy such as CF. 
HBECs and monocytes were examined, under these conditions, from patients with CF, 
SAID and NCFB and age- and sex-matched HCs. 
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Figure 3.1.2: NLRP3 inflammasome priming and activation. The NLRP3 inflammasome 
requires two signals to be primed and activated. The first priming signal, such as LPS/TLR/NF-
kB signaling or LPS/glycolysis/succinate/HIF1a signaling, generates the expression of NLRP3 
and IL1B. A second activating signal, such as K+ efflux from P2X7 ATP-activated channel or 
mROS-dependent NLRP3 activation, assembles the component parts of the NLRP3 
inflammasome. LPS- Lipopolysaccharide; TLR- Toll like receptor; mROS- mitochondrial 
ROS; K+- potassium; IL- interleukin, HIF1a- hypoxia inducible factor 1 alpha. 
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3.1.3 In vitro inflammasome inhibition 
 
It terms of the small molecule inhibition of NLRP3, MCC950 was used throughout due 
to its specificity and potency. Coincidently, the CFTR inhibitor 172 (CFTR172) not only 
potently inhibits the CFTR Cl- channel but also is able to inhibit NLRP3 activation (Jiang et 
al., 2017). The fact that this small molecule inhibited the ATP binding site of both proteins 
made its use impractical in the investigation of the relationship between loss of CFTR activity 
and NLRP3 activity, although it was used as an NLRP3 inhibitor as well as in other, non-CFTR 
related experiments. In addition, TLR4 and caspase-1 small molecule inhibitors were used to 
inhibit NLRP3 inflammasome priming and IL-1b/IL-18 cleavage, respectively. 
 
3.1.4 Pyroptotic cell death 
 
Pyroptotic cell death is the terminal phase of chronic, sustained inflammasome 
activation. This unique form of cell death stems from the unique secretory pathway that the 
pyrogens, IL-1b and IL-18 use to exit the cell, after caspase-1 processing. Active caspase-1 not 
only cleaves and activates IL-1b and IL-18 but also cleaves a novel, small molecular weight 
protein, named gasdermin D (GSDMD) (Kayagaki et al., 2015, Shi et al., 2015, He et al., 2015, 
Aglietti et al., 2016). Active GSDMD forms pores in the plasma membrane, providing a 
secretory route for IL-1b and IL-18. When inflammasome activation is prolonged, GSDMD 
pore formation is also sustained. leading to a loss of cell integrity and cell death or pyroptosis. 
Pyroptosis is an inflammasome-dependent, caspase-1-dependent, inflammatory form of cell 
death, akin to necrosis. ASC speck release is thought to occur passively upon pyroptosis, rather 
than being an active secretory pathway (Baroja-Mazo et al., 2014, Franklin et al., 2014, 
Rowczenio et al., 2017). This is partly due to the large molecular weight of fully oligomerised 
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ASC, as well as the timing of ASC speck release being correlated with pyroptotic cell death. 
However, the field of ASC speck research is still in its infancy. Therefore, pyroptosis is an 
informative measure of systemic and sustained inflammasome activation, with many 
implications for the pathogenesis of inflammatory disease (Bergsbaken et al., 2009, Miao et 
al., 2010, Shi et al., 2015). 
 
3.1.5 ASC specks 
ASC is an integral protein, within many inflammasome complexes, as when it binds to 
a sensor molecule (e.g. NLRP3), ASC will oligomerise and form a macromolecular signalling 
platform for pro-caspase-1 recruitment (Fernandes-Alnemri and Alnemri, 2008, Dick et al., 
2016). This oligomerisation can be observed using fluorescence microscopy, with large 
‘speck’-like macromolecules forming when an inflammasome is activated and assembled 
(Franklin et al., 2014). Under chronic or intense inflammasome activation, pyroptotic cell death 
will ensue- i.e., an inflammasome-dependent form of cell death. It has been previously reported 
that in cases of elevated pyroptosis the inflammasome components, particularly large ASC 
specks, can be detected using a flow cytometry-based assay (Fernandes-Alnemri and Alnemri, 
2008, Fernandes-Alnemri et al., 2009, Baroja-Mazo et al., 2014, Franklin et al., 2014). The 
original study from Fernandes-Alnemri et al. used GFP-tagged ASC fusion proteins in human 
THP-1 monocytic cell lines to detect ASC specks, or pyroptosomes intracellularly. The authors 
go on to describe how pyroptosomes cause pyroptotic cell death through membrane rupture, 
with release of the cell contents, including IL-1b and ASC pyroptosomes. Other studies have 
progressed the study of extracellular ASC by investigating whether these macromolecules have 
any inflammatory functions, once released from the cytoplasm. Seminal studies into ASC 
speck function describe how ASC specks remain intact long after the host cell has been 
degraded post-pyroptosis (Kuri et al., 2017). ASC specks continue to recruit extracellular pro-
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caspase-1 for auto-cleavage as well as processing pro-IL-1b into its active form, despite being 
released from the confines of a host cell. Extracellular ASC specks are able to disseminate 
inflammation beyond the local inflammatory environment. Multiple studies have detected ASC 
specks in the serum from a variety of inflammatory diseases, and even within macrophages 
that have phagocytosed extracellular ASC specks. These donor ASC specks are then able to 
escape endosomes and begin nucleating and oligomerising new pyroptosomes for capsase-1 
and IL-1b/IL-18 cleavage in the recipient macrophage (Muñoz-Arias et al., 2015, Kofahi et al., 
2016). In this study, a flow cytometry-based assay was used to detect extracellular ASC specks 
(see Methods section). 
 
3.1.6 Macrophage polarisation 
 
The capacity of human monocytes to differentiate into M1-type and M2-type 
macrophages in vitro can be utilised in order to understand whether there is any bias in 
differentiation state in specific diseases. M1-type macrophages are thought to have a 
proinflammatory role in peripheral tissues and are characterised by an inherent ability to 
produce proinflammatory IL-6 and TNF, whilst M2-type macrophages are archetypically 
associated with production of anti-inflammatory IL-10 cytokine. Peripheral monocytes were 
differentiated and activated to either M1-type or M2-type macrophages (Mia et al., 2014, 
Italiani and Boraschi, 2014) (figure 3.5.1.1). Macrophage cell surface markers and intracellular 
cytokines were measured using flow cytometry and ELISA (Tarique et al., 2017) and 
characterised into M1-type or M2-type (Tarique et al., 2017, Mills et al., 2000). 
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3.1.7 Pathogenic ion channel activity in CF 
 
The CFTR protein is widely expressed in a variety of cells and tissues, where it acts as 
an anion channel, conducting Cl- and HCO3-, and also a regulator of epithelial transport 
proteins (König et al., 2002, Konstas et al., 2003, König et al., 2001, Kunzelmann, 2003, 
Berdiev et al., 2009). In healthy lungs, CFTR inhibits the epithelial sodium channels (ENaC) 
and helps maintain normal volume and composition of airway surface liquid (ASL).  Loss of 
ENaC inhibition in CF leads to increased sodium absorption, a hallmark of CF, with 
reduced ASL volume and defective mucociliary clearance (Althaus, 2013, Berdiev et al., 2009, 
Bhalla and Hallows, 2008, Donaldson et al., 2002, Garcia-Caballero et al., 2009, Gwoździńska 
et al., 2017, Hobbs et al., 2013, König et al., 2002, König et al., 2001, Konstas et al., 2003, 
Kunzelmann, 2003, Mall et al., 2004, Zhou et al., 2011, Zhou et al., 2008).  
Several studies have provided insight into the potential importance of sodium 
homeostasis in the disease process. Overexpression of ENaC in mice results in a CF-like lung 
disease, with ASL dehydration and mucous obstruction (Althaus, 2013, Mall et al., 2004, Zhou 
et al., 2011, Zhou et al., 2008). In human patients, variants in the ENaC 
SCNN1B and SCNN1G genes have been associated with bronchiectasis and CF-like symptoms 
(Fajac et al., 2008). In contrast, rare mutations, which cause hypomorphic ENaC activity, can 
reduce disease progression in patients homozygous for F508del (Mall et al., 2004, Zhou et al., 
2011, Donaldson and Boucher, 2007). Furthermore, reduced ENaC activity is associated with 
multisystem pseudohypoaldosteronism type-1, a disease that results in production of excessive 
amounts of ASL (Bhalla and Hallows, 2008). 
Amiloride-sensitive Na+ channels have diverse functions, and as macrophages 
modulate inflammation and spontaneous channel depolarisation in patients with CF, excessive 
cytokine secretion can be inhibited by amiloride therapy (Sorio et al., 2011, Rolfe et al., 1992). 
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In dendritic cells, channel activation triggers proinflammatory signalling through superoxide 
production (Barbaro et al., 2017). 
 
3.2 Methods 
 
3.2.1 ELISA 
 
As in section 2.5. 
Briefly, serum was isolated from whole blood using clot-activating blood collection 
tubes that were centrifuged to separate out the sera from the whole blood. Serum was aliquoted 
and stored long-term at -80°C. Serum from healthy controls and patients with CF, diagnosed 
SAID and NCFB were collected and serum cytokines measured by ELISA. The growth media 
supernatants from stimulated cell culture plates were stored at -20°C before being used to detect 
IL-1b and IL-18 cytokine secretion levels by ELISA. 
 
3.2.2 ASC specks 
 
Sera was separated from whole blood (see Methods section) and stored at -80°C before 
being thawed and incubated with an ASC-PE antibody and analysed using an optimised flow 
cytometric assay. The number of events was equated to the number of ASC specks, normalised 
to the volume of sample ran through the cytometer (standardised at 200µL) and expressed as 
extracellular ASC specks/µL. HC serum or CF patients’ sera (200µl) were incubated with 5µl 
of anti-ASC-PE (TMS-1) antibody (Biolegend) and incubated for 1 hr at room temperature, 
and subsequently analysed on the LSRII flow cytometer instrument (BD Biosciences). Non-
fluorescent 1µm microspheres (Thermo Fisher Scientific) were used as a guide to gate around 
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ASC specks for counting. ASC speck events were reported as total events in the set gate divided 
by 200 (ASC speck/µl) (Rowczenio et al., 2017). 
 
3.2.3 Macrophage polarisation 
 
PBMCs were isolated using the Lymphoprep®, as described in section 2.2. A total of 
1x107 PBMCs were seeded overnight into T150 flasks (Corning) in ‘complete’ RPMI media 
to allow monocytes to attach. On day 0, attached cells were washed with PBS and then detached 
using 5mM EDTA.  In a 6-well plate, for each sample, two wells were seeded at 1x106 
cells/mL/well in ‘complete’ RPMI supplemented with either 20ng/mL human GM- CSF 
(PeproTech EC Ltd) for M1 differentiation or 20ng/mL human M-CSF (PeproTech EC Ltd) 
for M2 differentiation and incubated for 9 days, with supplemented-media changes every 3-
days. On day 9, for M1 activation the complete RPMI medium was supplemented with 
100ng/mL human IFN-g (PeproTech EC Ltd), 100ng/mL TNF and 50ng/mL LPS or for M2 
activation the medium was supplemented with 20ng/mL IL-13 and 20ng/mL IL-4 and 
incubated for 24 hours. Macrophages were periodically monitored for phenotypic changes 
using light microscopy: M1 macrophages display a rounded morphology, whilst M2 
macrophages display a tortuous, dendritic morphology (Mia et al., 2014, Italiani and Boraschi, 
2014). On day 10, macrophages were prepared for flow cytometry characterisation and day 10 
supernatant stored for cytokine analysis using ELISA. 
 Differentiated and activated M1 and M2 macrophages were characterised by surface 
marker expression and detection of intracellular cytokines by flow cytometry. Macrophages 
were washed with complete RPMI media and cultured with complete RPMI media 
supplemented with Golgi plug for 4 hours. Cells were then detached using 5mM EDTA for 40 
minutes on ice. EDTA was neutralised in complete RPMI and the cells were washed twice in 
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PBS. Cells were pelleted and suspended in Brilliant Stain buffer (BD Biosciences) 
supplemented with mouse and human serum (Sigma), to block Fc receptors. Cells were then 
washed and stained for surface markers for 30 minutes. Surface markers for M1-type (CD14+ 
CD16+ HLA-DR+ CD274+ CD86+) and M2-type (CD14+ CD16+ CD206+). Cells were then 
washed and fixed and permeabilised for 30 minutes. Cells were then washed and stained for 
intracellular markers (see below) for 30 minutes. The intracellular markers for M1-type and 
M2-type macrophages were the high expression of TNF and IL-10, respectively. Cells were 
then washed and suspended in brilliant stain buffer, ready for flow cytometry (BD Bioscience 
FACS Calibur). Monocytes were characterised as classical (CD14++CD16−), non-classical 
(CD14dimCD16++), and intermediate (CD14++CD16+). Flow cytometry analysis for 
characterisation of macrophage and monocyte populations used the following antibodies: 
CD14 (V500 BD Horizon™, V500 Mouse Anti-Human, CD14 RUO M5E2, Lot: 561391), 
CD206 (Mannose Receptor) (FITC BD Pharmingen™, FITC Mouse Anti-Human, CD206, 
RUO 19.2, Lot: 551135), CD16 (FcγRIII) (APC-H7, BD Pharmingen™ APC-H7, Mouse Anti-
Human CD16, RUO 3G8, Lot: 560195), TNF (BV421 BD Horizon™, BV421 Mouse Anti-
Human TNF, RUO MAb11, Lot: 562783), CD274 (B7-H1) (APC, BD Pharmingen™ APC, 
Mouse Anti-Human CD274, RUO MIH1, Lot: 563741), CD86 (B7-2) (PE-Cy7, BD 
Pharmingen™ PE-Cy™7 Mouse Anti-Human CD86, RUO2331 (FUN-1), Lot: 561128), IL-
10 (PE, BD Pharmingen™ PE Rat Anti-Human IL-10, RUO JES3-19F1, Lot: 559330) and 
HLA-DR (PerCP,Anti-HLA-DR PerCP, CE_IVD L243, Lot: 347402). 
 
3.2.4 Ionic concentration assay 
 
Sodium and potassium sensitive dyes, SBFI and PBFI, respectively (Molecular Probes) 
were used as cell permeant selective ion indicators for the fluorometric determination of Na+ 
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and K+ concentrations. Monocytes and HBECs were allowed to adhere in black 96-well cell 
culture plates overnight. Cells were then washed and incubated in the appropriate low serum 
media (see above) (1%) for 1 hour. The dyes (10mM final concentration) were loaded with 
Pluronic® F-127 (Sigma) and incubated for 100 minutes. Stimulants were then added to the 
wells as indicated and described above. All wells were washed with NaCl solution. Excitation 
at 344nm and 400nm with emission at 500nm was measured immediately to calculate the 
percentage change in fluorescence compared to an untreated control (Andersson et al., 2006). 
 
3.2.5 Capsase-1 activity 
 
A colorimetric assay to determine caspase-1 activity via cleavage of a caspase-specific 
peptide conjugated to a colour reporter molecule p-nitroalinine (pNA). The assay was 
performed in protein lysates and serum. 
 
3.2.6 Pyroptosis assay 
 
As in section 2.10. 
Briefly, the LDH Cytotoxicity Assay Kit (Pierce) was used, as per the manufacturer’s 
recommendations, with and without caspase-1 inhibitor, Ac-YVAD-cmk (InvivoGen), as a 
control for inflammasome dependent cell death (pyroptosis). Optimal cell density was 
calculated, and the chemical-mediated cytotoxicity assay was performed, whereby spontaneous 
and maximal LDH activity were calculated as controls for stimulation-mediated cytotoxicity. 
Absorbance was measured at 490 nm and 680 nm and subtracted from each other. 
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3.2.7 in vitro NLRP3 inflammasome activation and inhibition 
 
As in section 2.4. 
Briefly, the growth media supernatants from stimulated cell culture plates were stored 
at -20°C before being used in the above assays. All stimulations were optimised using the THP-
1 monocyte cell line, Beas-2b (WT) HBECs and HC PBMCs (appendix figure 1 and 2). The 
Don Whitley H35 Hypoxystation was used at 1% O2 for hypoxic conditions. Cells were 
cultured in the hypoxystation overnight before stimulation. Stimulations were performed as 
described in section 2.4.  
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3.3 Inflammatory serum cytokine levels in patients with CF 
 
3.3.1 Serum IL-1-family cytokines 
 
Serum cytokine levels provide an insight into the systemic inflammatory state of an 
individual, acting as biomarkers for underlying, chronic or acute inflammation. Initially, 
selected cytokines from the IL-1 family were investigated due to the pathology of CF being 
related to an ion channel (CFTR) defect and the universal NLRP3 inflammasome activator 
being ionic flux (K+ efflux). The IL-1 family of cytokines encompasses a large variety of both 
pro- and anti-inflammatory cytokines and chemokines. In this study, IL-18 and IL-1b were 
chosen as two potent proinflammatory cytokines that are cleaved and processed by active 
caspase-1 via inflammasome assembly. In patients with systemic autoinflammatory disease 
(SAID), these two cytokines are elevated in the serum before administration of the widely 
successful recombinant IL-1Ra therapy. The endogenous levels of this anti-inflammatory IL-1 
family cytokine receptor, IL-1Ra was also studied to provide some understanding of the 
systemic resolution of this IL-1 driven inflammation. IL-1Ra will be secreted in response to 
NLRP3 inflammasome activation as a pro-resolution mechanism and so, therefore, provides 
additional evidence for the activity of the inflammasomes and downstream IL-1 cytokine 
family secretion in the systemic inflammation present in patients with CF (Medicine, 1997). 
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(Figure 3.3.1.1 legend on next page) 
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Figure 3.3.1.1: IL-18, Il-1b and IL-1Ra levels in patient sera. ELISA assays were used to 
detect IL-18 (HC n=21, CF n=36, Autoinflammatory n=12, NCFB=4), IL-1β (HC n=10, CF 
n=31, Autoinflammatory n=13, NCFB=4) and IL-1Ra (HC n=20, CF n=37, Autoinflammatory 
n=7, NCFB=4). The Mann-Whitney non-parametric test was performed (p values * = £0.05, 
**= £0.01, ***= £0.001 and ****= £0.0001). 
 
 Levels of IL-18 was observed to be significantly elevated in sera from patients with CF 
(all ∆f508/∆f508) and SAID compared to that of HC individuals (p=0.0128 and p=0.0042 
respectively). Both IL-1b and IL-1Ra were also significantly increased compared to HC sera 
in both CF (0.0002 and <0.0001 respectively) and SAID (0.0039 and 0.0006 respectively) 
cohorts. There was no significant difference between HC and NCFB for any of the measured 
cytokines in this study. The ratio of IL-1b in serum from patients with SAID was not as high, 
relative to HC, CF or NCFB compared to that of the levels IL-18. IL-1b serum concentrations 
were comparatively low compared to other cytokine measurements.
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3.3.2 Serum ASC Specks 
 
Figure 3.3.2.1: Extracellular ASC specks in patient sera. Flow cytometry was used to detect 
ASC specks in sera of patients with CF and HCs (d) (HC n=10, CF n=10, Autoinflammatory 
n=10, NCFB=4). The gating of ASC specks using flow cytometry is detailed in appendix figure 
7. The Mann-Whitney non-parametric test was performed (no comparisons reached statistically 
significance p>0.05). 
 
Low amounts of ASC specks were detected in sera from HC or NCFB individuals. Sera 
from patients with CF had significantly elevated serum ASC specks compared to HC and 
NCFB sera. Autoinflammatory patient sera had around 10-fold greater ASC speck levels than 
that of CF sera. 
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3.3.3 Serum Caspase-1 activity 
 
 
Figure 3.3.3.1: Caspase-1 activity in patient sera. A colorimetric assay to detect caspase-1 
activity in sera of patients with CF, NCFB and SAID as a percentage of the average caspase-1 
activity from HC (n=10) with a mean absorbance of 0.20845 nm (HC n=10, CF n=21, 
Autoinflammatory n=4, NCFB=4). The Mann-Whitney non-parametric test was performed (no 
comparisons reached statistically significance p>0.05). 
 
Caspase-1 activity in serum samples from patients with CF, NCFB and SAID was 
measured and compared to a mean average of caspase-1 activity in a set of HC serum samples 
(n=10). Sera from patients with CF had elevated serum caspase-1 activity, with an average of 
around 50% increase. This elevated serum caspase-1 activity in patients with CF was 
significantly increased compared to patients with NCFB (p=0.0043), as was serum from 
patients with SAID (p=0.0286). 
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3.3.4 Other proinflammatory serum cytokines 
 
In order to understand the significance of elevated serum IL-1 family cytokines, as well 
as the presence of serum ASC specks in patients with CF, it is important to compare the 
inflammasome-related cytokines and macromolecules with other proinflammatory cytokines 
in serum. This will allow further interpretation of the data, in respect to whether these 
phenomena are due to hyper-activation of the inflammasome pathways or because of a general 
proinflammatory cytokine profile. Initially tumour necrosis factor (TNF) and IL-6 were 
measured in the same serum samples, as in sections 3.3.1 and 3.3.2 (Fig. 3.3.4) by ELISA. 
Different numbers of patients were used for each figure due to sample availability. 
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Figure 3.3.4.1: TNF and IL-6 serum concentrations. ELISA assay was used to detect TNF 
(a) and IL-6 in serum (b) (HC n=24, CF n=40, Autoinflammatory n=8, NCFB=4). The Mann-
Whitney non-parametric test was performed (no comparisons reached statistically significance 
p>0.05). 
 
3.4 In vitro inflammasome activation 
 
3.4.1 In vitro NLRC4, AIM2 and Pyrin inflammasome activation 
 
Figure 3.4.1 shows that the HBEC lines all activate the NLRC4, AIM2 and Pyrin 
inflammasomes in response to the appropriate stimulation (optimised in appendix Fig 1). There 
is little to no difference between the Beas-2b (WT) HBEC line and the HBEC lines with CF-
associated mutations. The stimulation with dsDNA created a more robust IL-18 response 
compared with flagellin and TcdB. Figure 3.4.1b shows monocyte stimulations and also 
indicates that the dsDNA, and thus AIM2 inflammasome, is the more potent stimulation. 
Again, there is no significant difference between HC monocytes compared to monocytes from 
patients with CF. IL-18 secretion from the same monocytic stimulations (Fig 3.4.1) supports 
the IL-1b data (Fig 3.4.1b), in that there is no difference between HC monocytes compared to 
monocytes from patients with CF with any of the inflammasome stimulations. However, a 
strong flagellin/NLRC4 IL-18 response was recorded, which was slightly elevated in CF 
monocytes. No difference was noted for the TcdB/Pyrin IL-18 response between HC and CF 
monocytes. The dsDNA/AIM2 stimulation again produced the highest cytokine secretion, 
although with HC monocytes producing more IL-18, compared to CF monocytes. 
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(Figure 3.4.1.1 legend on next page) 
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Figure 3.4.1.1: in vitro NLRC4, AIM2 and Pyrin Inflammasome activation. ELISA assays 
were used to detect IL-18 from supernatants of HBECs (a) (n=4) and monocytes (c) (n=10) as 
well as IL-1b from monocytes (b) (n=10). Cells were stimulated with LPS (10ng/mL) for 4 
hours before being stimulated for 4 hours with Flagellin (10ng/mL with Lipofectamine 2000), 
TcDB (10ng/mL) or poly(dA:dT) dsDNA (1µg/mL with Lipofectamine 2000). A repeated 
measures 2-way ANOVA statistical test was performed with Turkey’s multiple comparisons 
test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
3.4.2 In vitro NLRP3 inflammasome activation 
 
With no statistically significant difference in NLRC4, AIM2 or Pyrin inflammasome 
activation between WT HBECs or HC monocytes and cells harbouring CF-associated 
mutations, the NLRP3 inflammasome was then assessed, with and without small molecule 
inhibitors, using the same stimulation protocol (Methods section 2.4).  
Notably, HBEC lines harbouring CF-associated mutations hyper-responded to NLRP3 
activation in both ATP and ouabain stimulation, in terms of IL-18 secretion. However, only 
IB3-1 (Df508/W1282X) and CuFi-1 (Df508/Df508) cell lines produced a statistically 
significant increase in IL-18 secretion in vitro compared to the Beas2b (WT) HBEC line. All 
four inhibitors depleted IL-18 secretion in all four cell lines effectively, particularly inhibition 
of TLR4 by OxPAC, upstream of NF-kB priming of NLRP3 components. The two specific 
NLRP3 inhibitors, MCC950 and CFTR172, sufficiently blocked downstream IL-18 secretion in 
all cell lines after NLRP3 stimulation. The caspase-1 inhibitor, AC-YVADD-cmv, was also 
able to reduce IL-18 secretion by preventing cleavage and activation of the pyrogen by 
inhibiting upstream caspase-1 activity. However, despite caspase-1 inhibition the HBECs with 
CF-associated mutations maintained a statistically significant increase in IL-18 secretion post-
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stimulation with ATP for NLRP3 activation. IL-1b secretion was undetectable in HBEC line 
cultures. 
  
(Figure 3.4.2.1 legend on next page) 
  
90 
Figure 3.4.2.1: in vitro IL-18 secretion from NLRP3 Inflammasome activation in HBEC 
lines. ELISA assays were used to detect IL-18 from supernatants of HBECs using ATP (5mM, 
30mins) or ouabain (100nM, 24 hours) (n=3). Cells were stimulated with LPS (10ng/mL, 4 
hours) before being stimulated for 30 minutes with ATP (5mM, 30 mins) or Ouabain (100nM, 
24 hours). The following inhibitors were pre-treated, before NLRP3 inflammasome activation: 
MCC950 (15nM, 1 hour), CFTR172 (10µg/mL, 1 hour), AC-YVADD-cmv (2µg/mL, 1 hour) 
and OxPAC (30µg/mL, 1 hour). A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001).   
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(Figure 3.4.2.2 legend on next page) 
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Figure 3.4.2.2: in vitro IL-18 secretion from NLRP3 inflammasome activation in primary 
monocytes. ELISA assays were used to detect IL-18 from supernatants of primary monocytes 
using ATP or ouabain (HC n=6; CF n=6; NCFB n=4; SAID n=4). Cells were stimulated with 
LPS (10ng/mL, 4 hours) before being stimulated for 30 minutes with ATP (5mM, 30 mins) or 
Ouabain (100nM, 24 hours). The following inhibitors were pre-treated, before NLRP3 
inflammasome activation: MCC950 (15nM, 1 hour), CFTR172 (10µg/mL, 1 hour), AC-
YVADD-cmv (2µg/mL, 1 hour) and OxPAC (30µg/mL, 1 hour). A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
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(Figure 3.4.2.3 legend on next page) 
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Figure 3.4.2.3: in vitro IL-1b secretion from NLRP3 inflammasome activation in primary 
monocytes. ELISA assays were used to detect IL-1b from supernatants of primary monocytes 
using ATP or ouabain (HC n=6; CF n=6; NCFB n=4; SAID n=4). Cells were stimulated with 
LPS (10ng/mL, 4 hours) before being stimulated for 30 minutes with ATP (5mM, 30 mins) or 
Ouabain (100nM, 24 hours). The following inhibitors were pre-treated, before NLRP3 
inflammasome activation: MCC950 (15nM, 1 hour), CFTR172 (10µg/mL, 1 hour), AC-
YVADD-cmv (2µg/mL, 1 hour) and OxPAC (30µg/mL, 1 hour). A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
 Similar observations were made when the same experiments were carried out in 
primary monocytes from HC individuals and patients with CF, NCFB and SAID. In terms of 
IL-18 secretion, monocytes from patients with CF secreted significantly increased amounts of 
IL-18 cytokine compared to HC and NCFB controls. Monocytes from patients with SAID 
secreted large amounts of IL-18 upon stimulation with either ATP or ouabain, approximately 
twice the amount compared to that of HC. Again, all four small molecule inhibitors were able 
to supress IL-18 secretion in all patient cohorts. However, CFTR172 inhibition was not as 
effective in this regard, notably with monocytes from patients with SAID. IL-1b secretion was 
elevated in patients with CF and, to a greater extent, in SAID, compared to HC and NCFB 
control cohorts. All four inhibitors potently inhibited IL-1b secretion to the very lower limits 
of detection for this assay. 
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3.4.3 in vitro extracellular ASC speck release 
 
ASC is an integral constituent of many inflammasomes, linking the NLRs with caspase-
1. All of the inflammasomes in this study utilise ASC in the process of assembling an 
inflammasome complex. However, based on the above data indicating that the NLRP3 
inflammasome was significantly activated in CF, only NLRP3 was pursued further in this 
study. ASC specks (section 3.1.5) are released from the cell post-inflammasome activation, 
particularly under chronic or strong NLRP3 stimulation or with a lack of resolution signals. 
The following data show the detection of extracellular ASC specks, using a flow cytometry-
based assay (section 3.2.2) following NLRP3 activation in vitro (section 2.4). 
 
Figure 3.4.3.1: Extracellular ASC specks in in vitro monocyte supernatants. Flow 
cytometry was used to detect ASC specks in supernatant of primary monocytes from 
individuals with CF, NCFB, SAID and HCs (HC n=6, CF n=6, SAID n=6, NCFB=4). Cells 
were stimulated with LPS (10ng/mL, 4 hours) before being stimulated for 30 minutes with 
ATP (5mM, 30 mins). A repeated measures 2-way ANOVA statistical test was performed with 
Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= 
£0.0001).   
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It was particularly noticeable that extracellular ASC specks were observed in 
unstimulated monocyte supernatants from patients with SAID. Upon NLRP3 stimulation, the 
number of extracellular ASC specks, in monocytes from patients with SAID, increased around 
five-fold. Extracellular ASC specks were also detected in monocytes from HC individuals and 
patients with NCFB after stimulation with ATP. In concordance with IL-18 and IL-1b 
secretion, significantly elevated extracellular ASC specks were observed in stimulated CF 
monocyte supernatant, but significantly less than that of SAID monocytes. 
 
3.4.4 in vitro Caspase-1 activity 
 
Caspase-1 is the active zymogen component of any inflammasome, driving GSDMD, 
pro-IL-1b and pro-IL-18 cleavage and activation, and is ultimately the limiting factor for IL-
1b and IL-18 secretion. To measure caspase-1 activity, lysates from both HBEC lines and 
monocytes were used in a colorimetric enzyme activity assay. Increased caspase-1 activity was 
detected in all cohorts and cell types after NLRP3 stimulation with ATP or ouabain. This was 
enhanced in cells from patients with CF and SAID, compared to HC and NCFB controls. 
Again, the caspase-1 activity of a sample corroborated the corresponding pyrogen secretion 
and ASC speck release, from the aforementioned sample. The small molecule NLRP3 
inhibitor, MCC950 potently inhibited caspase-1 activity in all LPS/ATP and LPS/ouabain 
stimulated samples and across all cohorts. 
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(Figure 3.4.4 legend on next page) 
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Figure 3.4.4: Caspase-1 activity in HBEC lines and monocytes. A colorimetric assay to 
determine caspase-1 activity via cleavage of a caspase-specific peptide conjugated to a colour 
reporter molecule p-nitroalinine (pNA). The assay was performed in protein lysates from 
primary monocytes from individuals with CF, NCFB, SAID and HCs (HC n=10, CF n=10, 
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SAID n=4, NCFB=4) and HBEC lines (n=3). Cells were stimulated with LPS (10ng/mL, 4 
hours) before being stimulated for 30 minutes with ATP (5mM, 30 mins). A pre-treatment of 
MCC950 (15nM, 1 hour) was used before NLRP3 inflammasome activation. A repeated 
measures 2-way ANOVA statistical test was performed with Turkey’s multiple comparisons 
test  (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
 
3.4.5 In vitro Pyroptosis 
 
 In order to quantify pyroptosis and discriminate it from other forms of cell death, 
lactose dehydrogenase (LDH) is measured with and without a caspase-1 inhibitor. LDH is 
released from a necrotic cell, which provides a distinguishing factor between necrosis and 
programmed cell death, such as apoptosis where LDH is contained within the apoptotic 
vesicles, or blebs. To further distinguish pyroptosis from necrosis, a caspase-1 inhibitor is used 
in a control sample to prevent pyroptosis. Any LDH that is detected in the presence of the 
caspase-1 inhibitor is then termed necrosis and is taken away from the LDH release from the 
experimental sample, without a caspase-1 inhibitor pre-treatment. The remaining LDH level is 
presented as caspase-1-dependent pyroptosis, calculated as a percentage of complete necrotic 
cell death using lysis buffer and water controls. 
 Upon stimulation with LPS and ATP, increased pyroptosis is observed in WT HBECs, 
with the majority of necrotic cell death measured by LDH release being caspase-1 dependent 
and therefore pyroptosis. HBECs harbouring CF-associated mutations had increased pyroptotic 
activity with the IB3-1 (∆f508/W1282X) cell line significantly increased compared to Beas-2b 
(WT). Monocytes from HC individuals and patients with NCFB also presented with pyroptotic 
cell death upon NLRP3 inflammasome activation, but with a greater level of caspase-1 
independent necrosis in this cell type. The increase in pyroptosis was augmented in cells from 
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patients with CF and SAID, with the level of caspase-1 independent necrosis being elevated 
further in SAID monocytes compared to CF monocytes. 
 
Figure 3.4.5: Pyroptosis after NLRP3 inflammasome activation in HBEC lines and 
primary monocytes. The figure displays necrosis and pyroptosis as superimposed bar charts, 
representing the percentage of total necrosis that is caspase-1 dependent, or pyroptosis. 
Pyroptotic cell death was calculated by measuring total necrosis via the presence of lactose 
dehydrogenase (LDH) from cell culture samples in a 96-well plate, colorimetric assay. Each 
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sample/condition was repeated in parallel with a caspase-1 inhibitor (AC-YVADD-cmv 
(2µg/mL, 1 hour)) pre-treatment. The total necrosis level was then taken away from the capase-
1 inhibited sample, or ‘caspase-1 independent’ necrosis, with the remaining LDH level termed 
‘caspase-1 dependent necrosis’ or pyroptosis. The assay was performed with primary 
monocytes from individuals with CF, NCFB, SAID and HCs (HC n=10, CF n=10, SAID n=4, 
NCFB=4) and HBEC lines (n=3). Cells were stimulated with LPS (10ng/mL, 4 hours), 
followed by ATP (5mM, 30 minutes). A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values •, o, * = £0.05, ••, o o ,**= 
£0.01, •••, o o o ,***= £0.001 and ••••, o o o o, ****= £0.0001).   
 
3.5 Monocyte and macrophage phenotypes in CF 
 
3.5.1 M1 and M2 macrophage polarisation 
 
 To determine if elevated IL-1b and IL-18 levels correlate with a sustained, chronic 
inflammatory response, as seen in CF, the capacity of human CF monocytes to differentiate 
into M1-type and M2-type macrophages was analysed. M1-type macrophages are considered 
to have a proinflammatory role in peripheral tissues and are characterised by an inherent ability 
to produce proinflammatory IL-6 and TNF cytokines, whilst M2-type macrophages are 
archetypically associated with production of the anti-inflammatory cytokine, IL-10. Peripheral 
monocytes were differentiated and activated into either M1-type or M2-type macrophages. 
Macrophage cell surface markers and intracellular cytokines were measured, using flow 
cytometry and ELISA and characterised, as described in section 3.2.3 and Figure 3.5.1.1, with 
details of the gating in appendix figure 3. 
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Figure 3.5.1.1: Monocyte to macrophage in vitro polarisation. Surface markers for M1-type 
(CD14+ CD16+ HLA-DR+ CD274+ CD86+) and M2-type (CD14+ CD16+ CD206+) were 
analysed using flow cytometry. M1-type macrophage activation was achieved by 
supplementing growth media with 100ng/mL human IFN-g, 100ng/mL TNF and 50ng/mL 
LPS. M2-type macrophage activation was achieved by supplementing growth media with 
20ng/mL IL-13 and 20ng/mL IL-4. M1 macrophages display a rounded morphology, whilst 
M2 macrophages display a tortuous, dendritic morphology (appendix figure 4). 
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Figure 3.5.1.2: M1/M2-type macrophage polarisation. Monocytes from whole blood were 
differentiated into macrophages and characterised as M1-type (markers- CD14+ CD16+ HLA-
DR+ CD274+ CD86+ TNFHI) or M2-type (markers- CD14+ CD16+ CD206+ IL-10HI). Numbers 
of polarised macrophages are presented as percentage of total macrophages in samples (n=7). 
The Mann-Whitney non-parametric test was performed (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001). 
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Following ex vivo monocyte differentiation, we observed no significant difference in 
M1-type macrophages, although there is an elevated proportion of M1-type macrophages in 
patients with CF, compared to HCs. There was a significantly decreased number of M2-type 
macrophages from patients with CF compared to HC macrophages. Furthermore, these changes 
were associated with significantly increased production of IL-6 by M1-type macrophages, 
originating from CF patients, and also reduced IL-10 release by CF-derived M2-type 
macrophages compared to HC. 
  
(Figure 3.5.1.3 legend on next page) 
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Figure 3.5.1.3: M1/M2 macrophage cytokine secretion. IL-6 and IL-10 levels were 
measured by ELISA from macrophage supernatant (n=7). A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
3.5.2 Monocyte populations 
 
In addition to the above differences in M1-type and M2-type macrophage phenotype, 
there was some expansion of peripheral monocytes of intermediate and non-classical 
phenotype, known to be associated with other chronic inflammatory conditions, such as 
atherosclerosis and rheumatoid arthritis, and a related significant decrease in numbers of 
classical monocytes. Details of the gating in appendix figure 3. 
 
Figure 3.5.2.1: Peripheral monocyte populations. Monocytes were gated on based on 
forward and side scatter and then based on CD14 and CD16 expression as follows: classical 
(CD14++CD16−), non-classical (CD14dimCD16++), and intermediate (CD14++CD16+). 
Cells were stimulated with LPS (10ng/mL, 4 hours). The Mann-Whitney non-parametric test 
was performed (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
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3.6 Hypoxia 
 
Hypoxia was included as an experimental condition in this study as the lower lung is 
often observed as being hypoxic due to mucous plugging, with anaerobic P. aeruginosa present 
in the CF lung (Hassett et al., 2009, Legendre et al., 2011, Fritzsching et al., 2015, Montgomery 
et al., 2017). Under hypoxic conditions all HBEC lines secreted significantly increased IL-18, 
despite the absence of stimulation with LPS or ATP. Upon stimulation with LPS and ATP 
under hypoxic conditions, all HBEC lines secreted significantly increased IL-18 compared to 
the same stimulation at normoxia. Notably the HBEC lines, with CF-associated mutations, had 
significantly increased IL-18 secretion in normoxia and hypoxia compared to WT Beas-2b 
HBEC lines under the same conditions and stimulations; however, IL-18 secretion was around 
2-fold in all cell lines and MCC950 blocked all IL-18 secretion under both normoxic and 
hypoxic conditions. 
 Similar observations were made with IL-18 and IL-1b, using monocytes from HC and 
CF cohorts, with significantly higher amounts of both cytokines being secreted by CF 
monocytes, and this being exacerbated around 2-fold under hypoxic conditions. Notably, HC 
monocytes did not increase IL-18 secretion under hypoxia after stimulation compared to the 
same stimulations at normoxia. 
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(Figure 3.6.1 legend on next page) 
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Figure 3.6.1: in vitro IL-1b and IL-18 secretion in HBEC lines and primary monocytes 
under either normoxic or hypoxic conditions. ELISA assays were used to detect IL-1b and 
IL-18 from supernatants of primary monocytes (HC n=6; CF n=6) and HBEC lines (n=3). Cells 
were cultured overnight in the Don Whitley H35 Hypoxystation at 1% O2 for hypoxic 
conditions and at 21% O2 5% CO2 in a SANYO MC0 20A1C incubator for normoxia. After 
the overnight incubation, cells were stimulated with LPS (10ng/mL) for 4 hours before being 
stimulated for 30 minutes with ATP (5mM). A repeated measures 2-way ANOVA statistical 
test was performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, 
***= £0.001 and ****= £0.0001).   
 
TNF was also measured in the same supernatants. Interestingly, no elevation in TNF 
secretion was observed under hypoxia in any of the HBEC lines. However, CF monocytes 
increased TNF secretion by around 2-fold under hypoxic conditions compared to normoxia 
with the same stimulations, whereas HC monocytes did not, with no significant difference 
observed between normoxia and hypoxia as with the HBEC lines. MCC950 did not inhibit 
TNF secretion. 
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Figure 3.6.2: In vitro TNF secretion from in HBEC lines and primary monocytes in either 
normoxic or hypoxic conditions. ELISA assay was used to detect TNF from supernatants of 
primary monocytes (HC n=6; CF n=6) and HBEC lines (n=3). Cells were cultured overnight 
in the Don Whitley H35 Hypoxystation at 1% O2 for hypoxic conditions and at 21% O2 5% 
CO2 in a SANYO MC0 20A1C incubator for normoxia. After the overnight incubation, cells 
were stimulated with LPS (10ng/mL) for 4 hours before being stimulated for 30 minutes with 
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ATP (5mM). A repeated measures 2-way ANOVA statistical test was performed with Turkey’s 
multiple comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
3.7 Modulation of IFNg responses by NLRP3 activation 
 
Figure 3.7.1.1: IFNg gene expression and secretion in peripheral blood mononuclear cells. 
Taqman® RT-qPCR was used to measure IFNg gene expression and Luminex was used to 
measure IFNg secretion from peripheral blood mononuclear cells (PBMC) populations from 
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HCs and patients with CF-associated mutations (n=10). Cell stimulation was as follows: LPS 
(10ng/mL) 4-hours with an ATP (5mM) stimulation for the final 30 minutes. A repeated 
measures 2-way ANOVA statistical test was performed with Turkey’s multiple comparisons 
test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
In order to understand the consequences of elevated IL-1b and IL-18 on the adaptive 
immune system, PBMCs were stimulated with LPS and ATP in order to activate the NLRP3 
inflammasome within monocytes. Monocytes express TLR4/2, which detect LPS. It has been 
previously described that IL-18 and IL-1b are able to activate and cause proliferation and 
activation of natural killer (NK) cells, T-helper 1 (TH1) and TH17 cells. The hypothesis of this 
experiment is that the subsequent IL-18 and IL-1b secreted by the activated monocytes within 
the PBMC population, will then activate NK cells. IFNg gene expression and secretion were 
measured in LPS/ATP stimulated PBMCs to detect activated NK cells. Post-NLRP3 
inflammasome activation, IFNg gene expression and secretion in PBMCs were significantly 
increased in the PBMCs from patients with CF. 
 
3.8 Ionic fluxes 
 
3.8.1 Sodium flux 
 
Having established that the priming and activation of the NLRP3 inflammasome is 
exacerbated and hyper-responsive in HBECs and monocytes with CF-associated mutations 
through stimulation with LPS and ATP or ouabain, it was important to establish the precise 
mechanism behind this exaggerated response. NLRP3 was of interest, primarily due to its 
known activating event being K+ efflux in combination with the primary CF-causing mutation 
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being within an ion channel. Investigating ion channel flux and intracellular ion concentration 
was carried out by using fluorescent molecular probes, which bind to free, intracellular Na+ 
and K+ ions. Cells were cultured in 96-well plates and stimulated, as in previous experiments, 
for NLRP3 inflammasome activation, but with the addition of pre-treatments of key ion 
channel inhibitors in order to elucidate changes in intracellular ion concentration and NLRP3 
inflammasome activation. The hypotheses in these experiments are centred around the 
relationship between Na+ and K+ ion fluxes. As previously discussed (Section 1.1), Na+ influx 
is elevated in many CF genotypes, due to loss of control of ENaC activity owing to loss of 
functional CFTR surface protein. Dysregulated Na+ influx will produce various molecular 
consequences that cells with CF-associated mutations are required to adapt to in order to 
maintain cellular homeostasis. An important adaptation required to address the restoration of 
ionic or electrochemical homeostasis is the balance of ionic gradients. Na+ and K+ exist as an 
ionic gradient with a low intracellular Na+ concentration and a high K+ intracellular 
concentration. This gradient is maintained by the Na+/K+ ATP-gated channel, which will pump 
the aforementioned ions across the plasma membrane against the electrochemical gradient; this 
process requires energy in the form of ATP. With excess Na+ influx, the natural 
electrochemical gradient is disturbed, requiring the Na+/K+ ATP-gated pump to increase its 
activity in order to maintain this homeostasis. A consequence of this will be influx of K+. As 
K+ efflux is the common NLRP3 inflammasome activator it is of interest to probe this 
molecular adaptation, to further understand the role uninhibited Na+ influx has on the efflux of 
K+ upon stimulation. 
To understand the extent of Na+ influx in cells with CF-associated mutations, HBECs 
and monocytes from HC individuals and patients with CF were stimulated with amiloride, a 
potent Na+ channel inhibitor. When cells from all cohorts are treated with amiloride, the 
intracellular Na+ concentration is significantly reduced. Notably, the increase in intracellular 
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Na+ concentration after ATP stimulation was significantly higher in both HBECs and 
monocytes, possessing CF-associated mutations, compared with their WT equivalents. A 
significant decrease in Na+ concentration also occurred in response to pre-treatment with EIPA 
and the SPLUNC1-derived peptide S18, to a similar extent to that seen with amiloride across 
both cell types and WT or CF. Ouabain increased Na+ concentration within the cells as 
expected. Due to the nature of the assay, changes in intracellular ion concentrations from 
baseline or untreated control samples, basal levels of intracellular Na+ or K+ concentration 
cannot be compared across cell line or patients with confidence, as the quantification is 
arbitrary. 
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Figure 3.8.1.1: Intracellular Na+ flux in HBEC lines and primary monocytes. Intracellular 
Na+ was detected using an AM ester of sodium indictor SBFI (S-1263); changes in fluorescence 
were measured by fluorimeter post-stimulation in monocytes from patients with CF (a) (n=7) 
as well as HBECs (b) (n=3). Cell stimulation was as follows: amiloride (100mM, 1hour), EIPA 
(10µM, 1 hour), S18 derived peptide (25µM, 4 hours) and ouabain (100nM, 24 hours) were 
pre-treated before a stimulation with LPS (10ng/mL) for 4-hours with an ATP (5mM) 
a 
b 
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stimulation for the final 30 minutes. A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values •, * = £0.05, ••, **= £0.01, •••, 
***= £0.001 and ••••, ****= £0.0001) where the symbol • refers to the relevant level of 
significance between the indicated bar with that of the ATP alone stimulation for that bar’s 
cohort. 
 
3.8.2 Potassium flux 
 
Stimulation of both HBECs and monocytes with ATP will activate and open the P2X7 
purinoceptor. This is observed in Figure 3.8.2.1, with a 60% decrease in intracellular K+ 
concentration after stimulation. Interestingly, this efflux of K+ is greater in HBECs with CF-
associated mutations. Whether the amount of K+ efflux corresponds with the level of NLRP3 
activation and thus IL-1b and IL-18 secretion is not clear, but in these experiments the two 
observations seem to be strongly associated. A similar interpretation is made with monocyte 
stimulations, with greater ATP-driven K+ efflux in monocytes from patients with CF. When 
amiloride or the SPLUNC1-derived S18 peptide was used to inhibit ENaC Na+ influx, a notable 
reduction in K+ efflux was observed, indicating a relationship between amiloride-sensitive Na+ 
influx and ATP-dependent K+ efflux. The EIPA pre-treatment, which targeted all Na+ channels 
except for ENaC, where its inhibition is minimal, did not significantly modulate K+ efflux upon 
stimulation, compared to cells with no pre-treatment with ion channel inhibition. Ouabain 
increased K+ efflux within the cells, as expected. 
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Figure 3.8.2.1: Intracellular K+ flux in HBEC lines and primary monocytes. Intracellular 
K+ was detected using an AM ester of potassium indictor PBFI (P-1266); changes in 
fluorescence were measured by fluorimeter post-stimulation in monocytes from patients with 
CF (a) (n=7) as well as HBECs (b) (n=3). Cell stimulation was as follows: amiloride (100mM, 
1hour), EIPA (10µM, 1 hour), S18 derived peptide (25µM, 4 hours) and ouabain (100nM, 24 
hours) were pre-treated before a stimulation with LPS (10ng/mL) for 4-hours with an ATP 
a 
b b 
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(5mM) stimulation for the final 30 minutes. A repeated measures 2-way ANOVA statistical 
test was performed with Turkey’s multiple comparisons test (p values •, * = £0.05, ••, **= 
£0.01, •••, ***= £0.001 and ••••, ****= £0.0001) where the symbol • refers to the relevant 
level of significance between the indicated bar with that of the ATP alone stimulation for that 
bar’s cohort. 
 
3.9 Effects of ion channel inhibition on NLRP3 inflammasome activation 
 
3.9.1 Sodium Channel inhibition 
 
In order to study whether Na+ influx predisposes K+ efflux upon ATP stimulation in the 
context of inflammation, in particular NLRP3 activation, cytokine secretion, caspase-1 activity 
and pyroptosis were all measured in the presence of various channel inhibitors. The hypothesis 
that Na+ flux modulates K+ flux and, therefore, NLRP3 inflammasome has been previously 
tested (Munoz-Planillo et al., 2013, Yaron et al., 2015); however, in this study the hypothesis 
was tested in the context of a channelopathy (CF) wherein ENaC-driven Na+ influx is 
pathologically overactive. The following data describe how these ion channel inhibitors 
modulate NLRP3 inflammasome activation upstream, in cells with CF-associated mutations. 
To elucidate the role of Na+ influx in cells with CFTR mutations, selected Na+ channel 
inhibitors, with a range of potencies and specificities, were used to better understand which 
channel activities are pathogenic in CF and how modulating these channels may have anti-
inflammatory benefits in vitro in terms of NLRP3 inflammasome activation. n-amidino-3,5 
diamino-6-chloropyrazine carboxamide (amiloride), 5-(N-Ethyl-N-isopropyl) amiloride 
(EIPA) and SPLUNC1-peptide 18 (S18) were used to treat cells in order to diminish Na+ flux 
in both HBECs and monocytes. Amiloride targets ENaC with high potency, but is nonspecific, 
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and has been shown to inhibit a variety of other Na+ channels at higher doses. EIPA is a broad-
spectrum Na+ channel inhibitor but has poor inhibition of ENaC. 
 
(Figure 3.9.1.1 legend on next page) 
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Figure 3.9.1.1: The effects of amiloride on cytokine secretion in HBEC lines and primary 
monocytes. ELISA assays were used to detect IL-18 and IL-1β in monocytes from HC (n=10), 
patients with CF (n=10), SAID (n=4) and NCFB (n=4) as well as HBECs (n=3). Cell 
stimulation was as follows: Amiloride (100mM or 10mM, 1hour) was used as a pre-treatment 
before a stimulation with LPS (10ng/mL) for 4-hours with an ATP (5mM) stimulation for the 
final 30 minutes. A repeated measures 2-way ANOVA statistical test was performed with 
Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= 
£0.0001).   
 
Finally, S18 is an experimental compound, kindly gifted by Spyryx Biosciences, Inc 
®, which is highly specific for ENaC and has been demonstrated to have no off-target ion 
channel inhibition. S18 is a compound derived on the endogenous SPLUNC1 protein, 
described earlier. With the above compounds, the precise contribution of ENaC dependent Na+ 
influx on downstream NLRP3 priming and assembly can be assessed. The relationship between 
Na+ and K+ signalling is complex, with several channels with a multitude of activating signals 
and feedback mechanisms controlling the flux of both ions. The following experiments were 
designed to elucidate the role of the ENaC Na+ channel in modulating K+ and thus NLRP3 
inflammasome activation.  
In order to activate the NLRP3 inflamamsome, K+ efflux is required for assembly of 
the protein complex, decribed previously (Section 1.3). There are multiple molecules that are 
able to induce a strong enough K+ efflux for NLRP3 activation (optimised in appendix figure 
1). Previously ATP and ouabain were used to this end, however as ouabain is itself an ion 
channel inhibitor and ATP is capable of opening various ion channels, the pore forming toxin 
nigericin is used throughout sections 3.9.1-3 to ensure that the effects any ion channel inhibitor 
has on inflammation are not clouded by off-target ATP activity. 
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Figure 3.9.1.1 investigates the anti-inflammatory effects of amiloride at two 
concentrations commonly used in the literature (Rolfe et al., 1992). At 100mM, amiloride 
inhibited IL-18 secretion in all ATP stimulated HBEC lines with CF-associated mutations, 
which was statistically significant (Figure 3.9.1.1 A). CuFi-4 (∆f508/G551D) did not produce 
an increased IL-18 without amiloride pre-treatment. At the lower 10mM concentration, 
amiloride was unable to effect IL-18 secretion in any HBEC line. Amiloride, at either 
concentration, did not affect IL-18 secretion in the Beas-2b (WT) HBEC line. Without 
amiloride, CF and SAID monocytes secreted statistically significant IL-18 and IL-1b levels, 
upon stimulation with either LPS and ATP or nigericin, compared to HC and NCFB 
monocytes. When amiloride at 100mM is pre-treated before NLRP3 inflammasome activation, 
IL-18 and IL-1b secretion is no longer statistically significant compared to HC or NCFB 
monocytes under the same conditions. This reduction in IL-18 and IL-1b secretion does not 
occur in SAID, NCFB or HC monocytes, indicating a CF specific phenomenon. At 10mM, 
amiloride is able to reduce IL-18 but not IL-1b under the same conditions. 
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(Figure 3.9.1.2 legend on next page) 
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Figure 3.9.1.2: The effects of EIPA on cytokine secretion in HBEC lines and primary 
monocytes. ELISA assays were used to detect IL-18 and IL-1β in monocytes from HC (n=10), 
patients with CF (n=10), SAID (n=4) and NCFB (n=4) as well as HBECs (n=3). Cell 
stimulation was as follows: EIPA (10µM, 1 hour) was used as a pre-treatment before a 
stimulation with LPS (10ng/mL) for 4-hours with an ATP (5mM) stimulation for the final 30 
minutes. A repeated measures 2-way ANOVA statistical test was performed with Turkey’s 
multiple comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
EIPA is a broad-spectrum Na+ channel inhibitor but has been shown to inhibit ENaC 
with low potency. The data in figure 3.9.1.2 show the effects of an EIPA pre-treatment on the 
secretion of IL-18 and IL-1b after NLRP3 inflammasome activation. The amount of IL-18 
secretion did not change with EIPA pre-treatment in any of the HBEC cell lines. The absence 
of any anti-inflammatory effects of EIPA are also observed in stimulation of primary 
monocytes with neither IL-18 or IL-1b secretion being inhibited by EIPA in any of the patient 
cohorts. 
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(Figure 3.9.1.3 legend on next page) 
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Figure 3.9.1.3: The effects of S18 peptide on cytokine secretion in HBEC lines and 
primary monocytes. ELISA assays were used to detect IL-18 and IL-1β in monocytes from 
HC (n=10), patients with CF (n=10), SAID (n=4) and NCFB (n=4) as well as HBECs (n=3). 
Cell stimulation was as follows: S18 derived peptide (25µM, 4 hours) was used as a pre-
treatment before a stimulation with LPS (10ng/mL) for 4-hours with an ATP (5mM) 
stimulation for the final 30 minutes. A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001).   
 
The observation that a pre-treatment of amiloride (specifically at 100mM) is able to 
potently inhibit the secretion of the cytokines IL-18 and IL-1b, processed by the NLRP3 
inflammasome, in cells with CF-associated mutations suggests that overactive ENaC is 
regulating NLRP3 activation via modulating Na+ and K+ efflux. This potential mechanism is 
further corroborated by the failure of EIPA to replicate the anti-inflammatory effects of 
amiloride. In order to further confirm this hypothesis S18, a highly potent and specific 
inhibitory peptide based on the endogenous ENaC inhibitor SPLUNC1, was used to confirm 
that inhibition of ENaC modulates NLRP3 activation in cells with CF-associated mutations. 
 The peptide S18 was able to inhibit IL-18 and IL-1b secretion from both ATP or 
nigericin stimulated monocytes and HBECs with CF-associated mutations (Figure 3.9.1.3), to 
a similar extent to that of amiloride at 100mM (Figure 3.9.1.1). S18 had no effect on IL-18 and 
IL-1b secretion from monocytes and HBECs from HC, NCFB or SAID cohorts. 
 
 To understand the point at which inhibition of ENaC activity modulates IL-18 and IL-
1b secretion from monocytes and HBECs with CF-associated mutations, caspase-1 activity 
was measured using a colorimetric assay using cell lysates. These experiments are aimed at 
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deciphering whether it is the secretion of IL-18 and IL-1b that is being inhibited or the 
processing of the zymogens by active caspase-1 and, therefore, NLRP3 assembly. 
 Figure 3.9.1.4 displays data measuring caspase-1 activity as a percentage of non-
induced, or unstimulated sample. Upon stimulation with LPS and ATP, caspase-1 activity 
increases compared to the non-induced sample by around 30% in the Beas-2b (WT) HBEC 
line. This increase in caspase-1 activity is not altered by pre-treatment with amiloride (100mM 
or 10mM), EIPA or S18 peptide. Amiloride (100mM) was able significantly reduce caspase-1 
activity in IB3-1 (∆f508/W1282X) and CuFi-1 (∆f508/∆f508) HBEC lines, with S18 peptide 
able to do so in all three HBEC lines with CF-associated mutations. The reduction in caspase-
1 activity with amiloride (100mM) and S18 peptide also occurred in primary monocyte 
cultures, with the significant increase in caspase-1 in CF monocytes compared to HC 
monocytes diminishing to non-significant levels.
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Figure 3.9.1.4: Caspase-1 activity in HBEC lines and monocytes. A colorimetric assay to 
determine caspase-1 activity via cleavage of a caspase-specific peptide conjugated to a colour 
reporter molecule p-nitroalinine (pNA). The assay was performed in protein lysates from 
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primary monocytes from individuals with CF, NCFB, SAID and HCs (HC n=10, CF n=10, 
SAID n=4, NCFB=4) and HBEC lines (n=3). Cell stimulation was as follows: Amiloride 
(100mM, 1hour), EIPA (10µM, 1 hour) or S18 derived peptide (25µM, 4 hours) were used as 
a pre-treatment before a stimulation with LPS (10ng/mL) for 4-hours with an ATP (5mM) 
stimulation for the final 30 minutes. A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001).   
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Figure 3.9.1.5: The effects of sodium channel and NLRP3 inhibition on pyroptosis after 
NLRP3 inflammasome activation in HBEC lines and primary monocytes. The figure 
displays pyroptosis representing the percentage of total necrosis that is caspase-1 dependent, 
or pyroptosis. Pyroptotic cell death was calculated by measuring total necrosis via the presence 
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of lactose dehydrogenase (LDH) from cell culture samples in a 96-well plate, colorimetric 
assay. Each sample/condition was repeated in parallel with a caspase-1 inhibitor (AC-
YVADD-cmv, 2µg/mL, 1 hour) pre-treatment. The total necrosis level was then taken away 
from the capase-1 inhibited sample, or ‘caspase-1 independent’ necrosis, with the remaining 
LDH level termed ‘caspase-1 dependent necrosis’ or pyroptosis. The assay was performed with 
primary monocytes from individuals with CF, NCFB, SAID and HCs (HC n=10, CF n=10, 
SAID n=4, NCFB=4) and HBEC lines (n=3). Cell stimulation was as follows: Amiloride 
(100mM, 1hour), EIPA (10µM, 1 hour), S18 derived peptide (25µM, 4 hours) or MCC950 
(15nM, 1 hour) were used as a pre-treatment before a stimulation with LPS (10ng/mL) for 4-
hours with an ATP (5mM) stimulation for the final 30 minutes. A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
In order to assess the downstream significance of ENaC-driven NLRP3 inflammasome 
activation and elevated IL-18 and IL-1b secretion, pyroptosis was measured, as in section 3.4.5. 
In Figure 3.9.1.5, pyroptotic cell death (caspase-1 dependent necrosis) is shown to be increased 
in HBEC lines with CF-associated mutations after NLRP3 inflammasome activation. The 
percentage of pyroptosis after NLRP3 inflammasome activation decreased when either 
amiloride (100mM) or S18 peptide was added to the cell culture before NLRP3 inflammasome 
activation. Amiloride at 10mM was also able to significantly inhibit pyroptosis in IB3-1 
(∆f508/W1282X) and CuFi-4 (∆f508/G551D) HBEC lines. EIPA had no effect on pyroptosis 
in any of the HBEC lines. 
 A similar set of stimulations was used in primary monocyte cultures, with a similar 
outcome. Amiloride at 100mM and S18 peptide reduced pyroptosis in primary monocytes with 
CF-associated mutations but not in HC, NCFB or SAID cohorts. Pre-treatment with MCC950 
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almost completely abrogated pyroptotic cell death in primary monocytes from all patient 
cohorts. 
 
3.9.2 Chloride Channel inhibition 
 
By using small molecules and peptides to inhibit Na+ channels, an increased 
intracellular Na+ concentration and enhanced K+ efflux has been diminished in cells with CF-
associated mutations. Furthermore, the ENaC specific Na+ channel inhibitors were able to 
modulate and decrease caspase-1 activity, IL-18 and IL-1b secretion and pyroptosis in cells 
with CF-associated mutations. Next, Cl- channel inhibitors were used to understand whether 
the exacerbated NLRP3 inflammasome activation was in fact due to aberrant Na+ channel, 
specifically ENaC, activity or due to deregulation of Cl- flux, as is the case with mutations in 
the CFTR. 5-Nitro-2-(3-phenylpropylamino) benzoic acid (NPPB) inhibits calcium-sensitive 
chloride currents and the CFTR172 small molecule inhibits the conductance of chloride currents 
by the CFTR. Therefore, NPPB was used to inhibit global Cl- channels and CFTR172 to inhibit 
the activity of the CFTR specifically. 
As previously shown, HBECs with CF-associated mutations secreted increased IL-18 
and primary monocytes harvested from individuals with CF-associated mutations secreted 
increased IL-18 and IL-1b upon in vitro NLRP3 inflammasome activation. NPPB did not alter 
IL-18 secretion (Figure 3.6.2.1) in HBEC lines, except of IB3-1(∆f508/W1282X), where IL-
18 secretion significantly increased. NPPB was also ineffective and modulating IL-18 or IL-
1b in any of the primary monocyte cohorts. Notably, the CFTR172 small molecule decreased 
IL-18 in all HBEC lines and both IL-18 and IL-1b, particularly the latter in all primary 
monocyte cohorts.  
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(Figure 3.9.2.1 legend on next page) 
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Figure 3.9.2.1: The effects of NPPB on cytokine secretion in HBEC lines and primary 
monocytes. ELISA assays were used to detect IL-18 and IL-1β in monocytes from HC (n=10), 
patients with CF (n=10), SAID (n=4) and NCFB (n=4) as well as HBECs (n=3). Cell 
stimulation was as follows: NPPB (100µM, 1 hour) or CFTR172 (10µg/mL, 1 hour) were pre-
treated for 4-hours before a stimulation with LPS (10ng/mL) for 4-hours with an ATP (5mM) 
stimulation for the final 30 minutes. A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001).   
 
Again, in order to understand the role reduced Cl- flux has on NLRP3 inflammasome 
activation, caspase-1 activity was measured under the same conditions. NPBB did not change 
caspase-1 activity, upon LPS and ATP stimulation, in either HBEC lines or primary monocytes 
in any cohort or genotype. However, CFTR172 was able to reduce caspase-1 activity 
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significantly in all HBEC lines and primary monocytes in all cohort or genotypes. 
 
Figure 3.9.2.2: The effect of NLRP3 inhibition on caspase-1 activity in HBEC lines and 
monocytes. A colorimetric assay to determine caspase-1 activity via cleavage of a caspase-
specific peptide conjugated to a colour reporter molecule p-nitroalinine (pNA). The assay was 
performed in protein lysates from primary monocytes from individuals with CF, NCFB, SAID 
and HCs (HC n=10, CF n=10, SAID n=4, NCFB=4) and HBEC lines (n=3). Cell stimulation 
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was as follows: NPPB (100µM, 1 hour) or CFTR172 (10µg/mL, 1 hour) were pre-treated for 1-
hour before a stimulation with LPS (10ng/mL) for 4-hours with an ATP (5mM) stimulation for 
the final 30 minutes. A repeated measures 2-way ANOVA statistical test was performed with 
Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= 
£0.0001).   
 
Figure 3.9.2.3: The effects of CFTR and NLRP3 inhibition on pyroptosis after NLRP3 
inflammasome activation in HBEC lines and primary monocytes. The figure displays 
pyroptosis representing the percentage of total necrosis that is caspase-1 dependent, or 
pyroptosis. Pyroptotic cell death was calculated by measuring total necrosis via the presence 
of lactose dehydrogenase (LDH) from cell culture samples in a 96-well plate, colorimetric 
assay. Each sample/condition was repeated in parallel with a caspase-1 inhibitor (AC-
YVADD-cmv) pre-treatment. The total necrosis level was then taken away from the capase-1 
inhibited sample, or ‘caspase-1 independent’ necrosis, with the remaining LDH level termed 
‘caspase-1 dependent necrosis’ or pyroptosis. The assay was performed with primary 
monocytes from individuals with CF, NCFB, SAID and HCs (HC n=10, CF n=10, SAID n=4, 
  
135 
NCFB=4) and HBEC lines (n=3). Cell stimulation was as follows: MCC950 (15nM, 1 hour) 
or CFTR172 (10µg/mL, 1 hour) were pre-treated for 1-hour before a stimulation with LPS 
(10ng/mL) for 4-hours with an ATP (5mM) stimulation for the final 30 minutes. A repeated 
measures 2-way ANOVA statistical test was performed with Turkey’s multiple comparisons 
test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
Pyroptotic cell death was then analysed using CFTR172 and MCC950, the NLRP3 
inflammasome inhibitor. Both small molecules almost completely inhibited pyroptotic cell 
death in all HBEC lines, with MCC950 displaying slightly increased effectiveness. 
 
3.9.3 Sodium Potassium ATP gated Channels inhibition 
 
Finally, Na+/K+ ATP gated channel inhibition was tested for its ability to modulate 
NLRP3 inflammasome activation. Both ouabain and digoxin have been shown to inhibit the 
activity of the Na+/K+ ATP gated channel, with high efficacy. The Na+/K+ ATP gated channel 
has been shown to be highly active in CF epithelia. In the context of the hypotheses tested in 
this study, Na+/K+ ATP gated channel activity is thought to be increased as a compensatory 
mechanism to efflux excess intracellular Na+ concentration, in exchange for K+ hence the 
increased propensity, or decreased threshold for NLRP3 inflammasome activation. However, 
ouabain is a known NLRP3 inflammasome activator, due to its role in replenishing and 
maintaining intracellular K+. 
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(Figure 3.9.3.1 legend on next page) 
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Figure 3.9.3.1: The effects of sodium/potassium ATP gated channel inhibition on cytokine 
secretion in HBEC lines and primary monocytes. ELISA assays were used to detect IL-18 
and IL-1β in monocytes from HC (n=10), patients with CF (n=10), SAID (n=4) and NCFB 
(n=4) as well as HBECs (n=3). Cell stimulation was as follows: ouabain (100nM, 24 hours) or 
digoxin (100nM, 24 hours) were pre-treated before a stimulation with LPS (10ng/mL) for 4-
hours with an ATP (5mM) stimulation for the final 30 minutes. A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
Pre-treatment of either ouabain or digoxin increased IL-18 secretion in the IB3-1 
(∆f508/W1282X) HBEC line, although they had little effect in CuFi-1 (∆f508/∆f508) and 
CuFi-4 (∆f508/G551D) HBEC lines. IL-18 and IL-1b secretion did not change with incubation 
of ouabain or digoxin in any of the primary monocyte cohorts. Caspase-1 activity also remained 
unchanged with incubation of ouabain or digoxin in any of the HBEC lines or primary 
monocyte cohorts. 
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Figure 3.9.3.2: The effects of sodium/potassium ATP gated channel inhibition on caspase-
1 activity in HBEC lines and monocytes. A colorimetric assay to determine caspase-1 activity 
via cleavage of a caspase-specific peptide conjugated to a colour reporter molecule p-
nitroalinine (pNA). The assay was performed in protein lysates from primary monocytes from 
individuals with CF, NCFB, SAID and HCs (HC n=10, CF n=10, SAID n=4, NCFB=4) and 
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HBEC lines (n=3). Cell stimulation was as follows: ouabain (100nM, 24 hours) or digoxin 
(100nM, 24 hours) were pre-treated for 1-hour before a stimulation with LPS (10ng/mL) for 4-
hours with an ATP (5mM) stimulation for the final 30 minutes. A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test  (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
 
3.10 Discussion 
 
3.10.1 Systemic autoinflammation in CF 
 
IL-1 was first described by Auron et al as a protein with several biological activities 
regulating host defence and immune responses, which requires post-translational processing 
into its active form (Auron et al., 1984, Dinarello, 1998). This processing is predominantly 
achieved via assembly of inflammasomes and subsequent caspase-1 cleavage. It is now known 
that IL-1 is just one (IL-1b) of a family of related cytokines with both pro- and anti-
inflammatory effects. IL-1b is a highly potent cytokine that, despite being at low or 
undetectable levels in the circulation, mediates a systemic immune response (McDermott, 
2004, Church et al., 2008, Dinarello Charles, 2017). The predominant sources of IL-1b at sites 
of inflammation are myeloid and epithelial innate immune cells (Lei-Leston et al., 2017, 
Dinarello, 1996, Dinarello, 1998). It has been established that pulmonary inflammation in CF 
is driven by the innate immune system, with increased numbers of neutrophilic infiltrations, 
the presence of neutrophil extracellular traps (NETs) as well as myeloid cell recruitment (Law 
and Gray, 2017, Mall et al., 2004, Machen, 2006, Bruscia et al., 2009, Cohen and Prince, 2012, 
Gao and Su, 2015, Montgomery et al., 2017). 
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To address the importance of IL-1 cytokines in CF, serum levels of IL-1b, IL-18 and 
IL-1Ra were measured in the serum of patients with either CF, NCFB, or diagnosed 
autoinflammatory disease in addition to healthy controls (HC). Consistent with previous 
studies, members of this cytokine family are significantly elevated in sera from patients with 
CF, with levels comparable to that of individuals with functional mutations in the IL-1-
inflammasome pathway (Rimessi et al., 2015, Fritzsching et al., 2015, Iannitti et al., 2016, 
Montgomery et al., 2017). 
 With increased levels of IL-1b and IL-18 in the periphery, the hypothesis that these 
systemic cytokines contribute to the inflammatory phenotype observed in CF is supported. The 
fact the IL-1Ra is also elevated can be evaluated in two ways: firstly, it may be postulated that 
there is a potent anti-inflammatory response in CF that is specific to the inflammasome and IL-
1 cytokine pathway, and secondly that the presence of IL-1Ra further indicates the activation 
of the aforementioned pathway. Other serum inflammatory cytokines associated with innate 
immune activation and immunological pathologies, such as TNF and IL-6, were not elevated 
in CF to the same extent as members of the IL-1 cytokine family. These data suggest that IL-1 
cytokines are prevalent and play an essential role in CF disease pathology. Interestingly, the 
same CF patients with the higher IL-18 serum levels within the CF population, also had 
elevated TNF, caspase-1 activity, IL-1 and IL-1Ra serum levels. However, no associated with 
anti-inflammatory medication, exacerbation or genotype could be made to differentiate this 
group. 
Further evidence to support the hypothesis that the heightened, systemic inflammation 
in CF is autoinflammatory in nature comes from the fact that the cellular infiltrations into the 
lungs are innate immune cells (Veltman et al., 2016), and also the elevated caspase-1 activity 
and ASC speck release in serum from patients with CF. Using a flow cytometry-based assay, 
extracellular ASC specks were detected in sera from patients with CF, NCFB, SAID and HCs. 
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ASC is released from the cell when chronic inflammasome activation is sustained, leading to 
gasdermin D-dependent plasma membrane perforations and pyroptotic cell death. The presence 
of ASC in the serum indicates prolonged and elevated inflammasome-mediated inflammation 
and pyroptosis. In addition, increased caspase-1 activity in serum supports the hypothesis that 
increased pyroptotic cell death is a signature of systemic inflammation in CF. The case for 
autoinflammation in CF is further supported by data from the control cohorts in this study. The 
SAID cohort of patients have all confirmed diagnoses of mutations in well-characterised genes 
associated with sterile innate immune-driven inflammation. In addition, their disease is well 
controlled by biological therapies targeting established innate immune cytokines, such as 
anakinra for IL-1b. When analysing the serum data, comparing the CF and SAID cohorts 
allows for the conclusion that the nature and type of cytokine systemic cytokine response, 
particularly IL-18, is comparable across the two patient cohorts. Patients within the NCFB 
cohort have severe lung disease and bronchiectasis but have been confirmed not to have CF-
associated CFTR mutations. The serum cytokine levels, within the NCFB cohort, as well as 
the ASC speck and caspase-1 activity assays were analogous to that of HC, rather than CF or 
SAID. These observations provide evidence that the elevated serum cytokine levels, presence 
of ASC specks and increased caspase-1 activity in CF is due to an intrinsic molecular defect 
downstream from the CFTR mutation, rather than a symptom of respiratory infection, 
inflammation or scarring (bronchiectasis). 
These data also have implications beyond CF lung disease. As previously described 
(section 1.1), CF is a genetic disease that manifests as a multi-system, multi-organ disease. 
Many of the manifestations of CF are diseases in their own right, such as diabetes, arthritis, 
Crohn’s disease and liver disease. Interestingly, the individual pathologies and progression of 
all of these manifestations can be associated with IL-1 cytokine signalling. It is known that 
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there is a plethora of inflammasome priming and activating stimuli in the CF lung and there 
may be evidence for a sterile priming of NLRP3 and IL-1b. 
Therefore, based on these data there is a good reason to hypothesise that CF shares 
pathology with, or is in fact, an autoinflammatory disease. A further testable hypothesis is that 
excessive and inappropriate inflammasome activation in the CF lung causes elevated levels of 
systemic IL-1b and IL-18 secretion, which then drive secondary inflammatory complications 
in individuals with CF. 
This hypothesis, if accepted, justifies the use anti-inflammatory IL-1 targeted biologic 
therapy in CF to target systemic inflammation that stems from lung inflammation. This 
approach should proceed on the side of caution, as anti-inflammatory therapy in CF must be 
controlled so as not to compromise the individual’s immune response to infection. 
 
3.10.2 NLRP3 activation in CF 
 
To understand the cellular and molecular source of IL-1b, IL-18, IL-1Ra (and to a lesser 
extent IL-6 and TNF) in the sera of patients with CF, ASC specks and caspase-1 activity, in 
vitro assays were used to test monocytes and HBEC lines for inflammasome activation. Many 
inflammasomes from innate immune and epithelial cells utilise ASC as a component of the 
structural signalling platform, with IL-1b and IL-18 secretion and capsase-1 activity common 
to all inflammasomes, with only small variations in the preferential processing and secretion 
of IL-1b to IL-18. The next task was to identify the specific inflammasome responsible for the 
autoinflammatory-like state in CF. The experimental in vitro assay to distinguish 
inflammasomes is based on the unique and specific activating signals of each inflammasome. 
AIM2, NLRC4, Pyrin and NLRP3 inflammasomes were tested by priming expression of 
inflammasome components by activating the LPS/TLR4/NFkB signalling cascade (Figure 
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3.1.2). The second, activation or assembly signal is then administered (section 2.4). When 
testing AIM2, NLRC4 and pyrin inflammasomes, successful secretion of IL-1b and IL-18 was 
detected in HC and CF monocytes and the latter in HBECs from all genotypes. However, no 
significant difference was observed in terms of IL-1b or IL-18 secretion between HC and CF 
monocytes, or in IL-18 secretion between WT HBECs and HBECs with CF-associated 
mutations upon activation of AIM2, NLRC4 or pyrin inflammasomes. These data suggested 
that the elevated systemic inflammation observed in serum from patients with CF did not derive 
from AIM2, NLRC4 or pyrin inflammasomes. However, the case must be made that if there 
are excessive amounts of stimuli for the aforementioned inflammasomes then the observation 
that there is no intrinsic defect or difference in their activation compared to WT cells may not 
be relevant. These data do however fit the hypothesis that the link between CFTR mutation and 
inflammasome-driven autoinflammation in CF was centred around a disruption in ion flux. 
NLRP3 was an obvious candidate inflammasome for contributing to the pathogenic 
inflammatory state in CF, as its primary activating event is itself an ion flux- K+ efflux. In order 
to activate the NLRP3 inflammasome in vitro, specific stimuli that induce K+ efflux are used 
in combination with a selection of small molecule inhibitors, to elucidate the pathway in detail. 
Again, the LPS/TLR4/NF-kB signalling cascade was used to prime inflammasome expression, 
with ATP or ouabain being used as the K+ efflux inducing assembly/activating signal. Under 
these conditions IL-18 secretion was significantly increased in IB3-1 (∆f508/W1282X) and 
CuFi-1 (∆f508/∆f508) HBEC lines compared to Beas-2b (WT).  
Notably, the CuFi-4 (∆f508/G551D) HBEC line did not secrete significantly increased 
IL-18 upon NLRP3 inflammasome activation with either ATP or ouabain stimulation. This 
highlights an important phenomenon- there are genotypic differences in disease severity and 
progression in CF. In fact, there are often differences in disease severity and progression within 
CF-associated genotypes (Geborek and Hjelte, 2011, Najafi et al., 2015). For example, class I 
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mutations (of which W1282X is an example) are characterised by a lack of CFTR protein 
expression and are considered by many CF specialists to be one of the more clinically severe 
disease classes, whereas class IV mutations, characterised by poor CFTR channel conductance 
on the plasma membrane (of which R347H and R117H are examples), are less severe clinically 
with greater life expectancy (Marson et al., 2016). Each class of CF mutation may have 
differential downstream molecular mechanisms, in terms of inducing sterile inflammation, due 
to a disparity in surface CFTR expression, CFTR stability, CFTR conductance and CFTR 
folding within the ER. Clarifying the inflammatory mechanisms and consequences associated 
with these discrepancies is relevant but beyond the scope of this study. 
When HBEC lines are stimulated for NLRP3 inflammasome activation, as described 
above, in combination with a pre-treatment by small molecule inhibitors of NLRP3, caspase-1 
or TLR4, then subsequent IL-18, caspase-1 activity and pyroptosis are significantly inhibited. 
These data confirm that not only does the LPS and ATP/ouabain stimulate NLRP3 
inflammasome activation specifically, but that HBECs with CF-associated mutations 
inappropriately activate this pathway compared to WT HBECs. The most potent small 
molecule inhibitor for preventing IL-18 secretion in HBECs was the TLR4 inhibitor, indicating 
that the priming of the NLRP3 inflammasome was a crucial process in the secretion of IL-18. 
Similar data was generated when the NLRP3 inflammasome was stimulated under the 
same conditions, with the same inhibitors, in primary monocytes. Both IL-1b and IL-18 were 
secreted to a greater extent in primary monocytes from patients with SAID and CF than that of 
patients with NCFB or HC individuals. Again, TLR4 inhibition potently inhibited IL-1b and 
IL-18 secretion, as did MCC950 NLRP3 inhibitor. This suggests that inflammasome priming 
is essential and that inhibiting NLRP3, the PRR and initiator of ASC oligomerisation is crucial 
for downstream IL-18 and IL-1b secretion. The further upstream a small molecule targets, 
along the NLRP3 inflammasome pathway, the more effective the inhibitory effects on cytokine 
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secretion. This has implications for modern therapeutics, as current biologics act on the active, 
secreted cytokine (anakinra and canakinumab target IL-1b) rather than preventing its secretion 
upstream. Based on these data, targeting the upstream priming or assembly of aforementioned 
inflammasomes will be a more potent and successful approach for IL-1 mediated disease. 
 To further validate the above data, suggesting that the NLRP3 inflammasome 
is ‘inappropriately’ activated upon stimulation in CF comparable to that of SAID, caspase-1 
activity and pyroptosis were examined in vitro in HBEC lines and primary monocytes. 
Caspase-1 activity was elevated in NLRP3 stimulated (LPS and ATP) HBECs and monocytes 
with CF-associated mutations and primary monocytes from patients with SAID. This implies 
that more NLRP3 inflammasome complexes are being formed within cells with CF-associated 
mutations and primary monocytes from patients with SAID, with increased caspase-1 
expression and thus activity. When necrotic cell death was measured under the same 
conditions, elevated caspase-1 dependent pyroptosis cell death was increased in IB3-1 
(∆f508/W1282X) HBECs and primary monocytes from patients with CF and SAID. This 
confirms that chronic and inappropriate inflammasome activation is present in these cell types, 
leading to an increase in an inflammatory form of cell death. This was also supported by 
increased detection of extracellular ASC specks in primary monocyte cultures from patients 
with CF and SAID. Pyroptosis is, arguably, the most inflammatory form of cell death; with all 
the inflammatory consequences of necrosis but with active, assembled inflammasomes and the 
related cytokines also being released into the extracellular space. This this form of cell death 
heightened in cell with CF-associated mutations, one can conclude that the inflammatory 
response in CF is both excessive and pathogenic. 
 
3.10.3 Monocyte and macrophage polarisation in CF 
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An important aspect to consider regarding chronic NLRP3 inflammasome activation is 
the inflammatory phenotype of monocytes and macrophages, in the context of the CF lung, in 
combination with the potential intrinsic defects downstream of CFTR mutation. As previously 
discussed, monocytes differentiate into macrophages in vivo when entering tissues from the 
periphery and migrating to the site of inflammation. Macrophages can be put onto a spectrum 
of inflammatory phenotypes, with proinflammatory M1-type macrophages at one pole, and 
anti-inflammatory M2-type macrophages at the diametric opposite end of the spectrum (Italiani 
and Boraschi, 2014). These phenotypes are determined based on characterised cell surface 
markers and cytokine secretions. With a significant decrease in the ability of primary 
monocytes from patients with CF to differentiate in vitro into anti-inflammatory M2-type 
macrophages indicates that, due to intrinsic defects concomitant with CF-associated mutations, 
there is an autoinflammatory signature in CF. There is was more M1-type macrophage 
differentiation in monocytes from patients with CF, but the difference between HC M1-type 
macrophage differentiation was not statistically significant. The functionality of the 
differentiated macrophages was then analysed with CF macrophages producing significantly 
increased levels of IL-6 and significantly decreased IL-10. The observation that primary 
peripheral monocytes from patients with CF are predisposed to NLRP3 inflammasome 
activation and have a deficiency in the propensity for M2-type macrophage differentiation 
suggest that there autoinflammation is present in CF and is a major part of the pathology of 
chronic systemic inflammation in CF. Whether or not NLRP3 activation and/or priming is able 
to predispose a macrophage towards the M1-type, or rather away from the M2-type is an 
interesting hypothesis. There is evidence, in the literature, that this may be the case, but 
investigating this basic biological question is beyond the scope of this study. 
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3.10.4 Hypoxia exacerbates NLRP3 activation in CF 
 
 Hypoxia is an important factor in many disease states, including tumour 
microenvironments, rheumatoid arthritis joints and IBD (Mapp et al., 1995, Taylor and 
Sivakumar, 2005, Fearon et al., 2016, Montgomery et al., 2017). In CF, the lower airways have 
been described as being in a hypoxic environment due to an accumulation of viscous, 
dehydrated mucous with the presence of anaerobic P. aeruginosa (Hassett et al., 2009, 
Legendre et al., 2011, Fritzsching et al., 2015, Montgomery et al., 2017). Hypoxia has been 
described as a confounding factor in many inflammatory diseases, with the inflammatory 
transcription factor, HIF1a, a driving force behind the response to hypoxia in terms of cell 
adaptation, cell death, metabolism and inflammation (Tannahill et al., 2013a). Studying 
hypoxia in vitro was achieved by using a hypoxic cell culture chamber, in which cell cultures 
were exposed to various levels of O2. At 1% O2, NLRP3 inflammasome activation is 
exacerbated in Beas-2b (WT) HBECs and primary monocytes from HC individuals by around 
2-fold. However, when HBECs and primary monocytes with CF-associated mutations are 
cultured under the same conditions the increase in IL-18 and IL-1b secretion is exacerbated. 
When TNF was measured under the same conditions, it too was elevated but to a lesser extent. 
In combination with hypoxic environments, CF-associated mutations can cause vastly 
inappropriate and exaggerated responses to NLRP3 inflammasome activating stimuli. These 
data further support the hypothesis that there are multiple factors capable of stimulating various 
steps in inflammasome priming and assembly. A hypothesis to be discussed further in chapter 
4 (section 4.6.4) is that the hypoxia observed in the CF lower airways may be due to increased 
cellular metabolism in cells with CF-associated mutations, specifically oxidative 
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concentrations and hypoxia. This hypothesis, if proven, would suggest that the hypoxia in CF 
may be druggable, if specific metabolic pathways are targeted. 
 
3.10.5 NLRP3 activation activates the adaptive immune response 
 
To understand the implications of hyperbolic NLRP3 inflammasome activation, its 
downstream effects were analysed by measuring IFNg expression and secretion in response to 
monocytic NLRP3 activation, and subsequent IL-18 and IL-1b secretion, by other cells of the 
innate and adaptive immune systems. IFNγ is crucial to the inhibition of virus replication. As 
well as its immunomodulatory effects, IFN-γ is also a potent proinflammatory cytokine 
produced predominantly by natural killer (NK) and natural killer T (NKT) cells, as part of the 
innate immune response (Srivastava et al., 2013, Chaix et al., 2008). It is also secreted by TH1 
and cytotoxic T-lymphocyte (CTL) cells as part of antigen-specific, adaptive immunity but to 
a lesser extent. IL-18 and IL-1b have been implicated in the differentiation and activation of 
NK cells and effector T-cells (Srivastava et al., 2013, Chaix et al., 2008). In a sample of 
PBMCs, an LPS and ATP stimulation will activate the NLRP3 inflammasome in the monocyte 
population within that sample. The secreted IL-18 and IL-1b will then be capable of inducing 
IFNg secretion, predominantly by NK cells. When the mRNA from the PBMC sample was 
analysed for IFNg gene expression, increased transcripts were observed in samples stimulated 
with LPS as well as LPS plus ATP. These IFNg levels were confirmed at the secreted protein 
level by ELISA. 
These data suggest that IFNg secretion (derived from NK cell and T-cell) is enhanced 
in the CF PBMC population due to excessive NLRP3 inflammasome activation from myeloid 
cell types. The subsequent IL-18 and IL-1b secretion may be potentially inducing the IFNg 
secretion. 
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3.10.6 Sodium-mediated NLRP3 inflammasome activation in CF 
 
Having shown an autoinflammatory cytokine signature in vivo from CF patient serum 
and corroborated this finding in vitro with NLRP3 inflammasome activation in HBECs and 
monocytes, it was important to attempt to establish a link between CF-associated mutations 
and NLRP3 inflammasome activation. It has been well described that CFTR protein expression 
on the plasma membrane has inhibitory effects on the activity of the ENaC Na+ channel (König 
et al., 2001, König et al., 2002, Donaldson et al., 2002, Konstas et al., 2003, Mall et al., 2004, 
Berdiev et al., 2009). With the CFTR absent, misfolded, unstable or non-functional, control 
over ENaC activity has been described as being compromised. When bENaC is overexpressed 
in murine models, a CF-like lung disease develops from birth, characterised by innate immune 
cell infiltrations and an IL-1 cytokine signature (Keiser et al., 2015, Fritzsching et al., 2015, 
Montgomery et al., 2017). The hypothesis is therefore that increased Na+ influx via ENaC 
modulates NLRP3 activation in monocytes and HBEC lines with CF-associated mutations, via 
downstream modulation of K+ efflux. The relationship between ion fluxes and ion channels is 
complex and not fully understood. A seminal paper by Gabriel Nunez’s group, describing K+ 
efflux as the common activator of the NLRP3 inflammasome, also addressed the roles of Na+ 
and Cl- in modulating this pathway (Munoz-Planillo et al., 2013, Yaron et al., 2015). Without 
directly activating NLRP3 alone, Na+ influx was able to modulate the amount of K+ efflux and, 
thus, NLRP3 activation. 
With these baseline studies in mind, the intracellular Na+ and K+ concentrations of 
monocytes and HBECs were measured, upon NLRP3 stimulation and with the inhibition of 
Na+ channels. Notably elevated levels of intracellular Na+ in HBEC lines and monocytes from 
patients with CF were reduced, upon inhibition of Na+ channels with EIPA, and, more 
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specifically, by ENaC inhibition using amiloride and SPLUNC1-derived S18 peptide. Ouabain 
inhibition of Na+/K+ ATP-gated channels increased intracellular Na+ significantly in CuFi-1 
(∆f508/∆f508) HBECs and monocytes from patients with CF. By inhibiting Na+/K+ ATP-gated 
channels, elevated intracellular Na+ is less able to efflux from the HBEC lines and monocytes 
from patients with CF. These observations fit with the conclusions of previous studies that 
ENaC activity is elevated in CF lung. This is the first time these results have been replicated in 
human monocytes. Inhibition of ENaC by the SPLUNC1-derived S18 peptide achieved the 
greatest reduction in intracellular Na+, with statistically significant decreases observed in 
monocytes and HBEC lines regardless of CF-associated mutations. 
Intracellular K+ concentrations were analysed, under the same conditions of Na+ 
channel inhibition, in testing the hypothesis that upstream Na+ modulates K+ efflux and, thus, 
NLRP3 inhibition. When LPS primed WT HBEC lines and HC monocytes were stimulated 
with ATP, intracellular K+ concentration decreased by approximately 60% due to the opening 
of the P2X purinoceptor 7 (P2X7) K+ channel and efflux of K+. This known NLRP3 activation 
event was also shown to be present in HBEC lines with CF-associated mutations and 
monocytes from patients with CF. However, a significantly greater K+ efflux was observed in 
HBEC lines with CF-associated mutations of around 80% and monocytes from patients with 
CF experiencing an average K+ efflux of 85% under the same conditions. Whether the amount 
of K+ efflux effects the strength or amount of NLRP3 activation and assembly is not fully 
understood, but the two measurements in this study are correlated. With pre-treatment of 
amiloride or the SPLUNC1-derived S18 peptide, K+ efflux was significantly lessened, in both 
HBEC lines and monocytes with CF-associated mutations. This observation supports the 
hypothesis that modulating ENaC-dependent Na+ influx in cells with CF-associated mutations 
will modulate downstream K+ efflux and NLRP3 inflammasome activation, upon stimulation. 
When ouabain is used as a pre-treatment, K+ efflux is greater in all HBEC lines and monocytes 
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compared to with ATP alone. With inhibition of Na+/K+ ATP-gated channels, ouabain prevents 
the influx of K+, via these channels that would normally replenish the loss of K+ experienced 
upon ATP stimulation. 
The greater intracellular Na+ concentration present in cells with CF-associated 
mutations supports the fact that ENaC activity is elevated in CF, particularly as this 
intracellular Na+ concentration is modulated in vitro by small molecule and peptide inhibitors 
of the ENaC channel. The outstanding data in this section showed how inhibition of ENaC 
activity modulated downstream intracellular K+ concentration. When ENaC was inhibited by 
amiloride or S18 peptide, the intracellular K+ concentration was higher after ATP stimulation. 
These data support the hypothesis that ENaC activity primes NLRP3 inflammasome activation. 
A greater efflux of K+ in cells with CF-associated mutations suggests that a lower threshold of 
K+ efflux will induce potent NLRP3 inflammasome activation in CF cells (Figure 3.10.6). 
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Figure 3.10.6: Dysregulated ion channel activity modulates NLRP3 inflammasome 
priming and activation. Mutated CFTR (light blue) is unable to modulate ENaC (dark blue) 
activity via SPLUNC1 or any other means. Overactive ENaC induces an increased Na+ influx 
and subsequently increases the activity of the Na+/K+ ATP-gated pump (pink) in order to efflux 
the excessive Na+, in exchange for K+. The increased energy demands and K+ influx produced 
by the Na+/K+ ATP-gated pump, may induce NLRP3 inflammasome activation through 
metabolic reprogramming and a reduced threshold for K+ efflux, via the P2X7 ATP-gated 
channel, respectively. Na+- sodium; K+- potassium; Cl-- chloride; CFTR- Cystic fibrosis 
transmembrane conductance regulator; ENaC- epithelial sodium channel; ATP- Adenosine 
triphosphate; KCL- potassium chloride. 
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3.10.7 Anti-inflammatory effects of sodium channel inhibition 
 
 The hypothesis that inhibition of ENaC Na+ channel activity will negatively regulate 
NLRP3 inflammasome activation, by limiting K+ efflux, was tested by the treatment of HBEC 
lines and monocytes with various ion channel inhibitors before an NLRP3 inflammasome 
stimulation in vitro. Secretion of IL-18 and IL-1b, caspase-1 activity and pyroptotic cell death 
were measured under the above conditions. As previously described, two concentrations of 
amiloride were used, in these experiments, due to its known off-target effects (ubiquitous Na+ 
channel inhibition) at higher concentrations. In addition to amiloride, EIPA and S18 peptide 
were used to inhibit ENaC with low and high specificity respectively. Amiloride at 100mM 
significantly reduced IL-18 secretion in HBEC lines with CF-associated mutations. At the 
lower dose of 10mM, the reduction in IL-18 was not significant. This was also the case for IL-
18 and IL-1b secretion from primary monocytes with CF-associated mutations. Amiloride did 
not reduce IL-18 or IL-1b secretion by monocytes from patients with SAID, NCFB or HC 
individuals. These results imply that by inhibiting the amiloride-sensitive channel, NLRP3 
inflammasome activation is specifically reduced in cells from patients with CF. EIPA treatment 
had no effect on IL-18 secretion by any HBEC line, or IL-18 or IL-1b secretion by primary 
monocytes across all cohorts, despite being able to modulate intracellular Na+ concentrations 
under the same conditions. However, EIPA was unable to modulate K+ efflux and the decrease 
in intracellular Na+ with EIPA treatment was modest. The SPLUNC1-derived peptide S18 
potently and significantly reduced IL-18 secretion in HBEC lines with CF-associated 
mutations. S18 also significantly inhibited IL-18 and IL-1b secretion from primary monocytes 
with CF-associated mutations. S18 did not reduce IL-18 or IL-1b secretion in monocytes from 
patients with SAID, NCFB or HC individuals. These data support the hypothesis that inhibiting 
ENaC activity specifically, has anti-inflammatory effects restricted, specifically in cells with 
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CF-associated mutations. To understand whether these anti-inflammatory effects are NLRP3 
inflammasome-specific, caspase-1 activity and caspase-1 dependent cell death, pyroptosis, was 
analysed. As expected, amiloride and S18 peptide successfully inhibited caspase-1 activity and 
pyroptosis upon ATP stimulation in HBECs and monocytes with CF-associated mutations, 
with EIPA unable to replicate this inhibition. The NLRP3 inhibitor MCC950 potently 
abrogated caspase-1 activity and pyroptotic necrosis. Notably, secretion of TNF was not 
modulated by amiloride, suggesting that the inhibition of sodium channels modulates NLRP3-
driven inflammation specifically (appendix figure 5). 
 To investigate the role of chloride ion channels in the NRPR3 inflammasome assay, 
both the CFTR172 inhibitor and NPPB, a global chloride ion channel inhibitor to test the role 
of chloride signalling upstream of K+ efflux and NLRP3 inflammasome priming and assembly. 
NPPB pre-treatment was unable to modulate IL-1b, IL-18, caspase-1 activity or pyroptosis in 
any cell type, cohort or genotype. As previously mentioned (section 1.1.3) and described (Jiang 
et al., 2017) by others, the CFTR172 inhibitor inhibits NLRP3 activity as well as CFTR activity 
and so the observed reduction in IL-1b, IL-18, caspase-1 activity and pyroptosis in HC and 
disease cohorts as well as all HBEC lines indicated the validity of CFTR172 inhibitory action 
on NLRP3. 
 Finally, ouabain and digoxin were tested as a pre-treatment to inhibit Na+/K+ ATP-
gated pump activity. These stimulations were used to test the hypothesis that the link between 
the Na+ influx through ENaC and the K+ efflux through P2X7 are linked by the Na+/K+ ATP-
gated pump and by inhibiting this intermediate then the pathogenic effects of high Na+ influx 
are diminished. However, neither ouabain or digoxin had any anti-inflammatory effect and, 
actually, ouabain alone induced increased intracellular Na+ concentration and a greater K+ 
efflux, with consequential NLRP3 activation and secretion of IL-1b and IL-18 and increased 
caspase-1 activity and pyroptosis. The conclusion of these data is that the Na+/K+ ATP-gated 
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pump is not the pathogenic facilitator of downstream K+ efflux and NLRP3 activation but is 
the guardian of ion homeostasis within the CF cell and that an increased propensity for K+ 
efflux and NLRP3 activation is merely a consequence of this.  
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Chapter 4 
 
4.0 Mitochondrial Metabolism in Cystic Fibrosis  
 
4.1 Introduction 
 
4.1.1 Metabolism in CF 
 
Individuals with CF often have pancreatic insufficiency with malabsorption (Gibson-
Corley et al., 2016), and, therefore, have unique dietary requirements. Many patients with CF 
are given high-calorie, high-fat diets in order to compensate for this lack of nutrient absorption 
(Schindler et al., 2015). There is also evidence for metabolic alkalosis and increased metabolic 
rate (Lerman-Sagie et al., 1986, Bates et al., 1997, Baird et al., 2002). High-fat, high-glucose 
diets have been shown to induce obesity and have been associated with the development of 
diabetes, IBD and colitis (Gulhane et al., 2016, van der Heijden et al., 2015, Kim et al., 2012). 
However, the aforementioned diets do not typically induce weight gain among patients with 
CF, who are, in fact, more often characterised as being malnourished, due to their increased 
energy usage, increased energy demand and failure to consume enough daily calories (Culhane 
et al., 2013). 
It was these observations, in the clinic and literature, that led to the hypothesis that 
perturbed metabolism is a feature of CF, systemically, and this perturbation is a marker of, and 
contributing factor towards the inflammatory phenotype, described in chapter 3, at the cellular 
and molecular level. An alternative hypothesis is that the high-fat, high-glucose diet may alter 
the gut microbiome and nutrient availability, causing systemic metabolism to have an influence 
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on cellular metabolism, and, in particular, immune cell metabolism, which may be referred to 
as immunometabolism (Norata et al., 2015). 
 Acidification of the airway surface liquid (ASL) in CF is a well-studied, yet frequently 
debated and poorly understood phenomenon. As previously mentioned (section 1.1), the highly 
proteolytic and ‘acidic’ ASL causes degradation and denaturation of SPLUNC1, the 
glycoprotein which is highly expressed in the respiratory epithelium (Garland et al., 2013, Jiang 
et al., 2013). Recent studies have shown that the pH of ASL, from children with CF was neutral 
and not acidic and was, therefore, not significantly different from HC ASL (Schultz et al., 
2017), contradicting other groups that have reported the contrary (Tang et al., 2016). The 
hypothesis regarding the reduced pH in the CF lung is based on the fact that the CFTR is a 
HCO3- bicarbonate transporter, a basic (rather than acidic) molecule that will buffer an acidic 
solution. With CFTR absent or dysfunctional, the loss of HCO3- bicarbonate transport will 
allow ASL to become acidic. However, dysregulation of metabolism is another potential 
hypothesis to address in relation to the observed acidic nature of ASL in CF (Garnett et al., 
2016). Garnett et al reported that the hyperglycaemia observed in CF and CF-related diabetes 
(CFRD) was elevated compared to HC and was associated with bacterial infection. The authors 
went on to examine the metabolic consequences of hyperglycaemia in CF and CFRD, and 
demonstrated an increased metabolic rate, with elevated glycolysis and lactate production 
through monocarboxylate transporter (MCT) 2, which was glucose dependent; the authors 
designated these observations as a metabolic shift (Garnett et al., 2016). By inhibiting MCT2, 
they observed decreased lactate concentration and increased pH in CF ASL. In addition, the 
MCT transporters efflux H+ with lactate, further contributing to the acidic state of the ASL, 
particularly with the loss of HCO3- bicarbonate transport via the CFTR. Finally, the authors 
describe how P. aeruginosa stimulates a metabolic shift towards glycolysis during 
hyperglycaemia, potentially through LPS/TLR4 signalling and they propose that the acidity of 
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CF ASL may, in part, be due to glycolysis-dependent lactate and H+ secretion. With elevated 
glycolysis, fuelled by hyperglycaemic conditions, particularly in those individuals with CFRD, 
immune responses can also be ‘shifted’ towards a proinflammatory phenotype, in response to 
increased glycolysis. 
  
4.1.2 Cellular metabolism 
 
The mitochondria are intracellular organelles that share ancestry with that of early 
primordial aerobic bacteria (McInerney et al., 2015, Mills et al., 2017). It is often considered 
that the first instance of endosymbiosis began with the fusion, or phagocytosis, and subsequent 
mutualistic relationship of primitive bacteria and their eukaryotic hosts (a mutualistic 
relationship exists when two organisms of different species "collaborate together," to their 
mutual benefit). This relationship enabled elevated levels of energy expenditure, production 
and metabolism. Oxygen is a toxic molecule as it may cause oxidative processes. In the 
presence of a mutualistic relationship between aerobic bacterium and the eukaryote, oxygen 
could not only be scavenged but also converted to the desirable "molecular unit of currency" 
of intracellular energy transfer, ATP. In addition to ATP, the ‘bacterium’ provided 
macromolecules for essential intracellular processes, as well as reactive oxygen species (ROS), 
which are fundamental requirements for the killing of any phagocytosed pathogens. The 
bacterium, or mitochondria, benefited from a protected structure in which to survive and 
proliferate. Important evidence for the theory of endosymbiosis is that mitochondrial DNA 
(mtDNA) is near identical in structure to prokaryotic DNA as is highly immunogenic, 
activating the NLRP3 inflammasome and type I IFN responses (Zhang et al., 2010, Zhang et 
al., 2014, Rodríguez-Nuevo et al., 2018). 
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 Mitochondrial metabolism utilises fuels, such as glucose, to produce ATP molecules 
by exchange of protons, across the inner mitochondrial membrane via the electron transport 
chain (ETC), composed of a series of multiheteromeric enzyme complexes (Mills et al., 2017). 
Briefly, these complexes include NADH-dehydrogenase (complex 1), succinate 
dehydrogenase (complex 2), ubiquinone bc1 complex (complex 3), cytochrome c and 
cytochrome c oxidase (complex 4) and ATP synthase (complex 5). This metabolic pathway, 
occurring in the mitochondria, is termed oxidative phosphorylation (OXPHOS). In this 
biochemical process protons are pumped across the inner mitochondrial membrane to generate 
a membrane potential, which culminates in interactions with oxygen. ATP synthase (complex 
5) is driven by the proton gradient to produce ATP molecules from ADP. Upstream of 
OXPHOS, the Krebs cycle or the citric acid (TCA) converts acetyl CoA into six NADH and 
two FADH2 molecules through substrate-level phosphorylation, fuelling the ETC. Acetyl CoA 
is generated from pyruvate, the product of glycolysis. Generally, OXPHOS is a highly efficient 
(34 ATP per glucose per one molecule of glucose) but a relatively slow pathway, involving 
multiple enzymatic reactions required for energy production. Glycolysis is a rapid yet 
inefficient pathway occurring in the cytoplasm, producing just two ATP per glucose molecule 
(TCA also produces two ATP per glucose, bringing the total ATP per glucose to ~38 for the 
full glycolysis/TCA/OXPHOS pathway). 
 
4.1.2 Immunometabolism 
 
Immune cells utilise OXPHOS under resting or quiescent states (Mills et al., 2017). This 
mitochondrial metabolic pathway is, as previously stated, highly efficient but time consuming, 
culminating in abundant ATP production through a single glucose substrate. When an immune 
cell is then activated and, depending on the cell type, it proliferates and becomes an effector 
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cell from its naïve state, cellular metabolism is switched to upregulate glycolysis and bypass 
OXPHOS, for rapid ATP production, despite the relatively low yield. An example of this 
metabolic switch in immune cells is the activation of naïve T-cells into TH1 and TH2 effector 
cells (Roos and Loos, 1973, Loos and Roos, 1973). This adaptive immune cell type specifically 
defends the host against bacterial/viral and helminth infection respectively. Both T-cell 
effectors, when stimulated and activated in vitro, proliferate and induce well characterised 
transcription factors, cell surface markers and cytokine secretion profiles, specific for their 
function. In addition, activation of thymocytes induces a metabolic switch towards glycolysis 
and lactate production (Brand, 1985, Brand et al., 1989, Greiner et al., 1994, Chen et al., 2015, 
Macintyre et al., 2014). This exploitation of metabolism, depending on activation state, is 
characteristic of T-cells, with naïve cells utilising glucose, lipids and amino acids for TCA and 
OXPHOS pathways. Activation of T-cells is a unique process of T-cell receptor (TCR) 
signalling, along with costimulatory signals and Ca2+ store release. TCR activation is 
accompanied by increased levels of glycolysis, for rapid ATP production (Sena et al., 2013, 
Ron-Harel et al., 2016). 
Store-operated Ca2+ entry (SOCE) is a fundamental component of TCR activation and T-
cell signalling; it is a process in which stromal interaction molecule (STIM) 1 and STIM2 
activate Ca2+ release-activated Ca2+ (CRAC) channels (Vaeth et al., 2015). It has been shown 
that the switch to glycolysis in quiescent or naïve T-cells, upon TCR activation and 
differentiation into T-effector cells, is controlled by SOCE and its regulation of calcineurin 
(Vaeth et al., 2017). SOCE regulates the expression various glycolytic enzymes via nuclear 
factor of activated T cells (NFAT) and mTOR. The process of T-cell activation and the 
metabolic reprogramming of T-effector cells is controlled by ionic fluxes, in this case Ca2+. 
This is of particular interest, as pathogenic dysregulation of ion fluxes is central to CF 
  
161 
pathology, and can be hypothesised to influence metabolism, cell activation, cell phenotype 
and cell function, as observed in chapter 3. 
After TCR activation there is an increase in cell size and proliferation, which is 
complemented with an increase in mitochondrial size and number, to support T-cell effector 
cell functions (Rathmell et al., 2000). There are also differences in mitochondrial structure and 
function between T-effectors (as mentioned above) and T-memory cells (Liesa and Shirihai, 
2016). Fused, extended mitochondria are present in T-memory cells, for greater mitochondrial 
OXPHOS for prolonged cell survival in the T-memory cell pool (Buck et al., 2016). 
Mitochondria with loose cristae and increased fission are characteristic of T-effector cells, 
aiding mROS and decreased respiratory capacity, or OXPHOS, and therefore preferential 
glycolytic metabolism. A further characteristic of mitochondria that may be adapted, 
depending on cell function or activation state, is the presence of ETC super-complexes. ETC 
super-complexes are present in naïve and memory T-cells to support OXPHOS (Cogliati et al., 
2013, Mishra et al., 2014). T-cells in RA have been described as being hypo-glycolytic, with 
impairment in the function of glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 3 (PFKFB3) (Yang et al., 2013b). RA T-cells have been shown to be 
susceptible to apoptosis, due to insufficient ATP levels and being metabolically reprogrammed. 
With a switch to OXPHOS, RA T-cells became quiescent due to the association of OXPHOS 
with a resting state and the impairment of glycolysis and thus effector function. Overall, it is 
clear that metabolism is switched depending on the function and activation state of an immune 
cell.  
 
4.1.3 Immunometabolism in macrophages 
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 The NLRP3 inflammasome is an integral component of macrophage and monocyte 
function, to a much greater extent than other cells of the immune system, and these are also the 
major cell type present in CF lung infiltrates. Macrophage metabolism is a well-studied area 
and the links between OXPHOS and glycolysis and macrophage phenotype and function have 
been substantiated by various groups (Tannahill et al., 2013a, Baseler et al., 2016, Fleetwood 
et al., 2017, Kelly and O'Neill, 2015, Van den Bossche et al., 2015, Bertaux et al., 2018). 
Mitochondrial collapse is a phenomenon associated with M1-type macrophage activation with 
PAMPs (such as LPS), and describes the nitrosylating effects of nitric oxide (NO) on 
complexes 1, 2 and 4 of the ETC (Everts et al., 2012). This nitrosylation inhibits the activity 
of the ETC and therefore reduces mitochondrial ATP production via OXPHOS and redeploys 
the ETC for mROS production via complex 1, to aid innate immune responses. Therefore, M1-
type macrophages preferentially utilise glycolysis, whereas M2-type macrophages employ 
mitochondrial OXPHOS for the most part. 
 Macrophage metabolism not only supports cell phenotype function and proliferation, 
but the mitochondria itself acts as a signalling platform for innate immune cells. NLRP3 
inflammasome oligomerisation occurs on the outer membrane of mitochondria (Franchi et al., 
2014, Park et al., 2013, Subramanian et al., 2013). Cardiolipin translocates to the surface of the 
mitochondria upon mitochondrial membrane depolarisation. Once at the surface, cardiolipin 
acts as a signalling platform for NLRP3 inflammasome assembly, where they interact and 
induce the recruitment of ASC and pro-caspase-1. This is an interesting interaction as NLRP3 
is known to be potently activated by both mtDNA and mROS, supposedly independent of K+ 
efflux (Groß et al., 2016). Another key interaction that occurs on the surface of the outer 
mitochondrial membrane is interaction of the mitochondrial antiviral-signalling protein 
(MAVS), a protein activated as part of the anti-viral immunity and interferon regulatory factor 
(IRF) induction (Loo and Gale, 2011). This induction may be due to the direct interaction 
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between mROS and MAVS, independent of viral RNA (Seth et al., 2005). MAVS has also 
been shown to interact and recruit NLRP3 to the mitochondrial membrane. Therefore, the size, 
activity and integrity of the mitochondria influences NLRP3 signalling, particularly the 
presence of mtDNA and mROS. 
 
4.1.4 Succinate, itaconate, HIF1a and IL-1b 
 
 A key pathway recently elucidated by Mills et al. describes an important link between 
the metabolic switch from mitochondrial metabolism to glycolysis and innate immune 
responses, particularly IL1b expression (Mills et al., 2017, Mills et al., 2016). When an M1-
type macrophage is stimulated with LPS, the switch to glycolytic metabolism is associated with 
breaks in the TCA cycle, causing an accumulation of certain metabolites specific to these 
break-points. One of these metabolites is succinate. The breakpoint at complex 2 (SDH), which 
converts succinate to fumarate, as part of the TCA cycle, begins to oxidise succinate and 
induces reverse electron transport (RET). With electrons passing from complex 2 to complex 
1, RET increases mROS production by complex 1, which then activates the transcription factor, 
HIF1a. IL1b is a known transcriptional target of HIF1a; in fact, inhibition of SDH, complex 
1 or RET inhibits this process of HIF1a-induced IL1B. Studies using HIF1a knockout-mouse 
models have elegantly shown that the glycolytic switch within myeloid cells under anaerobic 
conditions is HIF1a-dependent and that HIF1a knockout-macrophages have reduced ATP and 
impaired function in anaerobic environments (Cramer et al., 2003). These investigations also 
elucidated the LPS/TLR4/SDH/RET/mROS axis, providing new detail into how LPS can 
induce M1-type macrophage activation, NLRP3 inflammasome assembly and mROS 
production (Chouchani et al., 2014, Littlewood-Evans et al., 2016, Mills et al., 2016, Tannahill 
et al., 2013a). 
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 However, a control mechanism exists that involves another break in the TCA cycle at 
isocitrate dehydrogenase, which converts citrate into succinate, rather than itaconate. However, 
in an M1-type induced macrophage, itaconate accumulates and has been shown to block RET 
and SDH-dependent succinate oxidation. Itaconate was shown to inhibit mROS-driven IL1B 
expression, when cells were pre-treated with itaconate in vitro and in vivo (Cordes et al., 2016, 
Lampropoulou et al., 2016). This anti-inflammatory aspect of itaconate is necessary for cell 
survival, as prolonged succinate accumulation and the associated downstream inflammation 
will cause chronic oxidative stress and autoinflammation. Interestingly, the metabolite-
inflammation association described above seems to be specific for IL-1b, suggesting that 
immunometabolism, and glycolysis in particular, has a large role to play in NLRP3 
inflammasome activity and the consequential macrophage phenotype. 
 
4.2 Methods 
 
4.2.1 Seahorse extracellular flux assay 
 
As in section 2.9. 
Briefly, live analysis of ECAR and OCR using the cell energy phenotype kit was 
performed, using the Seahorse XF-96 Extracellular Flux Analyser (Agilent Seahorse 
Bioscience), as per the manufacturer’s instructions. Details of seahorse OCR and ECAR traces 
are described in appendix figure 8 and 9. 
 
4.2.2 Intracellular fluorometric assay 
 
As in section 2.8. 
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Briefly, ATP and succinate (Assay kits, Abcam) were measured, as per the 
manufacturer’s instructions. 
 
4.2.3 Extracellular fluorometric assay 
 
As in section 2.8. 
Briefly, Extracellular glucose and L-lactate (Assay kits, Abcam) were measured, as per 
the manufacturer’s instructions. 
 
4.2.4 mitoSOX 
 
MitoSox was used with Flow cytometry to detect mROS intracellularly. 5 mM 
MitoSOX™ reagent stock solution was prepared by dissolving the contents (50 µg) of one vial 
of MitoSOX™ mitochondrial superoxide indicator (Component A) in 13 µL of 
dimethylsulfoxide (DMSO) to make a 5 mM MitoSOX™ reagent stock solution. The 5 mM 
MitoSOX™ reagent stock solution (prepared above) was diluted in HBSS/Ca/Mg or suitable 
buffer to make a 5 µM MitoSOX™ reagent working solution. Note: The concentration of the 
MitoSOX™ reagent working solution should not exceed 5 µM. Concentrations exceeding 5 
µM can produce cytotoxic effects, including altered mitochondrial morphology and 
redistribution of fluorescence to nuclei and the cytosol. Sterile DMSO is incorporated in one 
vial of MitoSOX™ (to make 5 mM MitoSOX™) and dissolved to the required amount to 
1/1000 in PBS to final concertation of 5 µM MitoSOX™ reagent working solution. Cells are 
loaded into FACS tubes at  0.5X106 per tube. Cells are stimulated and washed with PBS. 5 µM 
MitoSOX™ reagent working solution is added to cover entirely the cells ~500 ul of the mix 
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and incubated at 37°C for 10 minutes. Cells are washed 2x with PBS supplemented with 2% 
FBS. Cells are then resuspended in 200ul FACS buffer and passed through a flow cytometer. 
 
4.3 Basal metabolic phenotype 
 
4.3.1 Oxidative phosphorylation 
 
It is important to measure the activity of metabolic reactions or pathways rather than 
merely the presence or expression of protein or gene. This is because the broad presence of a 
metabolic enzyme or series of enzymes is not enough to be confident in stating that said 
metabolic pathway is active. This is particularly relevant in acute, in vitro experiments 
particularly with short stimulations with LPS, as is the case in this study. OXPHOS activity 
can be measured by oxygen consumption (see methods). This measure of OXPHOS activity is 
reliable as OXPHOS cannot take place without extracellular oxygen consumption as there are 
no ‘oxygen stores’ within a cell. Measuring this rate-limiting substrate is an accurate and 
precise measurement of OXPHOS. 
Figure 4.3.1 shows data from experiments performed measuring OXPHOS in vitro, 
using HBEC lines and primary monocytes and T-cells from HC individuals and patients with 
CF. The hypothesis being tested in these experiments was that cells with CF-associated 
mutations, particularly immune cells, are more metabolically active with higher levels of 
glycolysis due to an inflammatory phenotype, as characterised in the previous chapter. Not 
only is glycolysis a read-out of inflammation and inflammatory phenotypes in immune cells 
but elevated metabolism may be satisfying an elevated energy demand in cells with CF-
associated mutations. The potential molecular reasons behind this hypothesised increase in 
energy demands are discussed later in this chapter (section 4.6). 
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(Figure 4.3.1 legend on next page) 
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Figure 4.3.1: Oxygen consumption in HBEC lines, monocytes and T-cells. A Seahorse 
extracellular flux analyser measured the oxygen consumption rate (OCR) in HBECs (n=3), 
monocytes (n=4) and T-cells (n=4). Oligomycin (10µM), an inhibitor of ATP synthase, and 
the uncoupling agent, Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) 
(5µM), were used to metabolically stress and depolarise cellular mitochondrial membranes. 
Cell were pre-treated with amiloride (100mM, 1 hour) before an LPS (10ng/mL, 4 hours) 
stimulation. A 2-way ANOVA was performed (p values * = £0.05, **= £0.01, ***= £0.001 
and ****= £0.0001). 
 
Under basal conditions, oxygen consumption was significantly elevated in both IB3-1 
(∆f508/W1282X) and CuFi-1 (∆f508/∆f508) compared to Beas2b (WT) HBECs. This increase 
in oxygen consumption was not statistically significant in the CuFi-4 (∆f508/G551D) HBECs 
compared to Beas2b (WT) HBECs. After LPS stimulation, oxygen consumption was again 
significantly elevated in both IB3-1 (∆f508/W1282X) and CuFi-1 (∆f508/∆f508) compared to 
Beas2b (WT) HBECs. Pre-treatment with amiloride did not significantly decrease oxygen 
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consumption in any of the cell lines, although the significant difference found between IB3-1 
(∆f508/W1282X) and CuFi-1 (∆f508/∆f508) compared to Beas2b (WT) was lost, indicating 
that oxygen consumption across WT cells and cells with CF-associated mutations was similar 
with the amiloride pre-treatment. 
 No statistical difference was observed when oxygen consumption was measured in 
primary monocytes from HC and patients with CF-associated mutations. There were a few 
outlying data points in the CF monocyte cohort that indicate a potential trend towards increased 
oxygen consumption in CF monocytes, but there was not sufficient evidence to conclude this 
unequivocally. 
 CD3+ T-cells were also used to test for oxygen consumption, with and without LPS. 
There was increased oxygen consumption upon LPS stimulation in both HC and CF T-cells, 
which was an unexpected result as T-cells are not known for their efficient LPS responses. 
Notably, there was an elevated, statistically significant level of oxygen consumption present in 
CF monocytes with both unstimulated and LPS conditions compared to HC T-cells. 
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4.3.2 Extracellular acidification 
 
 
(Figure 4.3.2 legend on next page) 
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Figure 4.3.2: Extracellular acidification rate (ECAR) in HBEC lines, monocytes and T-
cells. A Seahorse extracellular flux analyser measured the extracellular acidification rate 
(ECAR) in HBECs (n=3), monocytes (n=4) and T-cells (n=4). Oligomycin (10µM), an 
inhibitor of ATP synthase, and the uncoupling agent, Carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone (FCCP) (5µM), were used to metabolically stress and depolarise cellular 
mitochondrial membranes. Cell were pre-treated with amiloride (100mM, 1 hour) before an 
LPS (10ng/mL, 4 hours) stimulation. A 2-way ANOVA was performed (p values * = £0.05, 
**= £0.01, ***= £0.001 and ****= £0.0001). 
 
The extracellular acidification rate (ECAR) was used as a measure of glycolysis, as this 
metabolic pathway produces lactic acid and H+ as a by-product, that then can be detected 
extracellularly (Figure 4.3.2). When ECAR was measured in HBECs, as a measure of 
glycolysis, only CuFi-4 (∆f508/G551D) HBEC lines were significantly increased compared to 
Beas2b (WT) at both unstimulated and during LPS stimulation. Interestingly, amiloride was 
able to decrease ECAR in IB3-1 (∆f508/W1282X) HBECs compared to Beas2b (WT), as well 
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as decreasing ECAR when amiloride was used as a pre-treatment to LPS stimulation in all 
HBEC lines with CF-associated mutations. 
 Primary monocytes from patients with CF-associated mutations had increased ECAR 
and, therefore, glycolysis upon LPS stimulation, compared to monocytes from HC individuals, 
and this difference was statistically significant (p=<0.0001). Pre-treatment with amiloride had 
little effect on ECAR in either patient cohort. 
 Again, both HC and CF T-cells responded with increased glycolysis upon LPS 
treatment, measured by ECAR. However, there was a heightened ECAR response in LPS-
activated T-cells from patients with CF-associated mutations compared to those isolated from 
HC individuals. 
 
4.3.3 ATP concentration 
 
ATP is a measure of the final product produced by both glycolysis, TCA cycle and 
OXPHOS. In this study it is used as a general measure of the metabolic rate of a cell and 
provides an insight into the energy demands the cell is trying to meet, in terms of ATP 
production. 
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Figure 4.3.3: Intracellular ATP concentration in HBECs and primary monocytes. 
Colorimetric assays were used to detect intracellular ATP in HBECs (n=3) and primary 
monocytes (n=7). Cell were pre-treated with amiloride (100mM, 1 hour) before an LPS 
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(10ng/mL, 4 hours) stimulation. A 2-way ANOVA was performed (p values * = £0.05, **= 
£0.01, ***= £0.001 and ****= £0.0001). 
 
ATP production is significantly higher than Beas2b (WT) in HBECs with CF-
associated mutations, at baseline (Figure 4.3.3). This correlates with the ECAR and OXPHOS 
readouts where at least one metabolic pathway was shown to be increased in activity in HBECs 
with CF-associated mutations compared to Beas2b (WT). This increased ATP concentration 
remained elevated when amiloride was added to the untreated cultures. ATP production 
increased in all HBEC lines upon LPS stimulation and then decreased in CuFi-1 (∆f508/∆f508) 
HBECs with a pre-treatment of amiloride before LPS stimulation. 
 Interestingly, ATP concentrations were, overall, less compared to that of epithelial cell 
lines. However, the increase in ATP concentration was also significantly increased in 
monocytes from patients with CF-associated mutations compared to monocytes from HC 
individuals. Upon LPS stimulation, both HC and CF monocytes increased ATP production by 
approximately 2-fold, although CF monocytes maintained their significantly elevated levels of 
intracellular ATP. Notably, pre-treatment with amiloride before LPS stimulation significantly 
decreased ATP production in CF monocytes but not HC monocytes. 
 
4.4 Glycolysis 
 
4.4.1 L-Lactate production 
 
L-lactate is the most abundant and biologically relevant isometric from of lactate and 
is produced during anaerobic glycolytic processes, in which pyruvate is reduced to lactate 
(typically the L-lactate isomer). By measuring L-lactate (referred to as lactate) in the 
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extracellular fluid of in vitro cultures, inferences can be made regarding the amount of 
glycolysis, particularly anaerobic glycolysis. 
 
 
 
 
Figure 4.4.1: Extracellular L-lactate secretion in HBECs and primary monocytes. 
Colorimetric assays were used to detect intracellular L-lactate production in HBECs (n=3) and 
primary monocytes (n=7). Cell were pre-treated with amiloride (100mM, 1 hour) before an 
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LPS (10ng/mL, 4 hours) stimulation. A 2-way ANOVA was performed (p values * = £0.05, 
**= £0.01, ***= £0.001 and ****= £0.0001). 
 
Significantly elevated levels of lactate were observed in all of the HBEC lines with CF-
associated mutations (Figure 4.4.1). Amiloride did not significantly decrease lactate secretion 
in any of the cell lines. LPS stimulation increased lactate production in all cell lines with 
HBECs with CF-associated mutations remaining significantly elevated compared to Beas2b 
(WT). 
 The increase in lactate secretion was also significantly increased in monocytes from 
patients with CF-associated mutations compared to monocytes from HC individuals. Upon 
LPS stimulation, both HC and CF monocytes increased lactate secretion although CF 
monocytes maintained their significantly elevated levels of lactate secretion. Notably, pre-
treatment with amiloride before LPS stimulation significantly decreased lactate secretion in CF 
monocytes but not in HC monocytes. 
 
4.4.2 Glucose consumption 
 
Glucose is an important substrate for ATP production for both glycolysis and 
OXPHOS, so distinguishing between these pathways using glucose alone is not sufficient. 
However, before OXPHOS is able to utilise glucose it must first be converted to pyruvate and 
acetyl CoA by glycolysis and then the TCA cycle. Therefore, as glucose molecules feed 
directly into the glycolytic pathway, glucose consumption is a measurement of the 
consumption of the substrate for glycolysis specifically. Glucose consumption, therefore, 
cannot infer what happens to the metabolites of aforementioned glucose. A cell’s consumption 
of glucose is strictly a measure of metabolism and glycolysis.  
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Figure 4.4.2: Glucose consumption in HBECs and primary monocytes. Colorimetric assays 
were used to detect intracellular glucose consumption in HBECs (n=3) and primary monocytes 
(n=7). Cell were pre-treated with amiloride (100mM, 1 hour) before an LPS (10ng/mL, 4 
hours) stimulation. A 2-way ANOVA was performed (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001). 
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The consumption of glucose is elevated in the HBEC lines with CF-associated 
mutations compared to the Beas2b (WT) line (Figure 4.4.2). Amiloride had a modest effect on 
reducing glucose consumption in any of the HBEC lines. Upon stimulation with LPS, all of the 
HBEC lines increased their consumption of glucose, although this increase was still statistically 
elevated in the HBEC lines with CF-associated mutations compared to Beas2b (WT). Pre-
treatment with amiloride was able to decrease glucose consumption significantly in IB3-1 
(∆f508/W1282X) and CuFi-1 (∆f508/∆f508) lines. 
 
4.4.3 Succinate accumulation 
 
Succinate was discussed earlier in this chapter (section 4.1.4) with regard to its 
influence on myeloid inflammation. Briefly, accumulation of succinate occurs when the TCA 
cycle activity reduces with multiple break points at key enzymatic reactions causing 
accumulation of substrates for aforementioned reactions. One such substrate is succinate, 
which has inflammatory signalling effects on the activation of inflammatory transcription 
factors and expression of inflammatory cytokine gene expression such as IL1b. Therefore, 
measurement of succinate is an excellent readout for not only the switch of cellular metabolism 
from OXPHOS to glycolysis, but also the potential downstream inflammatory effects of this 
metabolic switch. 
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Figure 4.4.3: Intracellular succinate concentration in HBECs and primary monocytes. 
Colorimetric assays were used to detect intracellular succinate in HBECs (n=3) and primary 
monocytes (n=7). Cell were pre-treated with amiloride (100mM, 1 hour) before an LPS 
(10ng/mL, 4 hours) stimulation. A 2-way ANOVA was performed (p values * = £0.05, **= 
£0.01, ***= £0.001 and ****= £0.0001). 
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 Succinate accumulation was significantly increased in HBEC lines with CF-associated 
mutations compared to Beas2b (WT) (p=<0.0001) (Figure 4.4.3). Amiloride was able to reduce 
the succinate accumulation but did not alter the statistically significant elevation in succinate 
in HBEC lines with CF-associated mutations compared to Beas2b (WT). Upon LPS treatment, 
succinate levels approximately doubled in both IB3-1 (∆f508/W1282X) and CuFi-1 
(∆f508/∆f508) HBEC lines compared to unstimulated, and CuFi-4 (∆f508/G551D) increased 
by around 50%. The Beas2b (WT) cell line did not increase succinate levels upon LPS 
treatment. Amiloride significant decreased succinate accumulation in both IB3-1 
(∆f508/W1282X) and CuFi-1 (∆f508/∆f508) HBEC lines. 
 Succinate accumulation was significantly increased in monocytes from patients with 
CF at both unstimulated and with LPS stimulation compared to HC monocytes (p=0.0003 and 
p=0.0003 respectively). Increased succinate accumulation was observed in both HC and CF 
monocytes with LPS stimulation compared to the relative unstimulated control. Amiloride was 
able to modulate succinate accumulation in CF monocytes when it was used to pre-treat cells, 
prior to LPS stimulation. 
 
4.4.4 Glycolytic flux assay 
 
The glycolytic flux assay measures ECAR, as with the basal metabolic phenotype data 
(section 4.3), but probes further into the key parameters of glycolytic flux (Figure 4.4.4). This 
assay is described in detail in the methods section of this chapter (section 2.9) but briefly, 
glucose is injected into the in vitro assay plate to measure the rate of glycolysis under basal 
conditions, then oligomycin (10µM) is injected to induce pyruvate production as well as ATP, 
NADH, H2O and H+ and the final injection of 2-deoxy-glucose (2-DG) is then injected onto 
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the cells to inhibit glycolysis, through competitive-binding to glucose hexokinase. By using 
the above injection strategy, the glycolysis stress test can determine the following parameters 
(Details of seahorse OCR and ECAR traces are described in appendix figure 8 and 9):  
 
Glycolysis- The amounts of glycolysis taking place in response to glucose. 
Glycolytic Capacity- the maximum amount of glycolysis that can take place in a cell in 
response to oligomycin (OXPHOS inhibitor), which drives the cell to use glycolysis to its 
theoretical maximum capacity. 
Glycolytic Reserve- how close a cell is to using its theoretical glycolytic capacity or the 
difference between glycolysis and glycolytic capacity. 
Non-Glycolytic acidification- at baseline, how much ECAR is taking place before glucose is 
added, indicating other sources of ECAR that are not due to glycolysis. This ECAR 
measurement is in addition, rather than a component part of, the above parameters. 
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(Figure 4.4.4 legend on next page) 
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Figure 4.4.4: Glycolytic flux in monocytes from HC individuals and patients with CF. A 
Seahorse extracellular flux analyser measured the extracellular acidification rate (ECAR) in 
HBECs (n=3) and monocytes (n=3). Oligomycin (10µM), an inhibitor of ATP synthase, and 
the uncoupling agent, Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) 
(5µM), were used to metabolically stress and depolarise cellular mitochondrial membranes. 
Cell were pre-treated with amiloride (100mM, 1 hour) before an LPS (10ng/mL, 4 hours) 
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stimulation. A 2-way ANOVA was performed (p values * = £0.05, **= £0.01, ***= £0.001 
and ****= £0.0001). 
 
Glycolysis is elevated upon LPS stimulation in both HC and CF monocytes, but more 
so in CF monocytes (Figure 4.4.4). There was no statistical significance due to large 95% 
confidence interval in the CF monocytes upon stimulation data. The median glycolytic capacity 
is higher in CF monocytes upon stimulation with LPS compared to HC monocytes under the 
same conditions. There was no statistical significance due to large 95% confidence interval in 
the CF monocytes upon stimulation data. There was no real difference observed between LPS 
stimulated or unstimulated conditions within either HC or CF cohorts. However, the median 
glycolytic reserve is higher in CF monocytes compared to HC monocytes. There was no 
statistical significance due to large 95% confidence interval in the CF monocytes upon 
stimulation data. There was no real difference between HC or CF cohorts in terms of non-
glycolytic acidification. However, the median non-glycolytic acidification is higher in the LPS 
stimulated or unstimulated conditions within either HC or CF cohorts. There was no statistical 
significance due to large 95% confidence interval in the CF monocytes upon stimulation data. 
 
4.4.5 HIF1a and IL-1b 
 
As glycolysis and the subsequent succinate accumulation are associated with 
downstream IL1b gene expression, a RT-qPCR was performed on monocytes from HC, CF 
and a SAID patient with Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis 
(PAAND) (a control cohort for elevated IL1b gene expression responses to LPS stimulation) 
after LPS stimulation (Figure 4.4.5). The hypothesis is based on the data shown in this chapter, 
suggesting metabolism is heightened (or energetic) in cells with CF-associated mutations, 
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particularly when challenged with LPS and that there is a metabolic switch to glycolysis, where 
glycolysis in the form of ECAR, lactate production, glucose consumption and succinate 
accumulation was shown to be elevated to a statistically significant level. 
 
 
 
Figure 4.4.5: Gene expression of IL1B in monocytes: Gene expression of IL1B was 
measured using RT-qPCR and a SYBR green detection assay in monocytes from HC (n=10), 
patients with CF (n=12) and PAAND (n=1). Cell stimulation was as follows: stimulation with 
LPS (10ng/mL) for 4-hours with an ATP (5mM) stimulation for the final 30 minutes. Data are 
presented on a logarithmic scale with A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001). 
 
Both CF and PAAND monocytes increased IL1b  transcript levels upon stimulation 
with LPS or LPS and ATP in combination, in comparison to monocytes from HC individuals. 
Statistically significant levels of IL1b were observed in the CF cohort, but not in the PAAND 
monocytes due to there being an n=1 for this rare condition. 
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4.5 Mitochondrial ROS 
 
Mitochondrial ROS (mROS) was investigated because, as previously discussed in 
Chapter 3 (section 3.1.1 and figure 3.1.2), the link between metabolism and NLRP3 
inflammasome activation may be due to the fact that a metabolic switch towards glycolysis 
causes RET and mROS production by complex I of the ETC. This mROS is a known activator 
of NLRP3. Therefore, the hypothesis to be tested here is that the increased glycolytic 
metabolism, described in this chapter, primes the inflammasome through mROS and perhaps 
even mitochondrial damage and mtDNA release, rather than TCA cycle break points inducing 
succinate-driven NLRP3 inflammasome priming. Details of mitosox flow cytometry gating are 
described in appendix figure 10. 
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4.5.1 mitoSOX 
 
 
 
Figure 4.5.1: Mitochondrial reactive oxygen species (mROS) levels in HBECs and 
immune cells from whole blood. Peripheral blood mononuclear cells (PBMCs) (n=3) were 
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isolated from whole blood and analysed using flow cytometry based on CD16 and CD66 cell 
surface marker expression, forward and side scatter (size and granularity) as well as mitoSOX, 
a fluorescent stain for mROS. Data is expressed as median fluorescence intensity (MFI). Cell 
stimulation was with LPS (10ng/mL) for 4-hours. A repeated measures 2-way ANOVA 
statistical test was performed with Turkey’s multiple comparisons test  (p values * = £0.05, 
**= £0.01, ***= £0.001 and ****= £0.0001). 
 
Using a specific fluorescent, intracellular probe for the presence of mROS, both HBEC 
lines and whole blood samples from patients with CF and healthy control individuals were 
examined for this form of ROS, using flow cytometry in order to quantify the amount of ROS 
in different populations (Figure 4.5.1). Elevated levels of mROS were detected in all three 
HBEC lines with CF-associated mutations, however only CuFi-1 (∆f508/∆f508) HBECs were 
significantly increased. There was no difference in mROS production between unstimulated 
and LPS-stimulated cells.   
 When CD66+ cells and CD16+ were gated on using whole blood, there was no 
significant difference between HC or CF cells or between unstimulated and LPS-stimulated 
cells in terms of mROS production. 
 
 
4.6 Glycolysis and NLRP3 inflammasome activation 
 
4.6.1 Inhibition of glycolysis modulates NLRP3 inflammasome activation 
 
With the data in this chapter thus far indicating a glycolytic metabolic shift in HBECs 
and immune cells with CF-associated mutations, the next hypothesis to be tested was that this 
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glycolysis is both a marker of and a contributing element to the proinflammatory phenotype 
and function of both these cell types, as observed in chapter 3. 2-DG was used to inhibit 
glycolysis and cytokine secretion was then measured from these in vitro cell cultures, to 
determine whether glycolysis is modulating the secretion of these cytokines. 
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(Figure 4.6.1 legend on next page) 
 
 
Figure 4.6.1: Effects of glycolysis inhibition on IL-18 and IL-1b secretion in HBECs and 
monocytes. ELISA assays were used to detect IL-18 and IL-1β in monocytes from HC (n=6), 
patients with CF (n=6) and NCFB (n=4) as well as HBECs (n=3). Cell stimulation was as 
follows: 2-DG (0.5mM) was pre-treated for 2-hours before a stimulation with LPS (10ng/mL) 
for 4-hours with an ATP (5mM) stimulation for the final 30 minutes. A repeated measures 2-
way ANOVA statistical test was performed with Turkey’s multiple comparisons test  (p values 
* = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
 
As demonstrated before (Section 3.4.2, Figure 3.4.2.1), HBEC lines with CF-associated 
mutations had increased levels of IL-18 secretion to a statistically significant level after LPS-
driven priming and ATP-driven assembly of the NLRP3 inflammasome. When HBECs were 
pre-treated with the small molecule 2-DG to inhibit glycolysis, IL-18 secretion was 
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significantly inhibited in all HBEC lines with CF-associated mutations as well as the Beas2b 
(WT) cell line (Figure 4.6.1). 
 IL-18 and IL-1b secretion was, as previously observed (Section 3.4.2; Figure 3.4.2.2) 
significantly elevated in monocytes from patients with CF-associated mutations compared to 
HC and NCFB monocytes. The pre-treatment of 2-DG significantly inhibited the secretion of 
both IL-18 and IL-b in monocytes from all cohorts, with no significant difference between HC, 
CF and NCFB monocytes with 2-DG pre-treatment and subsequent NLRP3 inflammasome 
activation (figure 4.6.1). 
 
4.6.2 Inhibition of glycolysis does not modulate TNF 
 
 
 
Figure 4.6.2: Effects of glycolysis inhibition on TNF secretion in HBECs and monocytes. 
ELISA assays were used to detect TNF in monocytes from HC (n=6), patients with CF (n=6) 
and NCFB (n=4) as well as HBECs (n=3). Cell stimulation was as follows: 2-DG (0.5mM) was 
pre-treated for 2-hours before a stimulation with LPS (10ng/mL) for 4-hours with an ATP 
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(5mM) stimulation for the final 30 minutes. A repeated measures 2-way ANOVA statistical 
test was performed with Turkey’s multiple comparisons test  (p values * = £0.05, **= £0.01, 
***= £0.001 and ****= £0.0001). 
 
To ensure that inhibition of glycolysis was indeed inhibiting the 
glycolysis/succinate/IL-1b axis, rather than inhibiting another inflammatory pathway or 
preventing secretion or inducing cell death through off-target effects of 2-DG, the 
proinflammatory cytokine, TNF was analysed under the same conditions as in section 2.6.1 
(Figure 4.6.2). TNF secretion was elevated in monocytes from patents with CF to a statistically 
significant level. Notably, inhibition of glycolysis with a 2-DG pre-treatment had no effect on 
TNF secretion in either patient cohort. 
 
4.6 Discussion 
 
4.6.1 Energetic metabolic phenotype in CF 
 
Based on the data presented in this chapter, it can be confidently stated that both HBEC 
lines and immune cells with CF-associated mutations not only have an energetic metabolic 
phenotype, perhaps due to an increased energy demand, but they also have an enhanced 
predisposition for a glycolytic metabolic switch, particularly when challenged with stimuli, 
such as LPS, to induce a proinflammatory immune response. Both OXPHOS and glycolysis 
are elevated in HBEC lines, monocytes and T-cells with CF-associated mutations, particularly 
upon stimulation. ECAR levels, as a readout of glycolysis, were notably upregulated in HBEC 
lines, monocytes and T-cells with CF-associated mutations. Further data to suggest that HBEC 
lines and monocytes with CF-associated mutations were upregulating metabolic pathways, 
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particularly glycolysis in response to LPS, was that intracellular ATP levels were also 
significantly increased, especially upon LPS stimulation. Notably, inhibition of Na+ channels 
with a pre-treatment of amiloride was able to modulate ECAR and ATP, but not oxygen 
consumption. These data suggest that inhibition of Na+ channels upstream have the following 
effects: 
1. Direct modulation of the proinflammatory phenotype (through modulation of 
NLRP3 inflammasome activation) and, therefore, less glycolysis is observed, 
as a marker of such inflammatory phenotypes. 
and/or; 
2. Lessening of the cell’s energy demands by reducing the effects of overactive 
Na+ channels and the consequential energy consuming compensatory 
mechanisms a cell may employ to re-establish electrochemical homeostasis and 
therefore reducing the need for enhanced metabolism to fuel such mechanisms, 
causing the downstream inflammatory effects of glycolysis to also reduce. 
 
The first of these hypotheses has been shown to be true in the previous chapter, with 
data describing the anti-inflammatory effect that inhibiting Na+ channels, particularly ENaC, 
has on NLRP3 inflammasome activation. If one considers the glycolytic metabolic switch to 
be a marker of a cell’s decision to move into a proinflammatory state or phenotype and that 
upregulating glycolysis is perhaps downstream of other inflammatory pathways and decisions, 
then there is good evidence of this throughout this and the previous chapter. Therefore, HBEC 
lines and monocytes (and T-cells) with CF-associated mutations are predisposed and possess 
an inflammatory phenotype, particularly post-LPS challenge, and this inflammatory phenotype 
is characterised by enhanced NLRP3 inflammasome activation, IL-18 and IL-1b secretion and 
a metabolic switch towards glycolysis. Furthermore, by modulating Na+ channels in HBEC 
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lines and monocytes, this inflammatory state can be diminished in terms of glycolytic 
metabolic shift, NLRP3 inflammasome activation and IL-18 and IL-1b secretion. 
The latter hypothesis regards the metabolic switch towards glycolysis as a driving force 
behind NLRP3 inflammasome activation and subsequent IL-18 and IL-1b secretion. A possible 
cause for an increased energy demand in CF in terms of disruption of ion flux concerns the 
increased activity of the Na+/K+ ATP-activated channel in CF; an important adaptation 
necessary to tackle the reestablishment of the balance of Na+ and K+. This balance is maintained 
by the Na+/K+ ATP-activated channel, which pumps Na+ and K+ ions across the plasma 
membrane against the electrochemical gradient. This process requires energy in the form of 
ATP. The excess Na+ influx, in CF cells requires the Na+/K+ ATP-gated pump to increase its 
activity in order to re-establish homeostasis. A consequence of this will not only be an influx 
of K+ as described in the previous chapter, but a huge energy demand to fuel this channel. The 
hypothesis under these circumstances is that a cell with CF-associated mutations upregulates 
both OXPHOS and glycolysis to fuel the increased energy demand described above. Therefore, 
when a cell is further challenged to produce a proinflammatory state, a predisposition to shift 
to glycolysis and therefore exaggerated downstream inflammatory responses, such as NLRP3 
inflammasome activation occur. 
A caveat with the metabolic T-cell data in figures 4.3.1 - 4.3.2 is that the existence of 
TLR4-expressing T-cells capable of responding to LPS is limited to CD4+ T-cell populations. 
The data presented in figures 4.3.1 – 4.3.2 is a population of CD3+ T-cells and is not purified 
for TLR4-expressing CD4+ T-cells and therefore will be contaminated with an unknown 
population of CD8+ T-cells, unable to respond to LPS stimulation. This limitation makes the 
interpretation of the increased metabolic read outs for CF T-cells in response to LPS 
inconclusive. A future experiment to clarify the metabolic phenotype of CF T-cells would to 
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be purify both CD3+ CD4+ and CD3+ CD8+ T-cells and challenge them with TLR4 and T-cell 
receptor (TCR) agonists. 
 Evidence for both of the above hypotheses exists and the reality may, in fact, be a 
combination of both: diminishment of the exacerbated Na+ influx in CF cells corrects an 
intrinsic pathogenic defect that underlies a predisposition to an inflammatory state and 
therefore both glycolysis and NLRP3 inflammasome activation are controlled downstream. 
 
4.6.2 Elevated glycolysis in CF 
  
 Although the energy phenotype assay provided data suggesting that metabolism is both 
energetic and glycolytic in cells with CF-associated mutations, additional markers of glycolysis 
were measured to probe this observation further. These included lactate production, glucose 
consumption, succinate accumulation, glycolytic flux and subsequent IL1b transcript levels. 
As described in section 4.4, all of these read outs suggest a highly glycolytic metabolic shift in 
cells with CF-associated mutations as well as heightened IL1b transcript levels, compared to 
HC cells. In addition, each of these read outs can be further interpreted to provide additional 
information regarding CF pathology. 
 Increased lactate production corroborates Garnett et als’ report in which the 
consequences of elevated hyperglycaemia, observed in CF and CFRD, involved elevated 
glucose-dependent glycolysis and lactate production through MCT2. This metabolic shift 
described by Garnett et al was also observed in this study. However, in contrast to Garnett et 
als’ report, the glycolysis studied in this study has been strongly linked with Na+-induced 
inflammation (rather than acidity of ASL). The MCT transporters that Garnett et al describe 
efflux H+ with lactate, a possible mechanism for the ECAR observed in this study. Garnett et 
al also describe how P. aeruginosa is capable of stimulating a metabolic shift towards 
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glycolysis during hyperglycaemia, potentially through LPS/TLR4 signalling. This is also 
confirmed in this chapter, with LPS stimulations directly inducing an exaggerated and 
somewhat inappropriate glycolytic and inflammatory state in cells with CF-associated 
mutations compared their WT equivalents. 
 Increased glucose consumption and the subsequent glycolysis may actually be 
exacerbated and worsened in terms of the potential inflammatory consequences, by the high-
calorie, high-fat diet. During in vitro experiments in which glucose was added to cells to 
measure glycolytic flux, cells with CF-associated mutations hyper-responded. This suggests 
that although the diet is there to compensate for malnutrition in individuals with CF, it may 
also be worsening the glycolytic inflammatory state observed in cells with CF-associated 
mutations throughout this study. Therefore, these data indicate that the CF diet should be 
altered to reduce hyperglycaemia and associated glucose consumption and glycolysis. 
 The understanding of how glycolysis and inflammation are linked and closely related 
is now well-described and understood. In this study, we conclusively show that succinate and 
IL1b are elevated in cells with CF-associated mutations. However, we were unable to detect 
HIF1a in either cell type or cohort. The link between succinate and IL1b is the activation 
HIF1a and this criticism of the data in this chapter only allows the link between succinate and 
IL1b to be correlated rather than stated with evidence-based vigour. 
 
4.6.3 Elevated mROS in CF 
 
To investigate the link between metabolism and inflammation in this study, it was also 
important to address mROS as a product of the metabolic switch to glycolysis and as a known 
activator of this study’s inflammatory pathway of interest, the NLRP3 inflammasome. As 
previously discussed, mROS is produced after RET and is dependent on complex one of the 
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ETC. As NLRP3 is a PRR, it will detect mitochondrial components as if they were foreign, 
due to the ancient origins of the mitochondrial relationship with eukaryotic cells (see section 
4.1.2). In this study, both HBEC lines and immune cells from whole blood were examined for 
mROS production, using a flow cytometry-based assay. Elevated mROS was observed in the 
CuFI-1 (∆F508/∆F508) HBEC line compared to the Beas2b (WT) cell line, with other two 
HBEC lines with CF-associated mutations also producing a higher amount of mROS compared 
to the Beas2b (WT) cell line, but this was not statistically significant. Notably, the HBEC lines 
did not respond to the LPS stimulation in terms of mROS production. This experiment was 
repeated multiple times as this was not an expected result, but if taken to be correct, then the 
logical conclusion is that HBEC lines did not respond to LPS challenge by upregulating mROS. 
It may be that the timing of this experiment was either too short or too long to see either a 
delayed or acute and transient mROS response, respectively. 
 When immune cells were analysed for mROS production from whole blood, the CD16 
and CD66 cell surface markers were used to gate on specific populations of immune cells. 
CD66 is a marker for granulocytes, particularly neutrophils and CD16 is a cell marker that is 
expressed broadly on immune cells, but particularly on monocytes, when the size and 
granularity are used to further select for monocytic cells. However, it must be stated that other 
cell types may have been selected based on flow cytometric gating for CD16 positive cells. 
When these cell types were analysed for mROS from both HC individuals and patients with 
CF, there was an observed increased mROS level in both CD16+ and CD66+ cells, when LPS 
was used as a stimulant for mROS production, although not statistically significant. There was 
also a higher level of mROS in both CD16+ and CD66+ cells from patients with CF-associated 
mutations, compared to cells from HC individuals, but, again, this increase did not reach 
significance. Notably, the LPS stimulation did not increase mROS in these cell types in this 
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assay, as was the case with the HBEC lines. This indicates that perhaps the LPS stimulation 
may not have been correct, in terms of dose or timing, as previously mentioned. 
 The fact that there is no real significant increase in mROS upon LPS challenge, suggests 
that further optimisation of this stimulation may be required. However, there are no statistically 
significant data to indicate whether there is more mROS present at baseline between cells with 
CF-associated mutations or those that have WT CFTR or from HC individuals. 
 
4.6.4 Oxygen consumption and hypoxia 
 
 An interesting result was that both oxygen consumption and ECAR were both elevated 
simultaneously in HBEC lines. When a metabolic switch is described in the literature, it is 
often described as an exclusive, ‘all-or-nothing’ switch to either OXPHOS or glycolysis. 
However, in this study evidence for both OXPHOS and glycolysis being simultaneously active 
may suggest there is a large number of elongated mitochondria, so that both pathways are able 
to take place, although further studies are required to investigate this theory. This phenomenon 
has been described in the literature (Zu and Guppy, 2004) and supports the hypothesis of an 
increased energy demand, within cells with CF-associated mutations, which are, therefore, 
highly metabolic in response. 
 As mentioned earlier (section 4.1.1), highly metabolic HBECs and immune cells with 
both increased oxygen consumption and ECAR will have profound effects on the CF lung. Not 
only will increased glycolytic activity and subsequent H+ and lactate acidify the CF ASL, but 
an increased OXPHOS and oxygen consumption will also have an overwhelming effect on the 
oxygen concentration. This is particularly relevant in the CF lung as oxygen consumption, in 
combination with dehydrated mucous, will promote hypoxia. Hypoxia in the CF lung is often 
contributed to the presence of dehydrated mucous alone, preventing oxygen from dispersing to 
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the lower airways. The data throughout this chapter suggest that the increased energy dynamics 
observed in cells with CF-associated mutations may also have a confounding effect on ASL 
oxygen concentrations, thereby contributing to hypoxia in the lower airways. 
 
4.6.5 Metabolism modulating macrophage phenotype 
 
 It is difficult to discern the true driving force behind the reduction in anti-inflammatory 
M2-type macrophages in CF after in vitro polarisation, as described in chapter 3 and by others 
(Tarique et al., 2017). The question of whether the inflammatory phenotype of CF cells is first 
driven by the intrinsic defect in ionic flux, leading to a predisposition towards NLRP3 
activation and subsequent induction of glycolytic metabolism; or the contrary, in which the 
intrinsic defect predisposes to glycolytic metabolism and, therefore, to an enhanced NLRP3 
inflammasome response. The data in this study suggest the latter. When 2-DG is used to inhibit 
glycolysis, NLRP3 inflammasome activation, in terms of IL-1b and IL-18 secretion, is 
diminished in both CF and HC monocytes and also in HBEC lines. This indicates that 
glycolysis is overactive in CF and that it is upstream of NLRP3 inflammasome activation. With 
glycolysis being a known influencer of macrophage phenotype, it can be inferred that the 
switch observed in metabolism in CF predetermines the lack of M2-type anti-inflammatory 
macrophages with CF-associated mutations. There is also evidence that NLRP3 expression and 
activation supports M2-type macrophages, via IL-14 signalling (Liu et al., 2018). 
 
4.6.6 Systemic metabolism and cellular metabolism 
 
 The hypothesis being tested in this study is that aberrant ENaC-dependent Na+ influx 
drives ATP-dependent ion channels, such as the Na+/K+ ATP-activated channel, in cells with 
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CF-associated mutations, which then increases cellular energy demands, subsequent energetic 
metabolism and downstream inflammatory phenotype reprogramming. Metabolically 
configured proinflammatory CF immune cells are then prone to excessive and inappropriate 
inflammatory responses to stimuli, in particular via the NLRP3 inflammasome. 
 There is another hypothesis that may also explain some of the observations made in this 
study. Systemic metabolism, that is nutrient availability and peripheral metabolite 
concentration, is affected by the gut microbiome and an individual’s diet. These factors will 
have a profound impact on the immune cells’ own metabolic pathways and, thus, their 
inflammatory phenotype. The metabolic microenvironment will influence epigenetic changes 
within immune cells, in terms of control over metabolic gene expression and pathway activity. 
Hyperlipidaemia, obesity and diabetes have been studied for links between systemic 
metabolism and immune cell metabolism and phenotype, with inflammatory consequences. 
This leads to a potential opportunity to therapeutically modify both diets and gut microbiome 
to modulate the degree of inflammation in a variety of conditions, including CF. 
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Chapter 5 
 
5.0 NLRP3 inflammasome and metabolism during Orkambi treatment 
 
5.1 Introduction 
 
The most successful new medicines for the treatment of CF have been the targeted 
small molecule drugs, which have led to the dawn of a new era of personalised, precision 
medicines. Vertex® Pharmaceuticals have pioneered this revolution in CF therapy, with their 
flagship small molecules VX-770 (ivacaftor) and VX-809 (lumacaftor), which respectively 
potentiate and correct specific CFTR mutations (Deeks, 2016, Wainwright et al., 2015, Zhang 
et al., 2016) (described in section 1.1, figure 1.1.2). In combination, ivacaftor/lumacaftor 
(orkambi) is used as a targeted therapy for the most common CF genotype- ∆f508/∆f508. The 
success of these molecules, particularly ivacaftor for class II mutations (Cholon et al., 2014), 
has provoked several pharmaceutical companies to target multiple ion channels in order to 
increase the length and quality of life for patients with all CF-associated mutations. This 
chapter will introduce the multitude of small molecules that have been developed for treatment 
of CF before presenting data generated by this study that will describe how the combination of 
ivacaftor/lumacaftor (orkambi) not only improved lung function, but also has anti-
inflammatory properties. 
 
5.1.1 Small molecule drugs for CF therapy 
 
Ivacaftor was the first, approved mutation-specific drug for use in CF (Accurso et al., 
2010). Ivacaftor targets class III mutations (Figure 1.1.2), which are characterised by CFTR 
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mutations causing gating defects leading to a permanently closed channel. The most common 
class III mutation carried by approximately 4% of CF patients is Gly551Asp or G551D. Other 
class III mutations account for a further 1% of patients. Ivacaftor was discovered using high-
throughput screening of over 200,000 small molecules for potentiation of CFTR, which showed 
increased conductance and open probability of CFTR in vitro (Wainwright et al., 2015). 
Ivacaftor improved multiple outcome measures in CF patients and is now used for various class 
III mutations as well as in combination with lumacaftor (Deeks, 2016). 
Lumacaftor was also discovered using high-throughput screening of small molecules 
for improvements in chloride transport of CFTR (Van Goor et al., 2011). Lumacaftor was 
shown to bind CFTR directly in vitro, and was able to stabilise TMD1, improving folding and 
interactions between the domains of CFTR (Ren et al., 2013). Lumacaftor improved chloride 
transport to around 14% of that of WT CFTR. The next generation of correctors has led to new 
analogues of lumacaftor, such as VX-661, as well as double- or triple-combination small 
molecule therapies for CF treatment (Mijnders et al., 2017). In class I mutations, no protein is 
produced and, therefore, small molecule modulators that directly bind and modulate CFTR are 
ineffective. Other potent CFTR correctors exist, such as GLPG2222 and GLPG2851, that, in 
combination with secondary C2 correctors such as GLPG2737, induce elevated CFTR 
expression and activity (Singh et al., 2016). 
Premature termination codons (PTCs) cause ribosomes to read the PTC and halt 
translation of the protein (Welch et al., 2007). This premature termination of translation results 
in an unstable and non-functional CFTR protein. PTCs can be targeted therapeutically, with 
aminoglycoside antibiotics that interfere with normal bacterial translation by binding to 16S 
ribosomal RNA and causing an accumulation of truncated proteins and bacterial cell death 
(Hermann, 2007). Synthetic aminoglycoside (geneticin), a read-through agent, was able to 
supress PTC detection by ribosomes in HeLa and IB3-1 cells, with full length CFTR being 
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expressed in the latter cell line (Howard et al., 1996). Ataluren (PTC124) is a systemic 
bioavailable read-through agent taken orally, which has been trialled for class I CFTR 
mutations as well as Duchenne muscular dystrophy caused by nonsense mutations (Bushby et 
al., 2014). Ataluren is similar to aminoglycoside in that it is able to supress PTC detection by 
ribosomes (Bushby et al., 2014, Kerem et al., 2014, McElroy et al., 2013, Wilschanski et al., 
2011, Kerem et al., 2008, Welch et al., 2007). A significant caveat to read-through agents is 
that there is the potential for significant off-target effects. 
Cavosonstat and Riociguat are two proteostasis regulators that act on the CFTR 
interactome, meaning their mechanism of action is indirect in terms of CFTR modulation 
(Solomon et al., 2015, Donaldson et al., 2017). Nitric oxide (NO) produces cyclic GMP 
(cGMP) by NO-sensitive guanylate cyclase, which then activates protein kinase G2, which is 
able to induce CFTR activity through phosphorylation (Bellingham and Evans, 2007). Notably, 
NO and cGMP are also able to inhibit amiloride-sensitive sodium channel activity, perhaps 
through recovery of CFTR activity (Jain et al., 1998). Riociguat increases sensitivity of soluble 
guanylate cyclase to NO. Cavosonstat is an inhibitor of S-nitrosoglutathione reductase, 
increasing NO levels and thus levels of CFTR phosphorylation and activity. 
Another approach to increase CFTR expression and amplification is through small 
molecule amplifiers. The small-molecule HDAC7 inhibitor SAHA1 amplifies Phe508del	
CFTR expression (Hutt et al., 2010). There is also evidence that SAHA1 also is able to 
modulate other HDAC7-senstive pathways that improve Phe508del	 folding, stability, 
trafficking and activity in addition to increasing CFTR expression. The specific CFTR 
amplifier PTI-428 increases CFTR protein levels that then allow correctors and potentiators to 
act on a larger pool of CFTR protein. 
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5.1.2 Targeting alternative chloride and sodium channels for CF therapy 
 
 Another tactic to restore ionic homeostasis is to target alternative channels. Epithelial 
cells are able to secrete chloride through calcium-activated chloride transport independent of 
CFTR. Stimulation of epithelial cells with agonists of calcium-release from intracellular stores 
induces chloride transport, independent of CFTR (Knowles et al., 1991). TMEM16A, or 
anoctamin-1 (ANO1), is a Ca2+-dependent chloride channels (CaCC) that murine knockouts 
for TMEM16A abrogates the above non-CFTR calcium-mediated chloride transport upon 
calcium agonist stimulation (Caputo et al., 2008, Schroeder et al., 2008, Yang et al., 2008). 
Interestingly, TMEM16A has been shown to be activated by asthma-related Th2 cytokines IL-
4 and IL-13 and TMEM16A has been shown to be elevated in airways of patients with asthma 
(Scudieri et al., 2012). TMEM16A may be a targetable alternative chloride ion channel for CF 
treatment with small molecule drugs. 
SLC26A9 is an anion channel transporter that selectively functions as a chloride 
channel, without bicarbonate transport (Loriol et al., 2008). SLC26A9 is a 12 transmembrane 
domain channel that forms a chloride channel pore. Again, asthma-related Th2-driven 
inflammation has also been shown to upregulate SLC26A9 and may be a valid targetable 
alternative chloride ion channel for CF treatment with small molecule drugs (Anagnostopoulou 
et al., 2010). 
Amiloride-sensitive sodium channels have been shown to be instrumental in CF 
pathology in terms of mucous dehydration (Kerem et al., 1999). In this study, said channels 
have been shown to be implicated in hyperinflammation and proinflammatory phenotypes of 
immune cells. ENaC is widely expressed and is involved in apical sodium uptake by absorptive 
epithelial cells. ENaC activity is elevated in CF, theoretically due to WT CFTR’s ability to 
inhibit ENaC whereas Phe508del	CFTR is unable to do so, although the precise mechanisms 
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remain unclear (Mall et al., 1998, Boucher et al., 1986, Knowles et al., 1981). In addition, the 
proinflammatory environment in the airways is able to activate ENaC directly and indirectly 
through neutrophil elastase and proteolytic cleavage and degradation of SPLUNC1 (section 
1.1) (Hobbs et al., 2013). The bENaC-Tg mouse overexpresses the b-subunit of ENaC, with 
subsequent increases in Na+ absorption leads to dehydration of the ASL and a CF-like lung 
disease, including periodic infection and inflammation (Mall et al., 2004, Zhou et al., 2011, 
Zhou et al., 2008). Targeting amiloride-sensitive sodium channels such as ENaC has been 
attempted in the early 1990’s using amiloride with little efficacy, most likely due to amiloride’s 
modest half-life and effectiveness (Graham et al., 1993, Knowles et al., 1990). There are recent 
studies showing that pre-emptive amiloride may be more effective, based on studies with the 
bENaC-Tg mouse (Zhou et al., 2008). Developing new ENaC inhibitors is an ongoing mission 
of multiple academic and pharmaceutical groups: high-throughput screening of small 
molecules (as with ivacaftor and lumacaftor), small interfering RNAs (siRNAs) (Gianotti et 
al., 2013), targeting the proteases that activate ENaC (Gaillard et al., 2010) and modifying 
endogenous ENaC inhibitors to increase their viability in the acidic CF lung (Garcia-Caballero 
et al., 2009), are all approaches for in vivo ENaC inhibition. 
Inhibitors of amiloride-sensitive sodium channels or stimulation of alternative Cl- 
channels are two therapeutic strategies that not only may have disease modifying effects but 
also offer therapeutic potential regardless of CFTR genotype. 
 
5.1.3 Ivacaftor and Lumacaftor combination therapy – CFTR modulation 
 
The outstanding disease modifying effects of ivacaftor have revolutionised treatment 
of patients with class III CFTR mutations. Due to the nature of the drug discovery process in 
the case of ivacaftor and lumacaftor, the precise molecular mechanisms of action of either drug 
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is not fully understood. This section will summarise what is known regarding how ivacaftor 
and lumacaftor work at the molecular level and the clinical trials that have followed, leading 
to their approval and use for treatment of CF. 
Ivacaftor, as previously described, was discovered using high-throughput screening of 
small molecules for potentiation of class III mutated CFTR, which showed increased short-
circuit current (Isc) in G551D CFTR FRT cells by around 4-fold and increased open probability 
(Po) of G551D CFTR by 6-fold in vitro (Eckford et al., 2012, Jih and Hwang, 2013). Greater 
effects of ivacaftor were observed in primary CF HBECs heterozygous for G551D, with an 
improved Isc of 10-fold. Ivacaftor also decreased ENaC-dependent Na+ absorption, rescuing 
cilia beating through mucous hydration (Eckford et al., 2012, Jih and Hwang, 2013). Studies 
investigating the in vitro molecular mechanisms of ivacaftor’s modulatory effects on G551D 
CFTR observed that ivacaftor binds directly to the MSD domains of CFTR to stabilise its post-
hydrolytic open state. Normally CFTR activity is controlled by phosphorylation, ATP and 
hydrolysis. Ivacaftor is able to activate CFTR in the absence of Mg-ATP through a 
nonconventional ATP-independent mechanism in which ivacaftor decouples the gating cycle 
and ATP hydrolysis cycle (Eckford et al., 2012, Jih and Hwang, 2013). Ivacaftor also increased 
the function of other class III and IV CFTR mutations. A multitude of trials have shown that 
ivacaftor is not only safe, but drastically improves lung function by at least 10%, reduces 
exacerbations by 55%, improves quality of life, increases weight gain and reduced sweat 
chloride by at least -48mmol/L by 48 weeks on average (Accurso et al., 2010, Cholon et al., 
2014, Davies et al., 2013a, Davies et al., 2013b). 
Lumacaftor, as previously described, was discovered using high-throughput screening 
of small molecules for correction of class II mutated CFTR (such as ∆f508/∆f508), which 
showed an increase in CFTR maturation through the ER by around 7-fold and an increase in 
Isc of 5-fold in vitro (Ren et al., 2013, Van Goor et al., 2011, Wainwright et al., 2015). 
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Equivalent effects of lumacaftor were observed in primary CF HBECs homozygous for ∆f508, 
with an improved maturation of 8-fold and an increased Isc of 4-fold. Click chemistry studies 
investigating the in vitro molecular mechanisms of lumacaftor’s modulatory effects on Phe508del	CFTR observed that lumacaftor binds directly to CFTR to induce correct folding 
in the ER (Sinha et al., 2015). Other studies have shown that lumacaftor’s mechanism of action 
is through direct binding of Phe508del	MSD1, correcting the defect to allow successful folding 
and escape from the ER (Ren et al., 2013). Clinical trials of lumacaftor did not produce 
improvements in lung function or patient outcome. However, when used in combination with 
ivacaftor (as in orkambi), there were significant improvements Isc of up to 25% of that of WT 
CFTR HBECs as well as hydration of ASL in vitro (Wainwright et al., 2015, Zhang et al., 
2016). In phase 2 and 3 trials of orkambi, both lung function and patient outcome, in terms of 
exacerbation rate and adverse events, showed significant improvements. 
 
5.2 Methods 
 
5.2.1 Patient cohort 
 
The patient cohort in this study, recruited from 2015-2018, is detailed in the table 
below. 
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Table 6: Available patient information form the ∆f508/Phe508del	CF Orkambi cohort 
recruited to this study. Details of baseline lung function FEV (l/s), FEV1, FEV1%, FVC (L), 
FVC%, weight (Kg) BMI, CRP (mg/L) and presence of infection are presented in this table 
from the patients enrolled onto the orkambi CF study (n=8), collected from clinical team at St 
James Hospital Adult CF ward, Leeds. Further details in appendix figure 12. 
 
5.2.2 Cell culture 
 
As in section 2.3. 
Briefly, patients’ blood samples were collected using Vacuette tubes (Greiner-bio-one) 
containing either clot activator or K3EDTA. Blood in clot activator tubes were allowed to clot 
for 60 min followed by centrifuging at 1000xg for 10 min. Sera were collected into 1mL tubes 
for storage at -80oC. Blood collected in K3EDTA tubes were used for PBMC isolation. EDTA 
treated blood were mixed with PBS in a 1:1 ratio, carefully layered onto 13mL of 
Lymphoprep® (Axis-Shield) in 50mL Falcon tubes and centrifuged at room temperature, 
1100xg for 20 mins without brakes. The PBMCs ‘buffy layer’ on top of the Lymphoprep® 
Baseline 
FEV
FEV1 
(l/s)
FEV1 
(%)
FVC   
(L)
FVC   
(%)
Weight  
(Kg)
BMI CRP 
(mg/L)
Pathogen
40 0.95 23 1.69 35 48.3 16 31 PA
26 1.09 35 1.54 43 58.3 22.6 24 M ABS
51 0.82 28 1.37 41 53.2 19.4 <5 PA
34 1.5 35 3.09 59 74.1 22.6 <5 PA
39 1.04 28 2.26 60 58 20.8 <5 BCC
31 0.86 33 1.37 46 55.1 23.2 16.3 PA
30 0.74 17 2.56 49 64.45 19.9 27 PA
36 1.18 26 2.04 40 58.25 18.7 <5 PA
Median at 
Baseline 0.995 28 1.865 44.5 58.125 20.35 25.5
IQR 0.85 25.25 1.4975 40.75 54.625 19.225 22.075
Deaths 0
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layer was extracted and washed in 3x volume PBS. Isolated PBMCs plated in 6 well plates, 
seeded at 1x106 cells/mL/well in 1mL RPMI medium (Sigma) supplemented with 10% FBS, 
50 IU/ml penicillin, and 50 g/ml streptomycin. 
 
5.2.3 ELISA 
 
As in section 2.5. 
Briefly, supernatants were collected from in vitro PBMC stimulations and serum was 
isolated from whole blood using clot-activating blood collection tubes that were centrifuged to 
separate out the sera from the whole blood. Serum was aliquoted and stored long-term at -
80°C. Serum from healthy controls and patients with CF, diagnosed SAID and NCFB were 
collected and serum cytokines measured by ELISA, as per the manufacturer’s instructions. The 
growth media supernatants from stimulated cell culture plates were stored at -20°C before 
being used to detect IL-1b and IL-18 cytokine secretion by ELISA. 
 
5.2.4 Intracellular fluorometric assay 
 
As in section 4.2.2. ATP and succinate (Assay kits, Abcam) were measured, as per the 
manufacturer’s instructions. 
 
5.2.5 Extracellular fluorometric assay 
 
As in section 4.2.3. Extracellular glucose and L-lactate (Assay kits, Abcam) were 
measured, as per the manufacturer’s instructions. 
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5.3 The effects of orkambi on serum cytokines 
 
Serum levels of selected proinflammatory cytokines were analysed by ELISA, over the 
course of 3-months of compassionate orkambi treatment. The cytokines measured were the two 
proinflammatory, NLRP3-associated cytokines, IL1b and IL-18, as well IL-6 and TNF, two 
other cytokines also associated with innate immune cell activation. 
 
5.3.1 Serum IL-18 and TNF 
 
 
 
Figure 5.3.1.1: Serum IL-18 levels in patients with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect IL-18 in serum from 
patients (n=8) with CF-associated mutations receiving compassionate orkambi treatment. 
Orange and black dotted lines indicate mean average IL-18 serum levels in CF and HC serum 
from figure 3.3.1.1, respectively. The Friedman paired test with Dunn’s multiple comparisons 
test was performed (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
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IL-18 is a cytokine that is constitutively expressed at the mRNA level but is only 
secreted upon inflammasome activation, predominantly NLRC4 and NLRP3 although this is 
cell type and pathogen specific. Active caspase-1 cleaves pro-IL-18 into its active form and 
allows its secretion through GSDMD-dependent pore formation. After 1-month of orkambi 
treatment, there was no statistically significant change in IL-18 serum levels. After 3-months 
of orkambi, there was a statistically significant reduction in serum IL-18 (p=0.0081). 
TNF is a proinflammatory cytokine implicated in many immunological diseases, 
including rheumatoid arthritis and ankylosing spondylitis. TNF expression and secretion are 
induced by TLR activation as well as paracrine and autocrine signalling via TNF receptor 
binding. After 1-month of orkambi treatment, there was no statistically significant change in 
TNF serum levels. After 3-months of orkambi, there was a statistically significant reduction in 
serum TNF (p=0.0179). 
 
 
 
Figure 5.3.1.2: Serum TNF levels in patients with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect TNF in serum from 
patients (n=8) with CF-associated mutations receiving compassionate orkambi treatment. 
Orange and black dotted lines indicate mean average TNF serum levels in CF and HC serum 
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from figure 3.3.1.1, respectively. The Friedman paired test with Dunn’s multiple comparisons 
test was performed (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
 
5.3.2 Serum IL-1b and IL-6 
 
 
 
Figure 5.3.2.1: Serum IL-1b levels in patients with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect IL-1b in serum from 
patients (n=8) with CF-associated mutations receiving compassionate orkambi treatment. 
Orange and black dotted lines indicate mean average IL-1b serum levels in CF and HC serum 
from figure 3.3.1.1, respectively. The Friedman paired test with Dunn’s multiple comparisons 
test was performed (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
 
IL-1b is a cytokine that is expressed upon TLR activation as well as paracrine and 
autocrine signalling via IL-1 receptor signalling, although many other transcription factors are 
able to induce IL1B expression such as HIF1a and XBP1s. IL-1b is secreted upon 
inflammasome activation, predominantly NLRP3, although this is cell type and pathogen 
specific. Like IL-18, active caspase-1 cleaves pro-IL-1b into its active form and allows its 
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secretion through GSDMD-dependent pore formation. There was no statistically significant 
change in IL-1b serum levels after 1-month or 3-months of orkambi. 
IL-6 is an atypical cytokine in that it can be both a proinflammatory and anti-
inflammatory with differential roles in specific tissue-types. IL-6 is secreted by T-cells and 
macrophages in response to TLR activation as well as various other cytokine-mediated 
signalling events. IL-6 mediates fever, as does IL-1b, through facilitating the synthesis of PGE2 
in the brain. The anti-inflammatory effects of IL-6 are limited to its role as a myokine, a small 
molecule released by myocytes during muscle contraction with a role in repair of damaged 
muscle fibres post-exercise. The distinction in signalling cascades between myocytes and 
macrophages determines the inflammatory effects of IL-6, with macrophages predominantly 
utilising NF-kB as a proinflammatory transcription factor, myocytes employ Ca2+ driven 
NFAT and p38 MAPK. In this study, IL-6 is acting on a systemic level, secreted by immune 
cells into the peripheral blood, rather than myocyte secreted IL-6, which acts in a paracrine 
manner rather than systemically. There was no statistically significant change in IL-6 serum 
levels after 1-month or 3-months of orkambi. 
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Figure 5.3.2.2: Serum IL-6 levels in patients with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect IL-6 in serum from 
patients (n=8) with CF-associated mutations receiving compassionate orkambi treatment. 
Orange and black dotted lines indicate mean average IL-6 serum levels in CF and HC serum 
from figure 3.3.1.1, respectively. The Friedman paired test with Dunn’s multiple comparisons 
test was performed (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
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5.4 The effects of orkambi on PBMC cytokine secretion 
 
5.4.1 PBMC secreted IL-18 and TNF 
 
 
Figure 5.4.1.1: IL-18 secretion in patient PBMCs with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect IL-18 secretion in 
PBMCs from patients (n=8) with CF-associated mutations receiving compassionate orkambi 
treatment at baseline, 1-month orkambi and 3-months orkambi. PBMCs were stimulated with 
LPS (10ng/mL) for 4 hours before being stimulated for 30 minutes with ATP (5mM). A 
repeated measures 2-way ANOVA statistical test was performed with Turkey’s multiple 
comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
Peripheral blood mononuclear cells (PBMC)s are immune cells isolated from whole 
blood with a single, round nucleus. PBMC isolation discriminates against platelets and 
erythrocytes (no nuclei) and granulocytes (multi-lobed nuclei). The cell types within PBMCs 
are predominantly monocytes and lymphocytes (B-cells, T-cells and NK cells). PBMCs were 
isolated from whole blood, along with serum (section 5.3), and stimulated in vitro with LPS 
and ATP for NLRP3 inflammasome priming and activation. This sample collection took place 
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parallel to the serum samples (section 5.3) at baseline (0-months), and after 1-month of orkambi 
and 3-months of orkambi therapy. 
There was no change in in vitro IL-18 secretion at either 1-month or 3-months of 
orkambi treatment with unstimulated PBMCs. Upon stimulation, PBMCs from 
∆f508/Phe508del patients on compassionate orkambi therapy secreted large amounts of IL-18 
at baseline, in a hyper-responsive reaction to NLRP3 stimulation that was also previously 
observed throughout chapter 3. After 1-month of orkambi treatment, PBMCs from 
∆f508/Phe508del patients on compassionate orkambi therapy secreted reduced IL-18 to a 
statistically significant level, upon stimulation with LPS and ATP. At the 3-months orkambi 
timepoint, IL-18 secretion in vitro was reduced compared to baseline and 1-month (p=<0.0001 
and p=<0.0001 respectively). 
There was no change in in vitro TNF secretion at either 1-month or 3-months of 
orkambi treatment with unstimulated PBMCs, with very little secreted TNF detected in any 
sample. Upon stimulation, PBMCs from ∆f508/Phe508del patients on compassionate orkambi 
therapy at baseline secreted large amounts of TNF, in response to the LPS rather than ATP. 
After 1-month of orkambi treatment PBMCs from patients with ∆f508/Phe508del mutations 
secreted reduced TNF but not to a statistically significant level, upon stimulation. At the 3-
month orkambi timepoint, TNF secretion in vitro was reduced compared to baseline and 1-
month (p=<0.0001 and p=<0.0001 respectively). 
These observations with IL-18 and TNF correlate with the serum data (Figure 5.3.1.1) 
in which IL-18 and TNF levels reduced, generally, over the 3-months of orkambi treatment. 
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Figure 5.4.1.2: TNF secretion in patient PBMCs with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect TNF secretion in 
PBMCs from patients (n=8) with CF-associated mutations receiving compassionate orkambi 
treatment at baseline, 1-month orkambi and 3-months orkambi. PBMCs were stimulated with 
LPS (10ng/mL) for 4 hours before being stimulated for 30 minutes with ATP (5mM). A 
repeated measures 2-way ANOVA statistical test was performed with Turkey’s multiple 
comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
5.4.2 PBMC secreted IL-1b and IL-6 
 
There was no change in in vitro IL-1b secretion at either 1-month or 3-months of 
orkambi treatment with unstimulated PBMCs, with very little secreted IL-1b detected in any 
sample. Upon stimulation, PBMCs from ∆f508/Phe508del patients on compassionate orkambi 
therapy at baseline secreted large amounts of IL-1b, in a hyper-responsive reaction to NLRP3 
stimulation that was also previously observed with in vitro PBMC IL-18 and TNF secretion 
and throughout chapter 3. After 1-month of orkambi treatment PBMCs from ∆f508/Phe508del 
patients on compassionate orkambi therapy secreted unchanged IL-1b levels, upon stimulation 
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with LPS and ATP. At the 3-month orkambi timepoint, IL-1b secretion in vitro was again 
unchanged compared to that of the other timepoints upon stimulation, with no statistically 
significant reduction between both 3-months and 1-month or baseline and 3-months. 
There was no change in in vitro IL-6 secretion at either 1-month or 3-months of orkambi 
treatment with unstimulated PBMCs, with very little secreted IL-6 detected in any sample. 
Upon stimulation, PBMCs from ∆f508/Phe508del patients on compassionate orkambi therapy 
at baseline secreted large amounts of IL-6, in response to the LPS rather than ATP. After 1-
month of orkambi treatment PBMCs from ∆f508/Phe508del patients on compassionate 
orkambi therapy secreted unchanged IL-6, upon stimulation. At the 3-month orkambi 
timepoint, IL-6 secretion in vitro was again unchanged compared to that of the other timepoints 
upon stimulation, with no statistically significant reduction between either 3-months and 1-
month or baseline and 3-months. 
These observations in IL-1b and IL-6 correlate with the serum data (Figure 5.3.1.1) in 
which IL-1b and IL-6 levels remained unchanged over the 3-months of orkambi treatment. 
 
 
(Figure 5.4.2.1 legend on next page) 
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Figure 5.4.2.1: IL-1b secretion in patient PBMCs with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect IL-1b secretion in 
PBMCs from patients (n=8) with CF-associated mutations receiving compassionate orkambi 
treatment at baseline, 1-month orkambi and 3-months orkambi. PBMCs were stimulated with 
LPS (10ng/mL) for 4 hours before being stimulated for 30 minutes with ATP (5mM). A 
repeated measures 2-way ANOVA statistical test was performed with Turkey’s multiple 
comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
 
 
Figure 5.4.2.2: IL-6 secretion in patient PBMCs with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect IL-6 secretion in 
PBMCs from patients (n=8) with CF-associated mutations receiving compassionate orkambi 
treatment at baseline, 1-month orkambi and 3-months orkambi. PBMCs were stimulated with 
LPS (10ng/mL) for 4 hours before being stimulated for 30 minutes with ATP (5mM). A 
repeated measures 2-way ANOVA statistical test was performed with Turkey’s multiple 
comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
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5.4.3 PBMC secreted IL-10 
 
 The anti-inflammatory cytokine IL-10 was also detected in in vitro PBMC stimulations 
(IL-10 was undetectable in serum by ELISA). IL-10 is a potent anti-inflammatory cytokine, 
secreted by an array of both lymphoid and myeloid cells with anti-inflammatory or suppressive 
phenotypes. A lack of IL-10 secretion is an indication of pathogenic inflammation as IL-10 
will induce the resolution phase of inflammation. IL-10 is known to be secreted along with 
TNF and IL-6 upon LPS stimulation, downstream of NF-kB. 
 Within the unstimulated PBMCs from ∆f508/Phe508del patients on compassionate 
orkambi therapy, very little IL-10 was detected with a small increase in spontaneous IL-10 
secretion over the 3-months of orkambi treatment, but this was not statistically significant. 
Upon stimulation with LPS and ATP, IL-10 secretion from in vitro PBMCs was detected and 
increased to a statistically significant level after 3-months of orkambi treatment, compared to 
baseline (p=0.0003). IL-10 secretion in vitro was significantly increased between 1-month and 
3-months of orkambi treatment, upon stimulation with LPS and ATP (p=0.0071). 
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Figure 5.4.3.1: IL-10 secretion in patient PBMCs with CF-associated mutations receiving 
compassionate orkambi treatment. ELISA assays were used to detect IL-10 secretion in 
PBMCs from patients (n=8) with CF-associated mutations receiving compassionate orkambi 
treatment at baseline, 1-month orkambi and 3-months orkambi. PBMCs were stimulated with 
LPS (10ng/mL) for 4 hours before being stimulated for 30 minutes with ATP (5mM). A 
repeated measures 2-way ANOVA statistical test was performed with Turkey’s multiple 
comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
 
5.5 The effect of orkambi on cellular metabolism 
 
Cellular metabolism and control of cytokine secretion are two processes that are 
inextricably linked. In order to understand the effects of orkambi on cytokine secretion, specific 
metabolic assays were also performed in parallel. L-lactate secretion and glucose consumption 
were measured in PBMC supernatants from patients with the ∆f508/Phe508del	 CFTR 
mutation on compassionate orkambi treatment. L-lactate secretion, glucose consumption, 
succinate and ATP concentrations were also measured in PBMC supernatants from HC 
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individuals and patients with the ∆f508/Phe508del	CFTR mutation (without compassionate 
orkambi treatment) and orkambi added as an in vitro pre-treatment to LPS and ATP. 
 
5.5.1 Cellular metabolism of PBMCs from orkambi treated patients with ∆f508/∆f508 
 
A small but statistically significant increase in L-lactate secretion in PBMC 
supernatants from patients with the ∆f508/Phe508del	CFTR mutation was observed after 3-
months of compassionate orkambi treatment compared to baseline measurements, before 
orkambi administration (p=0.0014). 
 
 
Figure 5.5.1.1: Extracellular L-lactate secretion in patient PBMCs with CF-associated 
mutations receiving compassionate orkambi treatment. Colorimetric assays were used to 
detect intracellular L-lactate production in PBMCs from patients (n=8) with CF-associated 
mutations receiving compassionate orkambi treatment at baseline, 1-month orkambi and 3-
months orkambi. PBMCs were stimulated with LPS (10ng/mL) for 4 hours before being 
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stimulated for 30 minutes with ATP (5mM). A repeated measures 2-way ANOVA statistical 
test was performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, 
***= £0.001 and ****= £0.0001).   
 
There were no significant differences observed in glucose consumption in PBMC 
supernatants from patients with the ∆f508/Phe508del	CFTR mutation over the 3-months of 
compassionate orkambi treatment. 
 
Figure 5.5.1.2: Glucose consumption in patient PBMCs with CF-associated mutations 
receiving compassionate orkambi treatment. Colorimetric assays were used to detect 
intracellular glucose consumption in PBMCs from patients (n=8) with CF-associated mutations 
receiving compassionate orkambi treatment at baseline, 1-month orkambi and 3-months 
orkambi. PBMCs were stimulated with LPS (10ng/mL) for 4 hours before being stimulated for 
30 minutes with ATP (5mM). A repeated measures 2-way ANOVA statistical test was 
performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, ***= 
£0.001 and ****= £0.0001).   
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5.5.2 Cellular metabolism of ∆f508/Phe508del	PBMCs stimulated with orkambi in vitro 
 
 PBMCs from HC individuals and patients with the ∆f508/Phe508del	CFTR mutation 
(without compassionate orkambi treatment) were isolated and cultured in vitro before being 
treated with laboratory-grade orkambi and a stimulation with LPS and ATP. The hypotheses 
behind these in vitro experiments were two-fold: (1) Orkambi is capable of modulating cellular 
metabolism in PBMCs from patients with CF-associated mutations directly; and (2) Any 
orkambi-driven improvement in in vivo lung function is independent to the metabolic changes 
seen in orkambi-treated CF PBMCs. By recruiting patients with the ∆f508/Phe508del	CFTR 
mutation and selecting those who had never received compassionate orkambi treatment, data 
could be generated to determine whether the changes in immunometabolism, observed with 
orkambi, were due to an improvement in lung function or due to orkambi itself. 
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(Figure 5.5.2.1 legend on next page) 
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Figure 5.5.2.1: Cellular metabolism in HC and CF PBMCs with in vitro orkambi 
treatment. Colorimetric assays were used to detect intracellular L-lactate production, glucose 
consumption, intracellular ATP and intracellular succinate in HC and CF PBMCs with in vitro 
orkambi (VX-770 5µM; VX-809 3µM) treatment for 48 hours. PBMCs were stimulated with 
LPS (10ng/mL) for 4 hours before being stimulated for 30 minutes with ATP (5mM). A 
repeated measures 2-way ANOVA statistical test was performed with Turkey’s multiple 
comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
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The experiments that generated the data displayed in this figure, as well as the design of the 
figure itself, were carried out by Dr Heledd Jarosz-Griffiths. The author of this thesis would 
like to fully acknowledge Dr Jarosz-Griffiths’ contribution. 
 
L-lactate secretion was increased in PBMCs from patients with the ∆f508/Phe508del	
CFTR mutation, as observed previously (Figure 4.4.1) to a statistically significant level, 
compared to PBMCs from HC individuals at baseline. Upon LPS stimulation both CF and HC 
PBMCs increased L-lactate secretion, with CF PBMCs maintaining their statistically 
significant increase in L-lactate secretion compared to PBMCs from HC individuals. A pre-
treatment of orkambi for 48-hours did not affect L-lactate secretion in either CF or HC PBMCs 
at either baseline or their response to LPS stimulation. 
Glucose consumption was increased in PBMCs from patients with the ∆f508/Phe508del	CFTR mutation, as observed previously (Figure 4.4.2) to a statistically 
significant level, compared to PBMCs from HC individuals at baseline. Upon LPS stimulation 
both CF and HC PBMCs increased glucose consumption, with CF PBMCs maintaining their 
statistically significant increase in glucose consumption compared to PBMCs from HC 
individuals. A pre-treatment of orkambi for 48-hours did not affect glucose consumption in 
either CF or HC PBMCs at either baseline or their response to LPS stimulation. 
Intracellular ATP concentration was increased in PBMCs from patients with the ∆f508/Phe508del	CFTR mutation, as observed previously (Figure 4.3.3) to a statistically 
significant level, compared to PBMCs from HC individuals at baseline. Upon LPS stimulation 
both CF and HC PBMCs increased intracellular ATP concentration, with CF PBMCs 
maintaining their statistically significant increase in intracellular ATP concentration compared 
to PBMCs from HC individuals. A pre-treatment of orkambi for 48-hours did not affect 
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intracellular ATP concentration in either CF or HC PBMCs at either baseline or their response 
to LPS stimulation. 
Intracellular succinate concentration was increased in PBMCs from patients with the ∆f508/Phe508del	CFTR mutation, as observed previously (Figure 4.4.3) to a statistically 
significant level, compared to PBMCs from HC individuals at baseline. Upon LPS stimulation 
both CF and HC PBMCs increased intracellular succinate concentration, with CF PBMCs 
maintaining their statistically significant increase in intracellular succinate concentration 
compared to PBMCs from HC individuals. A pre-treatment of orkambi for 48-hours increased 
intracellular succinate concentration in CF PBMCs at baseline, but not in HC PBMCs. Orkambi 
pre-treatment had no statistically significant effect on intracellular succinate concentration in 
LPS stimulated PBMCs. 
 
5.6 Discussion 
 
5.6.1 Effects of Orkambi- CFTR modulator, ENaC inhibitor or NSAID 
 
Orkambi is a combination of two small molecule drugs: ivacaftor, a ‘potentiator’ to 
increase the open probability of the defective CFTR and; lumacaftor, a ‘corrector’ to chaperone 
CFTR protein folding through the ER and Golgi. It has been shown that orkambi is able to 
chaperone and potentiate the Phe508del	mutated-CFTR in vitro and in vivo with modest 
improvements in patient lung function and outcome. The ability of orkambi to modulate 
inflammation is unknown. With partial restoration of functional CFTR in orkambi treated 
patients, ENaC inhibition is also partially restored (Cholon et al., 2014). Based on the data 
presented in this study, it can be hypothesised that orkambi is able to modulate inflammation 
in patients with CF, via restoration of ENaC-inhibition. Therefore, orkambi would be an 
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indirect ENaC inhibitor and the therapeutic effects observed with orkambi treatment are via 
controlling Na+ influx rather than restoration of Cl- flux. The ability of orkambi, based on the 
above theory, to modulate inflammation in WT cells will be limited. Based on the data 
presented in this study, there is increased Na+-induced inflammation in cells with CF-
associated mutations and Na+ channel inhibition is able to modulate the excessive 
inflammatory response. When WT cells are treated with Na+ channel inhibitors, cytokine 
secretion is not affected. Na+ channel inhibition corrects a pathogenic consequence of the 
primary CFTR defect in CF, and therefore the anti-inflammatory effect in WT cells is limited. 
Orkambi’s ability to decrease ENaC activity through restoration of CFTR then in theory would 
also have limited anti-inflammatory effects in WT cells. 
 
5.6.2. Differential modulation of cytokines 
 
Patients considered for compassionate orkambi treatment are those with a ‘suitable’ 
genotype that is compatible with the molecular mechanisms of ivacaftor and lumacaftor 
individually (e.g. ∆f508/∆f508). All patients in the compassionate orkambi study were 
confirmed to be ∆f508/Phe508del	homozygotes. In addition to genotype, patients must be 
without infection but have poor lung function, due to mucous accumulation or 
fibrosis/bronchiectasis. Orkambi is not offered by the National Health Service (NHS) in 
England, with Vertex® Pharmaceuticals providing the drug to patients on compassionate 
grounds based on specific criteria (section sections 1.1 and 1.5, figure 1.1.2). The data in this 
chapter can be interpreted based on these criteria, in terms of the general health and 
inflammatory state of the patient cohort. 
 Serum IL-18 at baseline is variable within the patient population, with a range of around 
200pg/mL to over 800pg/mL (HC median=117pg/mL). These data highlight that despite a 
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previous decline in lung function in all patients before being administered with orkambi, there 
is a variable inflammatory state within the overall population, in terms of serum IL-18. Serum 
TNF, IL-1b and IL-6 concentrations were also all above the average HC serum level for each 
respective cytokine. Serum IL-18 began to gradually decrease after 1-month, but this decrease 
was not statistically significant. This suggests that the initial period after administration with 
orkambi, may not yield positive results in terms of inflammatory markers. After 3-months of 
orkambi treatment, the decrease in IL-18 was statistically significant compared to baseline. 
These data indicate that orkambi is able to reduce systemic IL-18 after 3-months, with all 
patients ending the 3-month study period with serum IL-18 concentrations below the average 
for CF serum IL-18 (based on data in Figure 3.1.1). Serum TNF responded in a similar fashion, 
with no initial decrease after 1-month but a statistically significant decrease after 3-months. 
These data support a hypothesis that the beneficial anti-inflammatory effects of orkambi occur 
between 1-month and 3-months of treatment. 
 There was no notable change in serum IL-1b or IL-6 over the 3-month period of 
orkambi treatment in this study. However, this observation is itself noteworthy as it suggests 
there is a differential regulation of proinflammatory cytokines in CF with orkambi treatment. 
IL-1b was shown to be significantly elevated in CF serum compared to HC, NCFB and SAID 
cohorts (Figure 3.1.2). In this cohort, IL-1b was also elevated compared to the HC median from 
Figure 3.1.2 and this serum concentration remained unchanged over the 3-months of orkambi 
whereas IL-18, which is also processed by the NLRP3 inflammasome being significantly 
decreased over the same period. Differences in expression and regulation of IL-1b and IL-18 
occurs at the transcriptional level, with IL-1b being induced by upstream transcription factors 
such as NF-kB, HIF1a and XBP1s, with IL-18 being constitutively expressed. However, TNF 
expression is also induced by NF-kB, HIF1a and XBP1s and serum TNF concentrations 
decreased to a similar extent to that of IL-18. One way that orkambi may be differentially 
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regulating TNF and IL-1b is through prostaglandin E2 (PGE2). PGE2 is able to act as a pro- and 
anti-inflammatory mediator of inflammation, being able to inhibit TNF expression in response 
to LPS (Tang et al., 2017) and induce IL-1b expression (Zasłona et al., 2017). Markedly, PGE2 
also induces IL-6 expression and secretion (Cho et al., 2014, Ghezzi et al., 2000, Raychaudhuri 
et al., 2010, Kunkel et al., 1988, Hinson et al., 1996), which also remains elevated throughout 
the 3-months of orkambi treatment. Interestingly, data showing that dual-acting potentiator–
correctors, such as the C-18 Vertex® molecule induces elevated cyclo-oxygenase (COX)-2 
and the related metabolite PGE2. However, investigating the exact molecular mechanisms by 
which orkambi differentially regulates TNF and IL-1b is beyond the scope of this study. 
 The cytokine data generated using in vitro stimulation of PBMCs from patients 
receiving compassionate orkambi follow the same trend to that of the serum cytokine data: IL-
18 and TNF decline in concentration over 3-months of orkambi treatment, to a statistically 
significant level; whereas IL-16 and IL-1b are unaffected by orkambi treatment. This data 
supports the PGE2 hypothesis mentioned above, but this was no investigated further in this 
study. 
 An interesting observation was made when IL-10 levels from in vitro PBMC 
stimulations were analysed, with secretions of this anti-inflammatory cytokine increasing over 
the 3-month period. IL-10 could not be detected in serum. IL-10 may explain the observed 
reduction in IL-18 and TNF in serum and in vitro PBMC secretions but IL-10 does not 
differentially regulate IL-6 and IL-1b and so cannot explain the discrepancy in cytokine 
secretion over the 3-months of orkambi treatment. 
 An important observation to note is that the orkambi patient cohort have higher baseline 
levels on average that the other CF population used in chapters 3 and 4. This can be explained 
by highlighting the fact that compassionate orkambi administration is considered when this 
subset of Phe508del/Phe508del patients’ lung function is declining. Therefore, one can 
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correlate declining lung function and an elevated baseline serum cytokine concentration. 
Further details of clinical data across the 3-month study are displayed in appendix figure 12. 
There was no significant change in any of the parameters of lung function, inflammation or 
patient weight/BMI. This indicates stable clinical values across the 3-month study, with no 
worsening of patients on orkambi. 
 
5.6.3. Limitations 
 
 Limitations to the data generated from this study revolve around a lack of 
control around dosage of orkambi. It is common practise to adjust the orkambi dose initially to 
a lower level that that recommended by Vertex® to then increase the dosage over the first 
month to prevent adverse side-effects. All patients were at maximum dose by the time of the 
first 1-month sample collection. The cohort was not well defined due to the small size of the 
study. An additional limitation to the above data regards the use of PBMCs, rather than purified 
immune cell populations. The ratio of cell types within the heterogenous PBMC population is 
not controlled for and therefore may influence the differential secretion of the measured 
cytokines. Future experiments would utilise flow cytometry or cell separation assays to deepen 
the understanding of which cell types are pathogenic in CF and how orkambi effects individual 
immune cell types. 
 
5.6.4 Modulation of metabolism 
 
 Metabolism was measured within stimulated PBMC cultures over the 3-months of 
orkambi treatment. These data were generated in parallel with the cytokine assays to provide 
an insight into the inflammatory, metabolic phenotype of PBMCs over the 3-months of 
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orkambi treatment. With increased IL-10 and reduced IL-18 and TNF secretion, it was 
expected that glycolytic markers would decrease in the same samples. There was no change 
over the 3-months of orkambi treatment in glucose consumption after stimulation with LPS 
and ATP in patient PBMCs. However, L-lactate secretion significantly increased between 1-
month and 3-months and between baseline and 3-months of orkambi treatment. This indicates 
that glycolysis may be increasing over this period, perhaps fuelling IL-1b expression through 
succinate accumulation. When L-lactate secretion, glucose consumption and intracellular 
concentration were measure in CF PBMCs treated with 48 hours of orkambi in vitro, there was 
no change in these metabolic assays. When intracellular succinate concentration was analysed, 
there was an increase in samples pre-treated with 48 hours of orkambi in vitro. These data 
support the hypothesis that an increase in glycolysis during orkambi treatment maintains IL-
1b production, via succinate accumulation. 
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Chapter 6 
 
6.0 Discussion 
 
 In the following chapter, the data and observations described in this study will be 
discussed, in terms of what the results mean for the understanding of CF pathophysiology, the 
characterisation of CF and the implications that these novel findings have on future therapies 
for the treatment of CF. 
 
6.1 CF is an autoinflammatory disease 
 
 Autoinflammation is defined as an inappropriate inflammatory response, driven by 
dysregulated innate immune cells, without evidence of antigen-driven T cells, B-cells, or 
associated autoantibodies (McDermott and Aksentijevich, 2002, McDermott et al., 1999, 
McGonagle and McDermott, 2006, Pathak et al., 2016, Peckham et al., 2017, Kastner et al., 
2010, Stoffels and Kastner, 2016). Adaptive immune cells are sometimes associated with the 
downstream consequences of autoinflammation, as well as increased susceptibility to infection, 
autoimmunity and hyperinflammation (Wekell et al., 2016). These associated adaptive immune 
cells are not the cause of inflammation but are merely affected bystanders. Autoinflammatory 
disorders range from monogenic disorders, with mutations causing dysregulation of innate 
immune pathways to a number of systemic immunological diseases, with significant 
autoinflammatory features, such as psoriasis, gout and even a subset of  rheumatoid arthritis 
(Liang et al., 2017, Marrakchi et al., 2011, Onoufriadis et al., 2011, Sweeney et al., 2011), 
Aicardi-Goutières syndrome (AGS) (Crow et al., 2006) and rheumatoid arthritis (RA) 
(Choulaki et al., 2015, Littlewood-Evans et al., 2016, Mathews et al., 2014). 
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Immunodeficiencies, such as PLCG2-associated antibody deficiency and immune 
dysregulation (PLAID) (Chae et al., 2015) or haploinsufficiency of cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) (Kuehn et al., 2014), may show increased innate immune 
responses to inflammatory triggers to compensate for an immunodeficient adaptive immune 
system (Peckham et al., 2017). 
 Immunological diseases lie on a spectrum, with the autoinflammatory and autoimmune 
diseases at the antithetical ends of a continuum (McGonagle and McDermott, 2006). 
Immunological diseases that incorporate features of both autoinflammation and autoimmunity 
exist the two absolute ends of the spectrum (sections 1.6 and 3.10.1) (Peckham et al., 2017, 
McGonagle and McDermott, 2006). This study proposes that CF is an immunological disease 
that sits towards the autoinflammatory pole of the spectrum. Evidence for CF being an 
autoinflammatory disease is derived from the nature of the systemic inflammation observed in 
patients with CF-associated mutations, in combination with the inherent characteristics of the 
inflammation observed at the molecular and cellular level. This study contributes towards the 
latter observations, providing novel insights into the basic features of the inflammatory 
pathways active in cells with CF-associated mutations. 
 A large infiltrate of myeloid immune cells is a key feature of pulmonary inflammation 
in patients with CF-associated mutations (Bals et al., 1999, Bruscia and Bonfield, 2016a, Hartl 
et al., 2012). Neutrophils dominate this immune cell influx into the lung and are described as 
the ‘first-responders’ of inflammation (Aulakh, 2018, Cohen and Prince, 2012, Hayes et al., 
2011). The lung in patients with CF contains a milieu of myeloid-derived, proinflammatory 
cytokines and chemokines within the inflammatory environment , with significant levels of 
proinflammatory cytokines, including IL-8 (CXCL8), IL-6, TNF and IL-1 (IL-1a, IL-1b and 
IL-18), and reduced levels of anti-inflammatory IL-10 (Bals et al., 1999, Bruscia and Bonfield, 
2016a, Hartl et al., 2012, Keiser et al., 2015). Many studies have described the role of IL-8 in 
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CF lung inflammation due to its potent chemotactic abilities, which enable further recruitment 
of neutrophils to the site of inflammation (Armstrong et al., 2005, Bergin et al., 2013, Grassme 
et al., 2014, Hubeau et al., 2004, Keiser et al., 2015). IL-8 is secreted by epithelial cells and 
monocytes in the CF lung to exacerbate neutrophilic inflammation. A large proportion of the 
above cytokines and chemokines is produced by monocytes, driving the innate immune 
inflammation in the CF lung. IL-1b is a pivotal cytokine in the amplification of the systemic 
proinflammatory cytokine response, although the increased levels of IL-1b in the lung are not 
correlated to patient outcome (Bals et al., 1999, Hartl et al., 2012). The fact that the dominant 
cell infiltrates in the CF lung are innate immune cells supports the proposed classification of 
CF as an autoinflammatory disease. Autoinflammation is defined as inappropriate, innate 
immune driven inflammation, and inflammation in CF at the systemic cellular level fits the 
criteria of autoinflammation. 
 The presence of innate immune cells and inflammatory mediators in the CF lung is 
associated with infection however, there is strong evidence in the literature that lung 
inflammation in CF is in fact sterile. Mucous dehydration and obstruction occur early-on in 
patients with and models of cystic fibrosis and is associated with neutrophilic inflammation in 
the absence of infection (Keiser et al., 2015, Fritzsching et al., 2015). One theory is that the 
mucous obstruction induces a hypoxic environment, and the innate immune driven 
inflammation is in response to hypoxic cell death (Montgomery et al., 2017). Hypoxia-driven 
inflammation is induced by IL-1R, which is activated under hypoxic conditions by the release 
of necrosis-dependent IL-1a. Pharmacological inhibition of IL-1R significant depleted airway 
neutrophils and fibrosis in CF. Additional evidence for sterile inflammation in CF is from the 
sterile (caesarean section) ferret model of CF, where mucous is found to be significantly 
dehydrated after birth with increased levels of IL-8 and TNF in the sterile CF ferret lung (Keiser 
et al., 2015). The sterile CF ferret model presents with abnormalities in various aspects of the 
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innate immune response, such as complement, mammalian target of rapamycin (mTOR) 
signalling and eukaryotic initiation factor 2 (eIF2) signalling, suggesting downstream 
activation of the NF-kB signalling pathway. Sterile innate immune driven inflammation is not 
a prerequisite of autoinflammation, but many monogenic autoinflammatory diseases have 
features of sterile inflammation, in that the trigger may be non-pathogenic or non-infectious 
(Lukens et al., 2012). For example, the cryopyrin-associated periodic syndrome (CAPS), 
familial cold autoinflammatory syndrome (FCAS) is an inherited autoinflammatory disorder 
categorised by periodic rashes, fevers, joint pain due to systemic inflammation triggered by 
exposure to cold (Dodé et al., 2002, Hoffman et al., 2001). The convincing evidence for sterile, 
hypoxia-driven innate immune driven inflammation moves CF further towards the 
autoinflammatory end of the immunological disease spectrum. 
 The NLRP3 inflammasome has been previously reported (sections 1.2 and 3.10.1) as 
being active in as in vitro cell and in vivo murine models of CF (Iannitti et al., 2016, Rimessi 
et al., 2015). Elevated levels of systemic IL-1 and activation of an inflammasome are 
characteristic features of autoinflammatory disease. This study has added to the growing body 
of evidence that the NLRP3 inflammasome is a potent inducer of IL-1 derived inflammation 
in CF and is hyper-responsive. In addition, the data presented throughout this study suggests 
the intrinsic genetic defect in CFTR contributes to the hyper-responsiveness of this pathway. 
 Within the definition of autoinflammation, there is the addendum that the adaptive 
immune system may be present and active in autoinflammatory disease, but that it is not the 
pathogenic source of inflammation and is merely an external, downstream factor influenced by 
the inappropriate innate immune driven inflammation. This is further corroborated by the lack 
of antigen-driven T cells, B-cells, or associated autoantibodies. In CF, the adaptive immune 
system plays a negligible role in the induction and progression of inflammation (Bruscia and 
Bonfield, 2016b). There is evidence that an adaptive immune signature occurs in late or end-
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stage CF lung disease (Lammertyn et al., 2017), with the presence of tertiary lymphoid organs 
in the lung (Regard et al., 2018) as well as IgA autoantibodies (Aebi et al., 2000, Budding et 
al., 2015, Fasth and Kollberg, 1980, Hodson and Turner-Warwick, 1981, Hoiby and Wiik, 
1975, Lachenal et al., 2009, Nousia-Arvanitakis et al., 2000, Rotschild et al., 2005, Schiotz et 
al., 1979), but this may be evidence of chronic, persistent inflammation rather that a causative 
effect. A further addendum to the definition of autoinflammation is that there may be a 
predisposition to autoimmunity, infection and hyperinflammation. There is evidence for all 
three of these scenarios in the CF literature, with end-stage autoantibodies (Budding et al., 
2015) against components of neutrophils, in addition to characteristic and periodic lung 
inflammation due to infections by minor and often commensal pathogens (Filkins and O’Toole, 
2015) as well as hyperinflammation (Adam et al., 2015, Cohen and Prince, 2012, Cohen-
Cymberknoh et al., 2013, Montgomery et al., 2017, Peckham et al., 2017, Scambler et al., 
2018), the latter being demonstrated throughout this study. 
 
6.2 Sodium-driven inflammation in CF – ENaC inhibition 
 
The activity of ion channels is associated with the modulation and activation of 
numerous inflammatory pathways in both health and disease. Disturbances in the expression 
or performance of an ion channel can have profound effects on the immune response. Whether 
CFTR has a role in immunity is debated as CFTR expression is often low in immune cells and 
chloride’s role in immune pathways is not well described. In this study, data has been presented 
that suggests the disruption in sodium flux downstream of CFTR dysfunction, specifically via 
amiloride-sensitive channels, has a role in inducing a hyperinflammatory phenotype in 
epithelial and innate immune cells. There is further evidence for sodium-induced inflammation 
in myeloid cells in the literature. Dendritic cells (DCs) have been shown to be implicated in 
  
239 
hypertension when exposed to excessive extracellular sodium (Barbaro et al., 2017). Barbaro 
et al. describe how Na+ influx through amiloride-sensitive channels, such as ENaC, leads to 
Ca2+ influx and activation of protein kinase C (PKC), p47phox and gp91phox. NADPH oxidase-
dependent superoxides activate isolevuglandin (IsoLG)-protein adducts downstream, with 
subsequent IL-1b secretion and T-cell activation. Sodium transport is able to regulate 
inflammation through swelling, or oedema. By transporting sodium across plasma membranes, 
fluid also moves across cellular membranes. Sodium transport has been shown to be part of 
this inflammatory response and independent of the type of inflammatory trigger, with similar 
responses in terms of amiloride-sensitive potential difference or sodium channel activity in 
both allergic asthma and meningococcal septicaemia (Streb et al., 1983, Eisenhut and Southern, 
2002, Eisenhut and Wallace, 2011, Eisenhut et al., 2004). In the latter study of meningococcal 
septicaemia, transport of sodium and chloride was shown for the first time to be disturbed in 
an in vivo human study, with the patient’s sweat test at a similar level to that of a CF patient, 
with severe dysfunction in CFTR or ENaC (Eisenhut and Southern, 2002, Eisenhut et al., 
2004). This observation confirms that ion transport of sodium and chloride is inextricably 
linked with inflammatory responses. Therefore, one can hypothesise that in the scenario of a 
genetic defect in sodium or chloride transport inflammation will be disturbed. The data in this 
study support this hypothesis, with evidence of ENaC-driven NLRP3 inflammasome activation 
and inhibition of amiloride-sensitive channels being able to modulate IL-1b and IL-18 
secretion. Further data show that there is a proinflammatory phenotype of innate immune cells, 
in terms of reduced M2-type macrophage surface markers and glycolytic metabolism. 
Interestingly, inflammation can also modulate the expression and activity of ENaC. 
Cytokines associated with Th1 (IFNg) (Schmidt et al., 2007), Th2 (IL-4 and IL-13) (Danahay 
et al., 2002) and M1-type (IL-1b and TNF) (Schmidt et al., 2007) immune cells have all been 
shown to downregulate ENaC, whereas NO stimulates ENaC expression (Hardiman et al., 
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2004). This feedback loop, between proinflammatory cytokines and ENaC expression, further 
implies that the relationship between ion channels and inflammatory responses is a close and 
important one. 
This study has highlighted the significance of overactive ENaC as a pathogenic 
mediator of inflammation in CF. These data, in combination with the wealth of literature 
implicating ENaC as an influencer of and being influenced by inflammation, support the 
hypothesis that the disturbance in ion channels in CF contributes to the inflammatory 
phenotype characteristic of the systemic manifestations in CF. Evidence for inflammation 
impacting CFTR expression has also been described. The cytokines IL-2, IL-4, IL-15, IL-10 
and IL-1b (O'Loughlin et al., 2001, Colgan et al., 1994, Madsen et al., 1996) as well as 
numerous leukotrienes, prostaglandin E2 (PGE2) (Van Der Merwe et al., 2009) and H2O2 
(Mayol et al., 2006) have all been shown to increase CFTR expression at the mRNA and protein 
level. Notably, many cytokines have also been shown to reduce CFTR expression such as 
TGFb (Prulière-Escabasse et al., 2005), IFNg and TNF. The ability of IFNg and TNF to 
modulate CFTR expression involves the disruption of the stability of CFTR mRNA transcripts, 
reducing the overall stability of the mRNA compared to wild-type by around 65% (Nakamura 
et al., 1992, Besancon et al., 1994). The role of IL-1b to induce CFTR expression is 
concentration dependent, with higher IL-1b concentrations inhibiting, rather than inducing 
CFTR expression (Cafferata et al., 2000, Cafferata et al., 2001). The inhibition of CFTR by 
high-dose IL-1b encompasses reducing the expression of mRNA and protein rather than 
mRNA stability, as with IFNg and TNF. The study investigating the role of TNF and the 
expression of CFTR detailed the similarity (85%) in sequence homology between CFTR 
regulating sequence with the TNF-regulated collagen gene sequence (Nakamura et al., 1992). 
This implies that the inflammatory response requires control over ion flux and thus ion channel 
activity. 
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These data suggest that therapeutic interventions targeting ion channels will 
beneficially have downstream anti-inflammatory effects if designed correctly for appropriate 
ion channel and cytokine. This is particularly relevant for channelopathies with inflammatory 
complications, such as CF. Targeting ENaC may be a successful anti-inflammatory therapy as 
well as controlling fluid absorbance and mucous dehydration. Additionally, the anti-
inflammatory effects of CFTR modulation, with ivacaftor/lumacaftor demonstrated in this 
study, may be due to the relationship CFTR has with inflammatory mediators rather than the 
partial correction and potentiation of CFTR, the primary defect of CF. 
 
6.3 Glycolytic metabolism in CF – intrinsic defect or systemic? 
 
 This study contributes to the growing amount of evidence that ion channels and ion 
fluxes are integral in the control and activation of inflammatory responses through the study of 
CF, a channelopathy with inflammatory complications. Ion channel disruption induces 
inflammatory phenotype in CF innate immune cells and HBEC lines. Small molecule 
intervention, inhibiting overactive amiloride-sensitive sodium channels is able to modulate 
downstream inflammatory responses. Interestingly, cells with CF-associated mutations also 
had metabolic disturbances, particularly in glycolysis. Whether ion channel disruption induces 
glycolysis directly, perhaps through an elevated energy demand, or whether the glycolysis is 
merely a consequence of inflammation and an indication of a proinflammatory cell phenotype 
is yet to be elucidated. The data in this study suggest the former, with increased energy, in the 
form of ATP, being required to maintain ionic homeostasis in CF, causing a metabolically 
stressed phenotype as inhibition of amiloride-sensitive sodium channels was able to modulate 
certain glycolytic read-outs thought to be upstream of inflammation. A CF cell with such 
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disturbances in glycolysis will then be predisposed to a proinflammatory phenotype, due to the 
known downstream, proinflammatory cellular responses to glycolytic metabolism. 
An alternative hypothesis is that systemic metabolism, such as the alteration in the CF 
gut microbiome or the high-calorie, high-fat CF diet may alter inflammatory and metabolic 
phenotypes. Rather than an intrinsic ion channel defect causing a stressed metabolism directly 
and a subsequent proinflammatory phenotype, it may be that the high-fat, high-glucose diet, 
inducing hyperglycaemia, provides the fuel for glycolysis with successive overactivation of 
this pathway, particularly in innate immune cells and epithelia. This may certainly explain 
many of the systemic manifestations of CF such as arthritis and diabetes in which secondary 
sites to that of the lung experience chronic inflammation. Changes in the gut microbiome have 
also been associated with an alteration in the inflammatory phenotype of immune cells. 
Changes in the CF gut microbiome have been described and this may be due in part to the CF 
diet. Based on the data in this study and the deductions in the current literature, it is difficult to 
conclude whether metabolism and inflammation is affected by intrinsic or systemic influencers 
in CF. One piece of evidence that suggests the former is the successful ivacaftor therapy in 
patients with a G551D CFTR allele (Davies et al., 2013b). Individuals on ivacaftor begin to 
gain weight, a positive outcome measure in most trials. The patients do not change diet whilst 
on ivacaftor therapy, suggesting that correcting the intrinsic defect then alters metabolism and 
inflammation, with weight increasing, lung function improving and reduced number of 
exacerbations. Therefore, intrinsic ion channel defects in CF increase cellular energy demand, 
while inducing elevated metabolic activity and a glycolysis-dependent inflammatory 
phenotype and hyperinflammation. 
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6.4 Epithelia or immune cell inflammation 
 
 A debate within the CF research community exists in which the predominant cellular 
orchestrator of inflammation is the subject. CFTR is a channel highly expressed on epithelia in 
multiple organs with the majority of research in CF focussing on this cell type. The successful 
trials of small molecule modulators of CFTR focus on patient outcomes and epithelial CFTR 
function. The epithelia have a pivotal role in anti-microbial defence (Tecle et al., 2010), barrier 
function (LaFemina et al., 2014), mucociliary clearance (Kreda et al., 2012) as well as the 
detection of PAMPs and DAMPs (Lambrecht and Hammad, 2012, Armstrong et al., 2004). 
However, inflammation is not created by epithelial cells alone. The epithelial surfaces may 
orchestrate inflammation (Whitsett and Alenghat, 2015) by recruiting immune cells to sites of 
infection, such as the lungs in CF, but the vast majority of inflammation is carried out by 
leukocytes (Scambler et al., 2018). Despite the low expression of CFTR (Painter et al., 2006, 
Sorio et al., 2011, Johansson et al., 2014, Ettorre et al., 2014) and ENaC (Ottaviani et al., 2002, 
Barbaro et al., 2017, Gamper et al., 2000) channels in leukocytes many studies have shown 
defects in this cell type with disturbances in important cellular functions such as phagocytosis 
(Ng et al., 2014, Van de Weert-van Leeuwen et al., 2013, Hartl et al., 2012, Simonin-Le Jeune 
et al., 2013), chemotaxis (Sorio et al., 2016), cytokine secretion (Bals et al., 1999, Blohmke et 
al., 2012, Blohmke et al., 2008, Bonfield et al., 2012, Bruscia and Bonfield, 2016a, Bruscia et 
al., 2009, Cohen and Prince, 2012, Hartl et al., 2012, Keiser et al., 2015, Law and Gray, 2017, 
Machen, 2006, Mayer et al., 2013, Meyer et al., 2009), bacterial killing (Pezzulo et al., 2012) 
and cell death (Watt et al., 2005). Intrinsic defects due to CFTR mutations may be the source 
of these defects, as ion fluxes are known to be crucial in many inflammatory processes as 
previously discussed (section 6.2). Some of the mechanisms behind this may be ion-dependent 
cellular signalling, alterations in intracellular pH, oxidative stress, ER stress or epigenetics. 
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Many studies indicate that the defects in immune cell function in CF are secondary to epithelial 
inflammation, the environment in the lung and chronic infection. The data in this study suggest 
that it is in fact an intrinsic defect in ion channel expression and activity in immune cells 
themselves that is causing a hyperinflammatory state. This study has found ENaC expression 
in immune cells at the mRNA and protein level (Appendix figure 6). The function of this 
channel is not quite clear in immune cells however, but this is beyond the scope of this study. 
Therefore, it can be considered that CF epithelial cells are intrinsically hyperinflammatory and 
recruit excessive amounts of innate immune cells, which themselves are predisposed to 
proinflammatory phenotypes. This phenomenon in CF, coupled with recurrent respiratory 
infections, creates a chronically and inappropriately inflammatory environment resulting in 
bronchiectasis. This is highlighted by the fact that healthy individuals do not mount the same, 
aggressive inflammatory response to the pathogens common to the CF-lung. 
 
6.5 Orkambi is an anti-inflammatory drug in patients with CF 
 
 The observations in this study suggest that disturbances in ion channel expression and 
activity, as is the case with the CFTR-chloride ion channel in CF contribute and modulate 
inflammatory pathways. Therefore, CFTR correction and potentiation with small molecules 
such as orkambi, although partial, modulate the primary ion channel defect in CF cells. The 
downstream modulation of inflammation is therefore either through correction of chloride ion 
flux and/or CFTR-dependent ENaC suppression. To delineate the exact mechanism by which 
orkambi modulates inflammation was beyond the scope of this study, but a relevant question 
that may lead to greater understanding of the basic defects in terms of the relationship between 
CFTR and ENaC channels. Based on the data in this study, it can be hypothesised that orkambi 
  
245 
modulates inflammation, via promoting CFTR expression and subsequent CFTR-dependent 
ENaC inhibition. 
 
6.6 Concluding remarks 
 
 Based on the data generated as part of this study and the literature discussed throughout 
this thesis, it can be concluded that CF has many clinical and molecular similarities with 
autoinflammatory disease and should be treated as such. Multiple groups have postulated that 
biologic therapy in CF should be investigated, in particular the biological targeting of IL-1 
cytokines with anakinra and canakinumab. This should be however, approached with caution 
and the anti-inflammatory benefits balanced with the control of infection by inflammatory 
mediators. Furthermore, metabolism is disturbed in cells with CF-associated mutations which 
may be part of the basic pathology of CF as well as a potential therapeutic target. Therapies 
based on metabolic pathways may be through the use of therapeutic metabolites, such as 
itaconate, but also through control over the high-fat, high-glucose diet. Finally, the 
revolutionary small molecule CFTR modulator therapies have huge therapeutic potential, but 
the basic mechanisms behind how the drugs not only recover CFTR expression and activity 
but how they modulate other channels and produce anti-inflammatory effects must also be 
thoroughly investigated for the benefit of future, targeted and personalised therapies. 
 
6.7 Study limitations 
 
 The limitations in this study involve the patient cohorts recruited to this study as well 
as the narrow scope of the study in terms of cell types and pathways. The patient cohorts were 
not fully characterised, being only selected on genotype and age (Phe508del	allele positive 
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and above the age of 18 years old). These criteria were selected based on the fact that CF is a 
rare genetic disease, and a large sample size was required for confidence in any differences 
found in terms of statistical tests therefore, the selection criteria was minimal. The orkambi 
patient cohort was not controlled for adherence or dosage of orkambi in the initial month of 
the study, due to internal clinical procedures to optimise drug dosage for a more personalised 
medical approach.  
 The immortalised cell lines are a good model for basic scientific questions, comparing 
cells from different individuals with different CF genotypes and a WT CFTR control (Beas2b). 
All the cell lines were the same cell type and has underwent the same immortalisation 
procedure. However, the conclusions this study makes is based on data from both HBEC lines 
and primary immune cells. Ideally, primary epithelia would be collected to support the HBEC 
line data. In addition, immortalised myeloid cell lines with various CF-associated mutations 
would also be a useful research tool to probe further into the basic inflammatory pathways 
effected by CFTR-mutation. Additionally, the cell lines are grown in different media 
formulations. This may have an effect on the availability of certain ions due to differential salt 
concentrations. However, the differential growth media formulations are optimised to ensure 
no significant differences in inflammation due to the growth media in appendix figure 11. 
 Finally, the prior expertise of the McDermott lab was focussed on innate immune 
mediated inflammation and autoinflammatory disease. Therefore, the research interests and 
questions were focussed on this research area. This study cannot comment on other immune 
pathways, such as lymphoid signatures or other metabolic pathways. 
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6.8 Future Directions 
 
 There is sufficient evidence within this study, in combination with the various seminal 
studies in the literature, for a comprehensive human clinical trial of anakinra as an anti-
inflammatory therapy for CF. This approach may benefit from a prophylactic treatment regime 
rather than a specific therapy in response to infection. One can hypothesis that many so-called 
secondary manifestations, that is extra-pulmonary manifestations may benefit from such a 
regime. 
The study of ENaC as a therapeutic target is advanced, with active clinical trials taking 
place at St James’s University Hospital, Leeds and internationally for the SPLUNC1-derived 
peptide SPX-101. These trials, in addition to future studies using the transgenic b-ENaC-tg 
mouse model, should investigate immunometabolism to further understand the role of this 
channel in the pathology of the aggressive inflammatory phenotype in CF. 
The outstanding question of how metabolism disturbed in CF and whether this is intrinsic 
or systemic in origin may affect the role of dietitians in CF and may support a change in dietary 
guidelines for patients with CF in the future, turning towards a fibre-rich diet rather than high-
fat, high-glucose. 
Finally, how orkambi modulates inflammation is a key question that also needs further 
investigation. The hypothesis suggested in section 5.6.2 should be investigated further as this 
may also lead to more targeted therapeutics such as PGE2 based therapies 
.  
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Appendix 
 
 
 
Appendix figure 1: THP-1 in vitro Inflammasome stimulation optimisation. ELISA 
assays were used to detect IL-18 from supernatants of THP-1 monocyte cell growth medium 
(supplemented RPMI) (n=2). THP-1s were pre-treated with MCC950 (15nM) and a priming 
stimulation of LPS (10ng/mL) before being stimulated for 30 minutes with ATP (5mM) or 4 
hours with Flagellin (10ng/mL with Lipofectamine 2000), Nigericin (1µM), poly (dA:dT) 
dsDNA (1µg/mL with Lipofectamine 2000), TcdB (10ng/mL) or MSU crystals (100µg/mL). 
A repeated measures 2-way ANOVA statistical test was performed with Turkey’s multiple 
comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
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Appendix figure 2: in vitro NLRP3 Inflammasome stimulation optimisation. ELISA 
assays were used to detect IL-18 from supernatants of HBECs (a) and HC PBMCs (b) (n=2). 
Cells were stimulated with the indicated concentration of LPS (0-10µg/mL) before being 
stimulated for 30 minutes with ATP (5mM). A repeated measures 2-way ANOVA statistical 
test was performed with Turkey’s multiple comparisons test (p values * = £0.05, **= £0.01, 
***= £0.001 and ****= £0.0001). 
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(Appendix Figure 3 legend on next page) 
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Appendix figure 3: Flow cytometry gating for macrophage and monocytes surface 
marker analysis. Monocytes from whole blood were differentiated into macrophages and 
gated based on forward and side scatter. M1-type (markers- CD14+ CD16+ HLA-DR+ 
CD274+ CD86+ TNFHI). M2-type (markers- CD14+ CD16+ CD206+ IL-10HI) (a). 
Monocytes were gated on based on forward and side scatter and then based on CD14 and 
CD16 expression as follows: classical (CD14++CD16−), non-classical (CD14dimCD16++), 
and intermediate (CD14++CD16+) (b). 
 
 
Appendix figure 4: Macrophage and monocyte populations. Phenotypic differences in 
M1-type and M2-type macrophages by light microscopy (n=2) from HC subjects. 
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Appendix figure 5: TNF levels from stimulations of monocytes with inhibitors. Patients 
with CF and HC (n=6) pre-treated with amiloride (a) and MCC950 (b) were measured using 
ELISA. A repeated measures 2-way ANOVA statistical test was performed with Turkey’s 
multiple comparisons test (p values * = £0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
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Appendix figure 6: ENaC protein and gene expression in HBEC lines and monocytes. 
ENaC protein expression was detected using western blot in Beas2b, CuFi-1 and CuFi-4 
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HBEC lines as well as in HC monocytes (n=2) (A). To ensure that the correct band was being 
interpreted, SCNN1B (bENaC) was overexpressed in the Beas2b (WT) HBEC line (B). 
Taqman RT-qPCR was used to measure SCNN1B expression in HC (n=3) and CF (n=3) 
monocytes (C). This figure was produced by Dr Heledd Jarosz-Griffiths and Mr Samuel Lara 
Reyna. 
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Appendix figure 7: Detection of ASC specks using flow cytometry. 1µm beads were 
added to uncultured complete RPMI media in order to set a gate for an approximate size and 
granularity of ASC specks. 1µm beads had no significant amount of background PE 
fluorescence. PE fluorescence was then measured within the set 1µm gate in the samples of 
interest. In this representative image, unstimulated and stimulated monocytes from a patient 
with SAID are used to display the release of extracellular ASC specks upon NLRP3 
inflammasome stimulation. 
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Appendix figure 8: Seahorse cell energy phenotype assay trace. Oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) are used to calculate the metabolic 
potential and energy phenotype of a sample of interest. The relative usage of OXPHOS and 
glycolysis of a cell population within a sample is determined under both baseline (baseline 
phenotype) and stressed (stressed phenotype with oligomycin and FCCP stimulation) 
conditions. The response to an induced energy demand is a sample’s metabolic potential. 
 
 
 
 
 
 
HC
 
monocytes 
 
HC monocytes 
(10ng/mL LPS)  
 
CF monocytes 
 
CF monocytes 
(10ng/mL LPS) 
 
 
 
0.00
0.05
0.10
0.15
0.20
0.25
0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35
M
ito
ch
on
dr
ia
l	R
es
pi
ra
tio
n
O
CR
	(p
m
ol
/m
in
/u
g	
pr
ot
ei
n)
ECAR	(mpH/min/ug	protein)
Glycolysis
XF	Cell	Energy	Phenotype
CF006 CF006	LPS CF012 CF012	LPS CF020 CF020	LPS
HC1 HC1	LPS HC2 HC2	LPS HC3 HC3	LPS
Aerobic Energetic
GlycolyticQuiescent
0.00
0.05
0.1
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.00 0.05 0.10 0.15 0.20 0.25 0.30
M
it
o
ch
o
n
d
ri
al
	R
es
p
ir
at
io
n
O
CR
	(
p
m
o
l/
m
in
/u
g	
p
ro
te
in
)
ECAR	(mpH/min/ug	protein)
Glycolysis
XF	Cell	Energy	Phenotype
Beas2b Beas2b	LPS IB3-1 IB3-1	LPS 
Aerobic Energetic
GlycolyticQuiescent
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.00 0.05 0.10 0.15 0.20 0.25 0.30
M
it
o
ch
o
n
d
ri
al
	R
es
p
ir
at
io
n
O
CR
	(
p
m
o
l/
m
in
/u
g	
p
ro
te
in
)
ECAR	(mpH/min/ug	protein)
Glycolysis
XF	Cell	Energy	Phenotype
Beas2b Beas2b	LPS IB3-1 IB3-1	LPS 
Aerobic Energetic
GlycolyticQuiescent
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.00 0.05 0.10 0.15 0.20 0.25 0.30
M
it
o
ch
o
n
d
ri
al
	R
es
p
ir
at
io
n
O
CR
	(
p
m
o
l/
m
in
/u
g	
p
ro
te
in
)
ECAR	(mpH/min/ug	protein)
Glycolysis
XF	Cell	Energy	Phenotype
Beas2b Beas2b	LPS IB3-1 IB3-1	LPS 
Aerobic Energetic
GlycolyticQuiescent
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.00 0.05 0.10 0.15 0.20 0.25 0.30
M
ito
ch
on
dr
ial
	Re
sp
ira
tio
n
OC
R	
(p
m
ol
/m
in
/u
g	p
ro
te
in
)
ECAR	(mpH/min/ug	protein)
Glycolysis
XF	Cell	Energy	Phenotype
Beas2b Beas2b	LPS IB3-1 IB3-1	LPS 
Aerobic Energetic
GlycolyticQuiescent
  
257 
 
 
 
  
 
0.0
0.1
0.1
0.2
0.2
0.3
0.3
0.4
0.4
0.5
0 10 20 30 40 50 60 70 80
EC
AR
 (m
pH
/m
in
/u
g/
m
L)
Time (min)
Glucose Oligomycin 2-DG 
Unstimulated 
monocyte 
 
LPS 
stimulated 
monocyte 
 
  
258 
Appendix figure 9: Seahorse glycolytic function assay trace. The profile of the factors of 
glycolytic function detail the successive injections that allow the measurement of glycolysis, 
glycolytic capacity, and allow calculation of glycolytic reserve and non-glycolytic 
acidification. 
 
Appendix figure 10: MitoSox flow cytometry assay. Gated cells were used to measure the 
mean fluorescent intensity of MitoSOX (PE) of each cell line Beas-2b, IB3-1, CuFi-1, and 
CuFi-4 cell lines. n=3 biological replicates for each cell line. A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001). 
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Appendix figure 11: The effect of a change in media supplementation on HBEC line 
NLRP3 inflammasome responses. An ELISA assay was used to detect IL-18 secretion from 
HBECs (n=3). Cells were cultured in the indicated media for 24-hours before being 
stimulated. Cell stimulation was as follows: a stimulation with LPS (10ng/mL) for 4-hours 
with an ATP (5mM) stimulation for the final 30 minutes. A repeated measures 2-way 
ANOVA statistical test was performed with Turkey’s multiple comparisons test (p values * = 
£0.05, **= £0.01, ***= £0.001 and ****= £0.0001).   
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Appendix figure 12: Clinical data from orkambi patient cohort over the 3-month study. 
Clinical data from patients enrolled onto the orkambi study in chapter 5 was collected 
throughout. Details of baseline lung function FEV1%, FVC (L), FEV: FVC%, weight (Kg) 
BMI, CRP (mg/L), white blood cell (WBC) count and neutrophil count. 
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